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Following a review of the literature describing the bone health of children, 
teenagers and young people with leukaemia, this thesis is comprised of two 
main parts. The first part describes a retrospective review of patients with 
acute lymphoblastic leukaemia (ALL) who were recruited into the national 
study, UKALL 2003. This reports upon the UK prevalence of symptomatic 
osteonecrosis (ON) in young people with ALL, assessing the chronology of 
development of symptoms and subsequent diagnosis. This study also 
evaluated risk factors for the development of ON, and determined the joints 
most commonly affected. The surgical and medical management of patients 
is described, with a review of long-term outcomes of patients.  
This is the largest single UK study reporting symptomatic ON in childhood 
ALL, providing long term follow up data of patients. The overall prevalence of 
symptomatic ON was calculated to be 5.5%. Age at diagnosis of ALL 
significantly affected risk of development of ON, with the highest risk in those 
aged between 10 and 20 years at diagnosis of ALL. Affected patients had a 
high rate of surgical intervention, with hip replacements in 26% of patients. 
Core decompression was performed in 30% of hips affected by ON but we 
found no significant difference in femoral head survival between those 
patients who had core decompression compared with conservative 
management 
The second part of this thesis describes the establishment and interim 
findings of the British OsteoNEcrosis Study, a prospective longitudinal cohort 
study of patients aged 10-25 years diagnosed with ALL or lymphoblastic 
lymphoma. This is the first multi-centre prospective study using MRI imaging 
for assessment of asymptomatic ON in the UK, and combines physiotherapy 
assessment with imaging and biochemical results. The results suggest 
osteonecrotic lesions develop between induction and start of maintenance 
chemotherapy, with the majority of patients developing multiple 
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Chapter 1 Introduction 
Historically, the research agenda for young people with cancer has been set 
by researchers and professionals caring for young people with cancer. 
However, there is increasing awareness of the importance of identifying the 
priorities of the young people and carers themselves. The top 10 research 
priorities for teenage and young adult were determined by the Teenage and 
Young Adult Cancer Priority Setting Partnership, a national consultation 
identifying unanswered research questions by young people, carers, 
significant others and professionals [1].  
Two of the top 10 questions addressed the issue of short and long term 
effects of cancer treatment. Within the specific field of short and long term 
side effects, one of the questions was: 
 “What cancers and treatments cause avascular necrosis, how does it 
develop, how common is it, what are the physical and psychological effects 
and what can be done to improve early diagnosis and treatment?” 
Whilst the whole of this question is beyond the scope of this thesis, through 
this work I hoped to move some way towards gaining a greater 
understanding of how the bone health of children with acute lymphoblastic 
leukaemia (ALL) is affected, with an emphasis on bone fragility and 
osteonecrosis (ON), which is also known as avascular necrosis.  
Chapter 1 describes bone health, the first part considering normal bone 
anatomy, physiology and metabolism. The second part of the chapter 
reflects upon factors that impact bone fragility and the development of ON, 
specifically with regard to glucocorticoid exposure. The chapter ends with a 
description of historic and current treatment of ALL, and the use of 
glucocorticoids in ALL.  
Chapter 2 provides an overview of the literature underpinning this thesis. 
The first part of this chapter describes ON in young people with ALL, 
followed by a review of bone mineral density changes in this population. The 
last part of this chapter focusses on efficacy and safety of 2 potential 
therapeutic strategies, namely bisphosphonate therapy and vitamin D 
supplementation.  
Chapter 3 presents a retrospective analysis of ON in young people with ALL, 
analysing the cohort of patients enrolled in the national trial for children and 




 Reports the UK prevalence of symptomatic ON in young people with 
ALL 
 Describes the chronology of the development of symptoms related to 
ON and subsequent diagnosis of ON 
 Identifies risk factors for the development of ON 
 Determines which joints are affected by ON and methods of diagnosis 
of ON in patients with ALL 
 Describes the medical and surgical management of patients 
diagnosed with ON in UKALL 2003 
 Establishes the long-term outcomes of patients affected by ON in 
UKALL 2003 
The second part of this chapter includes a subset analysis, focussing on the 
surgical management of patients, and includes an analysis of the use of core 
decompression as a therapeutic intervention. The aims of this were to: 
 Characterize the surgical procedures performed in patients affected 
by symptomatic ON in UKALL 2003, including the identification of 
sequential procedures in individuals.  
 Evaluate the efficacy of femoral head core decompression in 
prevention of joint collapse in young people with symptomatic ON.  
Chapter 4 describes the development of a prospective study assessing the 
natural history of osteonecrotic lesions in young people with ALL and 
lymphoblastic lymphoma (LBL). Interim results of the study are presented.  
The aims of this study are to: 
 Identify the incidence of symptomatic and asymptomatic ON in older 
children, teenagers and young adults being treated for ALL or LBL in 
the UK at different time points in their treatment 
 Identify the risk factors for progression and the development of 
symptomatic ON in this population 
 Identify specific radiological features which might predict for either 
progression or regression in those with asymptomatic ON  
 Evaluate functional ability and explore the correlation of this with MRI 
findings  
 Evaluate changes in BMD and VF incidence during treatment for ALL 
or LBL 
The Chapter 5 is a discussion of the results presented in the preceding 2 
chapters, and Chapter 6 concludes with clinical implications and avenues for 




1.1 Normal bone anatomy and physiology 
The human skeleton is composed of around 270 bones at birth, which 
decreases to 206 by adulthood (excluding sesamoid bones), as some bones 
fuse together [2]. Each bone constantly undergoes a process of modelling 
and remodelling to adapt to changing biomechanical forces and remove 
micro-damaged bone. The 4 main categories of bones are long bones (e.g. 
humeri, femurs, tibiae), short bones (e.g. carpal and tarsal bones, patellae), 
flat bones (skull, mandible, sternum) and irregular bones (vertebrae, 
sacrum).  
Bones are predominantly composed of cortical and trabecular bone (also 
known as cancellous bone), with different bones having different ratios of 
cortical to trabecular bone. Long bones have epiphyses at the ends, followed 
by metaphyses, with the diaphysis (shaft) in the middle (Figure 1) [3]. 
Cortical bone forms the hard exterior of bones. It is heavily calcified and has 
a mainly structural and protective role. Trabecular bone is much less dense 
than cortical bone, is highly vascular and can contain red bone marrow, 
where haematopoiesis occurs. In long bones the diaphysis (the shaft of the 
bone) is composed predominantly of cortical bone. In contrast, the 
metaphysis, which is the area below the growth plate, and the epiphysis, 
which is above the growth plate, are composed of trabecular bone 
surrounded by a relatively thin shell of cortical bone (Figure 2) [4]. The 
vertebrae are composed of predominantly trabecular bone, with a cortical to 
trabecular bone ratio of 25:75. This ratio is 50:50 in the femoral head and 
95:5 in the radial diaphysis [5]. 
Figure 1. Structure of a long bone  
 
 
Reproduced from source: Blausen.com staff (2014). “Medical gallery of Blausen Medical 2014”. WikiJournal of 
Medicine 1 (2). DOI: 10.15347/wjm/2014.010. ISSN 2002-4436. This file is licensed under the Creative Commons 




Figure 2. Cross-section of a long bone 
 
Reproduced from source: https://commons.wikimedia.org/wiki/File:Bone_cross-section.svg. This file is licensed 
under the Creative Commons Attribution 3.0 Unported license.  
 
Cortical bone is composed of osteons, whilst trabecular bone is composed of 
trabeculae. Each osteon is composed of concentric lamellae of compact 
bone, surrounding a central canal, known as a Haversian canal (Figure 3) 
[6]. Unlike osteons, trabeculae in general do not have a central canal with a 
blood vessel. Both cortical and trabecular bone are composed of organic 
and mineral matrix, with type 1 collagen forming approximately 95% of the 
organic matrix, and calcium and phosphate ions (in the form of 
hydroxyapatite) forming the majority of the mineral matrix. The organic 
matrix provides bone with resistance to tensile forces, whilst the mineral 
matrix provides bone with strength under compressive loads. Most bones 
have approximately 60-70% mineral matrix, depending on site and stage of 
development.  
Figure 3. Bone composition 
 
Reproduced from source: U.S. National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) 
Program. This file has been identified as being free of known restrictions under copyright law, including all related 
and neighbouring rights. 
 
The vascular supply to bone is critical to ensure it receives adequate 
oxygenation and nutrient supply, as well as removing metabolic waste 




reflecting the requirements of bone cells, marrow, and endothelial cells [7, 
8]. The main blood supply of long bones is derived from one or more 
principle nutrient arteries, which penetrate into the medulla of the bone and 
connect to the smaller periosteal arteries to enable perfusion [9]. Drainage is 
into arterio-venous sinuses in the medullary cavity, with exit via multiple 
small veins that penetrate the cortex. This vascular supply to bone allows 
the rapid growth and remodelling that differentiates bone from essentially 
avascular cartilage.  
1.1.1 Bone remodelling 
Bone remodelling is a continuous process that allows repair of micro-
damage and enables skeletal adaptation to mechanical use. It also facilitates 
maintenance of plasma calcium levels in the physiological range by the 
release of minerals from the bone matrix. The 3 main cell types involved in 
the process of remodelling are osteoblasts, osteoclasts and osteocytes. 
Bone lining cells are also involved in the process of bone remodelling, but 
their function is not yet fully elucidated. These four cell types form the bone 
forming unit (BFU), an anatomical structure present during the remodelling 
cycle.  
Osteoblasts are cells located along the bone surface, and their main function 
is that of bone formation [10]. They are derived from mesenchymal stem 
cells found in the bone marrow, and produce collagen and other matrix 
proteins. Commitment of mesenchymal stem cells to osteoblast formation 
requires activation of the Wnt/ß-catenin pathway [11]. Osteoblasts 
synthesise new collagenous organic matrix, and regulate matrix 
mineralisation by the release of membrane bound vesicles that concentrate 
calcium and phosphate, and destroy mineralisation inhibitors.  
Osteoclasts are multinucleated cells that originate from the 
monocyte/macrophage lineage under the influence of factors including  
receptor activator of nuclear factor kappa-B ligand (RANKL), secreted by 
osteoblasts, osteocytes and stromal cells, and macrophage colony-
stimulating factor (M-CSF) [12]. The function of the osteoclast is the 
localised breakdown of bone matrix and mineral. Bone resorption requires 
osteoclast secretion of hydrogen ions and cathepsin K enzyme. Hydrogen 
ions acidify the area below the osteoclast to dissolve the mineral component 
of the bone matrix, whilst cathepsin K digests the organic matrix.  
Osteocytes comprise 90-95% of total bone cells, and are terminally 




Osteocytes connect with one another and the bone surface via multiple 
cytoplasmic canalicular processes. They are linked through gap junctions 
and the primary function of the osteocyte-osteoblast/lining cell unit is 
mechanosensation, transducing stress signals from bend or stretch of bone 
into biologic activity.   
Bone remodelling occurs in both cortical and trabecular bone, and is a 
sequence of 4 events; activation of osteoclasts, osteoclast mediated bone 
resorption, reversal and osteoblast mediated bone formation. Osteoclast 
mediated bone resorption takes approximately 2-4 weeks, and is regulated 
by the ratio of RANKL to osteoprotegerin, IL-1, IL-6, PTH, 1,25 vitamin D, 
calcitonin and colony stimulating factor [12]. The subsequent step is 
reversal, where bone resorption transitions to bone formation. Bone 
formation takes between 4 and 6 months to complete, and at the completion 
of bone formation 50-70% of osteoblasts undergo apoptosis, with the 
remaining cells becoming osteocytes or bone lining cells. The osteoblasts 
surrounded by and embedded within matrix become osteocytes, with an 
extensive canalicular network which connects them to the other cells of the 
bone forming unit [14].  
Remodelling can become imbalanced in specific situations, such as in a 
patient with reduced oestrogen levels or as a consequence of decreased 
mechanical stimulation [15]. In these conditions there is a net increase in 
bone breakdown, via relative increases in osteoclast activity, with a 
concurrent reduction in bone strength and increased fracture risk.  
1.1.2 Endocrine regulation of bone metabolism 
Many systemic and local hormones influence bone growth and remodelling. 
As bone is a reservoir of calcium, phosphate, magnesium and trace 
elements, helping to maintain mineral homeostasis, particularly calcium 
homeostasis, is one of the functions of bone. The primary hormonal 
regulators of calcium are parathyroid hormone (PTH) and activated vitamin 
D (1, 25 dihydroxycholecalciferol, (1,25(OH)2D)).  
In response to hypocalcaemia the parathyroid gland increases the 
production and secretion of PTH. This acts on the renal tubule to decrease 
calcium excretion and inhibit phosphate reabsorption, and stimulates 
1,25(OH)2D production [16]. PTH also has direct actions on bone via PTH 
receptors in osteoblasts, activation of which results in increased calcium and 




dependent osteoclastic bone resorption [18]. The effects of both PTH and 
1,25(OH)2D result in restoration of normal plasma calcium levels.  
When there is sufficient calcium supply, 1,25(OH)2D can improve calcium 
balance largely without direct effect on bone cells. However, in calcium 
deficiency 1,25(OH)2D enhances bone resorption whilst simultaneously 
inhibiting bone mineralisation. When the calcium levels normalise 
1,25(OH)2D may provide a drive to re-mineralise the skeleton via action on 
osteoblastic cells [19].  
Calcitonin is a hormone released in response to rising calcium levels, and 
opposes the effects of PTH. The precise biological role of calcitonin in 
calcium homeostasis is uncertain as calcitonin deficient patients do not 
experience alterations in regulation of serum calcium levels.  
Oestrogen is an important regulator of bone remodelling, and also has a role 
in closure of epiphyseal growth plates. Oestrogen receptors are present on 
both osteoblasts and osteoclasts. Most effects are mediated by the nuclear 
hormone receptor transcription factors oestrogen receptors α. This is likely to 
play the dominant role in regulating bone mass in both males and females 
[20]. Oestrogens act on osteoblasts to increase bone formation and restrict 
activation of osteoclasts. Loss of oestrogen causes loss of trabecular bone 
through increased osteoclast numbers.  
1.2 Bone fragility 
The foundations of adult bone health are developed during childhood and 
early adult years. Bone strength is determined by peak bone mass, bone 
size, geometry and microarchitecture, which is primarily established as final 
height is attained. Heritable factors account for 60-80% of variation in bone 
strength [21, 22], but in order to achieve one’s genetic potential, bone health 
needs to be optimised during the first 2 decades of life, with peak bone mass 
established by the third decade of life [23-27]. If this is compromised there 
may be an associated lifetime risk of osteoporosis and fractures [28, 29]. 
Whilst in adults osteoporosis is typically defined on the basis of bone mineral 
density (BMD) assessment [30], the definition is more complicated in the 
paediatric population.  
The International Society for Clinical Densitometry (ISCD) 2013 official 




“The finding of one or more vertebral compression (crush) fractures is 
indicative of osteoporosis, in the absence of local disease or high-energy 
trauma… 
In the absence of vertebral compression fractures, the diagnosis of 
osteoporosis is indicated by the presence of both a clinically significant 
fracture history and BMD Z-score ≤-2.0.” [31].  
It is important to note that a vertebral compression fracture (loss of vertebral 
height at any point of >20%) alone, unless caused by high energy trauma, is 
sufficient to diagnose osteoporosis, regardless of bone mineral density data 
due to its implication of significant bone fragility. A clinically significant 
fracture history is defined as one or more of the following: 
 Three or more long bone fractures at any age up to 19 year 
 Two or more long bone fractures by age 10 year  
Given these guidelines, clinicians require tests that both evaluate bone 
mineralisation and detect vertebral fractures. Bone densitometry is 
commonly used to evaluate skeletal mineral status, and aims to identify 
individuals at risk for skeletal fragility. The most common conventional 
technique used for non-invasive bone mineral measurements is dual-energy 
X-ray absorptiometry (DXA).  
1.2.1 Bone mineral density and DXA interpretation 
Bone densitometry is a surrogate measure of bone strength, with DXA the 
most commonly used method of assessment due to its widespread 
availability, low radiation dose and acceptability to the patient. DXA allows 
measurement of paediatric bone status by measuring the amount of mineral 
within a given area of bone. 
The goal of bone densitometry is to identify individuals at risk for skeletal 
fragility, determine magnitude of compromised bone mass, and guide and 
monitor treatment [32]. Although DXA scans are commonly used to assess 
BMD in patients, the interpretation of BMD results in children requires 
considerable thought. 
The 2013 ISCD official position is that DXA is the preferred method for 
assessing bone mineral content and areal bone mineral density, with the 
posterior–anterior lumbar spine and total body less head (TBLH) the 
preferred sites for measurements [31]. These sites were chosen following 
results from a study looking at DXA measurements in 450 children with 




current standard for reporting DXA results is the areal BMD Z-score, which 
provides an estimate of the standard deviation away from the mean for 
chronological age and sex [24, 34]. 
One of the challenges in the interpretation of paediatric DXA measurements 
is the need to adjust for the influence of bone size. DXA relies on the 
differential absorption of X-rays to differentiate tissues of different 
radiographic density and also quantifies the bone mineral content (BMC) at 
various body sites. The BMD is calculated by dividing the BMC by the bone 
area. Therefore, DXA-derived BMD is based on the 2-dimensional projected 
area of a 3-dimensional structure. This will mean that smaller bones will 
have a lower areal BMD than larger bones, even if the volumetric BMD is the 
same, and several mathematical models of estimating volumetric BMD have 
been proposed to negate for the confounding effects of bone size on DXA 
measurements [35-37].  
The ALPHABET study (Amalgamated reference data for size adjusted bone 
densitometry measurements) is the most recent study to develop UK size 
adjusted DXA measurements, and has allowed the development of robust 
reference data for accurate scan interpretation [38]. This study has produced 
reference curves adjusted for age, sex, ethnicity and body size for lumbar 
spine bone mineral apparent density (BMAD), lumbar spine areal BMD and 
TBLH areal bone mineral density . These are applicable for both GE Lunar 
and Hologic scanners, which are the most common DXA scanners used in 
the UK, and are validated in patients up to 20 years of age. The prediction 
equations generated for TBLH BMC also take into account body 
composition, as several studies have shown a high correlation between 
muscle mass and bone mass in children, and are consistent with the widely 
accepted mechanostat theory [39]. The results of the ALPHABET study 
allow accurate interpretation of UK DXA data, particularly given its UK cohort 
of 3598 children.  
1.2.2 Alternative methods of measuring bone mineral density 
Lumbar spine quantitive computerised tomography (QCT), peripheral 
quantitative computerised tomography (pQCT) and high-resolution pQCT 
(HRpQCT) are 3-dimensional densitometric techniques that can measure 
volumetric bone mineral density, distinguish trabecular from cortical 
components of bone, and determine bone geometry.  
As previously discussed, there are significant differences in the 




of cortical bone compared to the highly vascular trabecular bone. Tibial 
pQCT and DXA bone Z-scores have been found to be positively correlated, 
with gains in DXA bone mineral content associated with gains in trabecular 
volumetric BMD Z-scores [40]. HR pQCT has spatial resolution to measure 
trabecular geometry and microarchitecture, however is expensive, can only 
be used to study the peripheral skeleton (tibia, radius) and is currently only 
used for research purposes due to a lack of standard protocols and 
normative data.  
1.2.3 Vertebral fracture detection 
Vertebral fractures (VFs) are a significant marker of bone fragility but may 
often go unrecognised, and it is estimated that one third of VFs are 
asymptomatic [41, 42]. Methods of accurate detection of VFs are essential, 
particularly as it is recognised that fractures are not always associated with 
reduced bone mineral density as measured by DXA [43]. VFs have 
historically been assessed by use of lateral spine radiographs, but more 
recently lateral spine DXA has been shown to be of comparable image 
quality and diagnostic accuracy [44-46]. Therefore increasing interest has 
been shown in the use of this imaging modality, due to the significantly 
reduced radiation exposure to patients, high patient acceptability and 
availability at the same time as a DXA scan [44].   
Among diagnostic protocols to diagnose VFs, the method proposed by 
Genant is currently one of the most commonly used in clinical practice, with 
severity of VFs assessed in a semi-quantitative fashion [47]. The fracture is 
assessed by visual determination of the extent of vertebral height reduction 
and morphological change, and vertebral fractures are differentiated from 
other non-fracture deformities. A normal vertebral body is graded 0, a grade 
1 deformity is a mild deformity, with moderate and severe deformities 
classified as grades 2 and 3 respectively. The approximate degree of height 
reduction determines the assignment of grades to each vertebra. A grade 1 
deformity is defined as a 20-25% reduction in anterior, middle and/or 
posterior height and a reduction in area of 10-20%, with a 25-40% reduction 
in height in grade 2 fractures, and a 40% reduction in height in grade 3 
fractures. Other classification systems, such as the algorithm based 
qualitative (ABQ) technique have been developed [48], with a simplified ABQ 
technique described to classify vertebrae as normal, fractured with <25% 
height loss, fractured with >25% height loss or non-osteoporotic deformity 




specialists found that they were most likely to initiate treatment in patients 
with VFs with a height loss of 25% or more, in the presence of pain [49].  
1.3 Osteonecrosis and the role of glucocorticoids 
Osteonecrosis is bone death secondary to ischaemia, with all cell types 
(osteocytes, haematopoietic cells and adipocytes) in the bone and marrow 
affected.  
The nutrient and periosteal blood supply to bone have been described. The 
nutrient blood supply delivers blood to the medullary cavity and inner half of 
the cortex, whilst the periosteal blood supply provides vascular support to 
the external half of the cortex. Both systems provide the most blood to the 
metaphyseal regions- the growth regions of the bones in children. If either or 
both systems become impaired the bone will become osteonecrotic. In 
young children the central portion of the bone, supplied by the medullary 
blood supply, is occupied by marrow cells (such as polymorphonucleocytes, 
lymphocytes and monocytes) but in older patients the majority of the cells 
are lipocytes.  
There are a number of known risk factors for ON, but the pathogenesis is 
incompletely understood as ON is often diagnosed late with no readily 
accessible bone tissue to sample. However, it is recognised that the earliest 
pathological characteristics of ON are necrosis of haematopoietic cells and 
adipocytes, followed by interstitial marrow oedema [50]. In animal models 
there is osteocyte necrosis after 2-3 hours of oxygen deprivation [51], which 
is followed by a reactive hyperaemia and revascularisation. This results in 
bone remodelling that incompletely replaces the areas of bone loss, with 
bone resorption exceeding formation [52-54]. When this occurs in 
subchondral trabecular bone there is a loss of structural integrity of the 
trabeculae, with an associated risk of subchondral fracture.  
The loss of vascularity to the subchondral microcirculation may be due to a 
number of different factors, including:  
 Mechanical vascular interruption (post traumatic) 
 Intraluminal obliteration (emboli and thrombosis) 
 Interosseous extravascular compression  
 Direct cytotoxic effects on bone marrow and bone cells.  
Mechanical interruption of the blood supply may result from a fracture of the 




interruption is most common in regions with a blood supply that can easily 
be completely or partially interrupted by injury, such as in the femoral head.   
Intraluminal obliteration may result from a number of different mechanisms. 
Interosseous fat emboli with intravascular coagulation and ON has been 
described [55], with an overload of subchondral fat emboli, 
hypercoagulability, stasis and endothelial damage by free fatty acids 
hypothesised to cause end organ damage. Glucocorticoids causing 
dyslipidaemia may promote the formation of fat emboli, although fat emboli 
are also found in healthy bones which do not go on to develop 
osteonecrosis. The role of hypercoagulability is unclear. Some studies have 
shown procoagulant abnormalities in patients with ON [56], and 
thrombophilia-hypofibrinolysis may be a risk factor for development of 
idiopathic ON [57].  
Extraluminal obliteration of blood flow in the intraosseous blood vessels may 
occur when blood pressure increases within the bone marrow. Lipid 
deposition and adipocyte hypertrophy are the most likely causes of 
increases in intraosseous extravascular pressure. Patients with femoral 
head ON were found to have significantly elevated bone marrow pressures, 
even before necrosis was detectable [58, 59]. In one animal study it was 
found that glucocorticoid administration resulted in increased adipocyte size 
in the bone marrow [60], with a proportionate decrease in intraosseous blood 
flow, and MRI studies have shown that fat conversion in the marrow occurs 
in the proximal femur of steroid treated patients, with higher conversion in 
patients with ischaemic bone lesions [61]. However, elevated intraosseous 
pressures can be found in other conditions, such as osteoarthritis, which 
does not lead to development of ON, and it may be that the observed 
elevations in intraosseous pressure are not causally related to the 
pathogenesis of ON [62].  
Direct cell toxicity can also contribute to the development of ON. Increased 
osteocyte apoptosis and inhibition of osteoblastogenesis in patients with ON 
related to glucocorticoid therapy has been suggested in a number of studies 
[63-65], and reduced replication of osteoblasts may also play a role in 
glucocorticoid induced ON [66]. Murine models found that mice treated with 
asparaginase (ASP) treatment alongside dexamethasone had a higher rate 
of ON than those receiving only dexamethasone after 6 weeks of treatment, 
with higher rates of epiphyseal arteriopathy observed in mice with dual 




plasma exposure to dexamethasone, hence this study suggests that ASP 
could potentiate any osteonecrotic effect of glucocorticoids [67].  
It is clear that glucocorticoids can influence the development of ON in a 
number of different ways, and Figure 4 illustrates a proposed 
















1.4 Glucocorticoids and bone fragility 
The potential role of glucocorticoids in the development of ON has been 
described, however, glucocorticoids at physiological concentrations are 
essential for the development of a wide range of tissues. Differentiation of 
osteoblasts is driven by endogenous glucocorticoids, and glucocorticoid 
signalling in mature osteoblasts controls skeletal development [68]. 
However, when exogenous glucocorticoids are administered at 
pharmacological doses patients can experience bone loss of up to 12% 
during the first year of therapy [69], resulting in increased bone fragility. 
Trabecular bone is typically more affected than cortical sites, making spine 
and rib fractures more common than hip and non-vertebral fractures [70, 71]. 


















Figure 4. Proposed pathophysiology for development of 




partially attributed to the reduction in bone mineral density, with patients with 
similar BMD but no glucocorticoid use suffering significantly fewer fractures 
[72, 73]. This suggests an impact of glucocorticoids on bone quality as well 
as density. It is important to note that following cessation of glucocorticoid 
therapy, the fracture risk gradually declines, and returns to background 
levels within a few years [71]. 
Glucocorticoids have both direct and indirect pathways contributing to bone 
loss, with glucocorticoids causing a reduction in intestinal calcium 
absorption, an increase in renal calcium clearance, and suppression of 
growth hormone and sex hormones (testosterone and oestrogen) [74].  All of 
these factors may result in increases in bone loss and interfere with bone 
metabolism, with an attenuation of linear growth removing the impetus for 
bone strength to be increased via the link to periosteal apposition. However, 
the main mechanisms by which glucocorticoids impact upon bone health is 
likely to be by their direct action on bone cells.  
Pharmacological doses of glucocorticoids inhibits osteoblast differentiation 
and function, and also induces osteoblast apoptosis [75-77]. This results in a 
profound suppression of bone formation. High concentrations of 
glucocorticoids result in a down regulation of signalling pathways that 
promote osteoblastogenesis, namely Wnt/ ß-catenin [78] and bone 
morphogenic protein-2 (BMP-2) signalling [79], and increases pro-apoptotic 
factors of the Bcl-2 family [76, 77]. Animal studies have also suggested that 
in the presence of excess glucocorticoids there is also an increase in 
expression of transcription factors that are crucial for adipocyte 
differentiation, resulting in increasing mesenchymal stem cell commitment to 
the adipocyte lineage, rather than differentiation into osteoblasts [79]. A 
reduction in osteoblastogenesis also results in a loss of osteoblast-
generated proteins, such as collagen and osteocalcin [79], which further 
reduces bone integrity.  
Excess glucocorticoids also impact upon osteocytes and osteoclasts. It has 
been described that osteocytes are the terminal differentiation product of 
osteoblasts, and are located in the lacunar-canalicular network of 
mineralised bone [80]. This is a fluid-storage system and also contains a 
vascular network allowing communication and nutritional support to the 
enclosed osteocyte population. In murine models high concentrations of 
glucocorticoids result in a reduction of intra-osseous vasculature and a 
reduction in solute transport from the circulation to the lacunar-canalicular 




bone fragility. The osteocyte network acts as a mechanosensor which 
maintains bone integrity by recruiting osteoclasts and osteoblasts as 
appropriate to sites of active bone remodelling in response to mechanical 
stimulation [82]. In vivo models have shown an increase in osteocyte 
autophagy in situations of glucocorticoid excess [83, 84]. This can result in 
an accumulation of autophagasomes which create a toxic environment for 
osteocytes [84]. Glucocorticoids also increase osteocyte apoptosis, which 
has been linked to activation of proapoptotic factors Pyk2 and JNK [85].   
Osteoclasts are bone resorbing cells derived from the monocyte-
macrophage lineage. A study of glucocorticoid treatment in patients with 
multiple sclerosis reported an initial increase in osteoclast activity and 
number [86]. However, with prolonged use of glucocorticoids there was a 
suppression in the proliferation of osteoclast precursors, as well as a block in 
osteoclast function [87].  
It is clear that prolonged glucocorticoid use appears to have a role in 
ultimately suppressing both osteoclastic and osteoblastic function, with an 
overall reduction in bone turnover. Bone remodelling is crucial in removing 
ineffectual tissue and replacing it with new material. Disruption of this 
process is likely to be a cause of the poor bone quality experienced by 
patients receiving these drugs.  
1.5 Background of current UK treatment for acute 
lymphoblastic leukaemia  
The first case of leukaemia diagnosed by microscopic examination was 
described by Henry Fuller in 1850, but at that time the condition was 
universally fatal. In 1948 ‘temporary remission’ induced by aminopterin, a 
folic acid antagonist, was described in 5 children with acute leukaemia [88], 
beginning the era of chemotherapy for ALL. In the past 60 years there has 
been significant progress in the treatment of childhood leukaemia, 
predominantly through increasing intensification, use of combination 
chemotherapy and a prolonged maintenance phase of chemotherapy. 
Outcomes for patients diagnosed with ALL have improved dramatically due 
to well-designed sequential clinical trials.  
In the USA in 1961 a complete remission rate of 59% and a 2 year survival 
of 20% was described in 39 patients for whom a combination of 
mercaptopurine and methotrexate was used [89]. However, for the majority 




component therapeutic approach for patients at St Jude’s Hospital, USA in 
1962 [90]. Since 1970 the UK Medical Research Council Working Party on 
Childhood Leukaemia has conducted a series of therapeutic trials for ALL 
and has shown a stepwise improvement in prognosis for children with ALL, 
from a 5 year Event Free Survival (EFS) of 35% in 1972 to 87% in 2010. 
Results of the early trials highlighted the importance of uninterrupted 
therapy, and sustained exposure to maximum tolerated doses of therapy 
[91, 92]. The most significant prognostic factors were found to be age, 
leukocyte count, gender [93], genetic factors and response to initial therapy, 
with routine fluorescence in situ hybridization (FISH) screening for high risk 
genetic abnormalities and risk stratification introduced in 1997 [91, 94].  
In ALL 97 and ALL 97/99 there was randomisation of the efficacy of 
dexamethasone 6.5mg/m2 for 28 days and prednisolone 40mg/m2 for 28 
days and for 5 days in monthly pulses during maintenance. It was found that 
there was a major improvement in central nervous system (CNS) relapse 
rate in ALL 97/99, with the rates nearly halved for both standard and high-
risk patients (from 7% to 4%). This was regardless of type of steroid, but the 
best results were in patients who were randomised to dexamethasone, in 
whom the actuarial isolated CNS relapse rate was only 1.8% at 5 years, 
compared to 3.7% in those randomised to prednisolone [91].   
By 2002 there was recognition that analysis of minimal residual disease 
(MRD) was the strongest predictor of outcome in children undergoing 
therapy [95], and in October 2003 UKALL 2003 opened. The results from 
UKALL 2003 provided further evidence of the benefit of treatment 
intensification to patients defined as high risk by MRD measured at day 29 of 
induction [96]. UKALL 2003 also included a randomised treatment change 
based on MRD at day 29, with low risk patients (undetectable MRD at the 
end of induction/week 11) randomly assigned to 1 or 2 courses of delayed 
intensification (DI). There was found to be no significant difference in EFS 
between the groups, with a reduction in relapse risk resulting in a 5 year 
EFS of 87%, with an overall survival of 91% [96]. 
1.6 Current treatment for acute lymphoblastic leukaemia 
With the significant improvement in survival after treatment for ALL, there 
has been an increasing focus on reducing the toxicity of treatment. The 
majority of young people diagnosed with ALL or LBL between 26/04/2012 




(ISRCTN64515327, Eudract 2010-020924-22). UKALL 2011 [97] was 
designed to improve survival and quality of survival by addressing: 
 treatment related mortality and morbidity 
 poor prognosis of CNS relapse 
 poor prognosis of very early marrow relapse 
 superior outcomes seen for young adults treated on paediatric protocols 
The aim was to define whether further refinement of MRD based risk 
stratification and treatment regimen improves survival whilst reducing overall 
burden of therapy in children and young adults (age 1 to 24 years and 364 
days) diagnosed with ALL or LBL (T-cell non-Hodgkin’s Lymphoma (NHL) or 
Smlg-ve precursor B-NHL).  
At the time of diagnosis patients with B cell precursor ALL (BCP ALL) are 
stratified into standard or high risk using the National Cancer Institute (NCI) 
risk stratification approach. Standard risk therapy is used for patients who 
are aged ≥1 year and < 10 years old at diagnosis and with a highest white 
cell count (WCC) before starting treatment of <50 x 109/L. Patients in this 
group receive a 3-drug induction, known as Regimen A. Patients aged ≥ 10 
years at diagnosis and/ or with a diagnostic WCC of ≥50 x 109/L receive a 4-
drug induction, known as Regimen B. All patients with T cell ALL, or either B 
cell or T cell LBL, receive Regimen B induction, as do patients who have 
known high risk cytogenetics at the start of treatment. All patients with Down 
syndrome receive Regimen A induction. If patients have CNS disease at 
diagnosis they receive additional weekly intrathecal methotrexate until 2 
consecutive clear samples of cerebrospinal fluid (CSF) are obtained. If CSF 
is clear by day 29 they continue with NCI and MRD directed therapy. If there 
is persistence of CNS disease the patient transfers to Regimen C with MRD 
measured at week 14. Those that remain at high risk were taken off protocol, 
as were patients who fail to respond adequately to induction therapy (≥25% 
of blasts at day 29 or T-ALL with MRD >10%).  
As the focus of the latter parts of this dissertation is on the therapy and bone 
toxicity for patients over the age of 10 years at diagnosis of ALL or LBL, the 
emphasis will now be on this group of patients. Figure 5 illustrates the 
chemotherapy regimen for these patients.  
Post induction treatment for patients over the age of 10 years is determined 
by MRD in ALL patients, or tumour volume assessment in patients with 
lymphoblastic lymphoma. Patients with no MRD results are assessed by 




There were originally 2 randomisations within UKALL2011, the first in 
induction and the second in maintenance.  The objective of the first 
randomisation was to reduce toxicity through the introduction of a short (14 
day) course of high dose (10mg/m2/day) dexamethasone, rather than the 
standard 28 days of 6m/m2/day. The primary outcome measure of this 
randomisation was steroid induced morbidity and mortality, defined as all 
serious adverse events and grade 3 or 4 adverse events related to induction 
and categorised as steroid related or steroid contributory (including ON). The 
first randomisation was closed in March 2017 following an interim review of 
data with a formal futility analysis by the independent Data Monitoring 
Committee. This confirmed no clear benefit in administering a short course 
of dexamethasone in reducing adverse events, compared with adverse 
events experienced on standard dexamethasone.  
The second randomisation was at the start of interim maintenance and 
investigated the effect on CNS relapse and quality of life in patients receiving 
either high dose methotrexate without prolonged intrathecal therapy or the 
current standard UK CNS-directed ALL therapy with protracted intrathecal 
therapy. It also aimed to assess the effect on bone marrow relapse risk and 
quality of life in patients receiving monthly pulses of vincristine and 
dexamethasone in maintenance therapy. The methotrexate and pulses 
randomisation had a factorial design, with patients being randomised to 
receive either high dose methotrexate or standard interim maintenance 
followed by a single DI and either maintenance with pulses or without pulses 
of vincristine and dexamethasone. If a patient was randomised to high dose 
methotrexate therapy, they will have subsequent intrathecal methotrexate in 
maintenance, but could be randomised to either pulses or no pulses. If they 
were randomised to either standard or Capizzi interim maintenance they 
were randomised to maintenance therapy with or without pulses, and all 
patients received intrathecal methotrexate.  
Following the results of previous studies, all patients in UKALL2011 are 
given a single block of DI, and augmented therapy is limited to those who 
are not MRD low risk.  
Treatment lasts 2 years from the start of interim maintenance for female 
patients, and 3 years from the start of interim maintenance for male patients.  
Details of all chemotherapeutic agents are provided in Appendix 1.  
It should be noted that for patients who have a BMI >98th percentile the 




children with a BMI <2nd percentile medication doses are calculated as for a 
patient with a weight at the 2nd percentile. There is also capping of doses for 
dexamethasone and vincristine as described in Appendix 1.  
Patients who did not consent to participate in UKALL2011, or who were 
diagnosed after the trial closed (December 2018), receive the same 
treatment as those on the trial. At the point of randomisation they receive 
standard interim or Capizzi interim maintenance, depending on their risk 
stratification. At the next randomisation point they receive maintenance 





Figure 5. UKALL 2011 trial schema for patients over 10 years of age 
 
MRD: Minimal residual disease    BFM: Berlin-Frankfurt-Munich  




1.7 Glucocorticoid therapy in acute lymphoblastic leukaemia 
Steroids have been used in the treatment of ALL in some studies since the 
1970s, and both prednisolone and dexamethasone have been shown to be 
effective in improving outcome as a component of therapy [98]. However, 
the balance between efficacy and toxicity is critical, and numerous studies 
have looked at this relationship.  
The CCG-1922 study randomised NCI standard risk patients to prednisolone 
versus dexamethasone during all phases of therapy except DI [99], and 
found a significant improvement in EFS for patients randomised to 
dexamethasone, with significantly lower CNS relapse. The UK Medical 
Research Council (MRC) ALL-97/99 study, open to standard and high risk 
patients, also randomised patients to dexamethasone (6.5mg/m2) or 
prednisolone (40mg/m2) except during DI, and also found an improved EFS, 
as well as improved risk of relapse in the dexamethasone group [100].  
In contrast to these studies, where substitution of dexamethasone for 
prednisolone was at a ratio of 1:6, the use of higher relative doses of 
prednisolone (1:7.5 or 1:10) was found to negate the impact of 
dexamethasone on relapse [101, 102].  
As dexamethasone became more commonly used, concerns about 
increases in treatment related mortality also increased. In the MRC ALL-
97/99 study [100] major steroid related toxicities included behavioural 
problems, myopathy, osteopenia, weight gain and liver enlargement. There 
was a higher incidence of toxicities in the dexamethasone rather than the 
prednisolone group, and this was also seen in the AIEOP-BFM ALL-2000 
trial [103], particularly in patients over 10 years of age. In the DFCI 91-01 
study, which randomised between dexamethasone and prednisolone after 
induction therapy, significantly more patients receiving dexamethasone had 
infections compared to those receiving prednisolone, but with no difference 
in remission death rates between steroid groups [104].  
There were specific concerns about an increased risk of ON in patients 
treated with dexamethasone, but there are conflicting results between 
centres [100, 105-107], and this will be covered in more detail in the 
literature review. The differences between centres may be due to differences 
in ascertainment, as well as the different patient populations and 
environments. Phase of exposure, and continuous versus split dosing of 




challenges in understanding ON in patients with ALL, as ALL has the highest 
incidence in infants aged 1-4 years, and incidence drops sharply through 
childhood and adolescence. As ON predominantly affects older children and 
adolescents, who are less commonly diagnosed with ALL, side effects of 
treatment in this population are more challenging to identify and understand.  
Although the clinical benefits of therapeutic glucocorticoids can hardly be 
overestimated, unwanted effects, such as a reduction in bone health [108] 




Chapter 2 Literature review 
This literature review consists of 3 main parts. The first part reviews the 
medical literature around the development of ON in young people with ALL. 
The second part of the chapter reviews the medical literature around BMD 
and fracture risk of young people with ALL. The final part reviews potential 
therapeutic interventions. For the purpose of this thesis, the focus is on the 
use of bisphosphonates for the management of ON in young people with 
ALL, and the role of vitamin D supplementation. 
2.1 Osteonecrosis in young people with acute lymphoblastic 
leukaemia  
2.1.1 Research questions 
Within this review I aim to cover the following questions: 
1. What is the prevalence and incidence of ON in children and young adults 
being treated for ALL at different time points in their treatment? 
2. What are the current classification systems for ON? 
3.  What is the natural history of ON in young patients with ALL?  
4. What are the risk factors for development and progression of ON in this 
population? 
2.1.2 Search strategies 
The literature identified within this review was achieved by a search using 
the following databases to identify original published studies: Medline 1946-
2015, Embase 1996-2015, EBM databases, Journals @Ovid, Books@Ovid. 
In addition, I searched the reference lists of relevant studies.  
There were no MeSH headings for ‘osteonecrosis’, ‘avascular necrosis’ or 
‘aseptic necrosis’, so these were searched as keywords. Results were 
combined with AND ‘leukaemia’ as a MeSH term.  
Duplicate references were manually removed and eligibility judgements were 
made on the basis of relevant clinical or disease information found in the 
article abstract and full article when appropriate.   
Further searches included the terms ‘steroids’ or ‘glucocorticoids’ or 
‘dexamethasone’ or ‘prednisone’ or ‘prednisolone’ AND ‘leukaemia’, but no 




My initial search had a yield of 185 articles. Of these, 40 articles or abstracts 
were found to be relevant to my study questions. During the research period 
weekly reports from Ovid and Embase with any of the above terms in the 
abstract, title or as a keyword were reviewed and added, and was last 
updated in May 2019.  
A summary of relevant studies are presented in tabulated format. 
Retrospective studies are presented in Table 1, prospective studies in Table 




Table 1. Retrospective studies reporting prevalence and risk factors for symptomatic osteonecrosis in children and young 
adults with acute lymphoblastic leukaemia 
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Table 2. Prospective studies reporting prevalence and risk factors for symptomatic osteonecrosis in children and young 
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Table 3. Main studies assessing genetic risk factors for development of osteonecrosis in children and young adults with 
acute lymphoblastic leukaemia 
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2.1.3 Prevalence and incidence of osteonecrosis in children and 
young adults being treated for acute lymphoblastic 
leukaemia at different time points in their treatment 
It is important to recognise from the outset that amongst the studies there is 
significant variation in reporting of ON, with a range of methods used for 
diagnosis of ON and potentially varying indices of suspicion. When 
assessing prevalence and incidence of ON, the majority of studies provide 
results for prevalence, but provide insufficient information about follow up 
time to allow an incidence rate to be calculated. Only a few studies provide 
results for cumulative incidence of ON, which gives additional information 
about timing of lesions. From Tables 1-3 it can be seen that the reported 
prevalence and cumulative incidence of ON in patients treated for ALL varies 
considerably, depending on study type, patient population and method used 
for diagnosis of ON.   
The cumulative incidence of ON is unsurprisingly much lower in 
retrospective studies compared with prospective studies, with 5 year 
cumulative incidence ranging from 1-15% in retrospective reports [109, 111, 
112, 115, 123, 148, 149], compared with a cumulative incidence of up to 
53.9% in prospective studies where asymptomatic lesions are also reported 
[132]. The cumulative incidence of ON is higher in studies evaluating only 
high risk patients [105, 119, 134], and higher rates of symptomatic ON have 
been consistently reported in patients over 10 years of age at diagnosis of 
ALL [95, 119, 150]. In one retrospective study of high risk patients reported 
by Mattano et al, the 3 year cumulative incidence for symptomatic ON was 
9.3%, which rose to 18% when only those aged 16-20 years were assessed 
[119].  
A lower incidence of ON was reported in older studies with no planned 
reporting of ON [116]. This may be due to reduced clinician awareness of 
ON, combined with less steroid intensive therapeutic regimens. In the 
retrospective studies assessed there was considerable variability in method 
of diagnosing ON. Some studies based the diagnosis on symptom report, 
whilst others required imaging, using either plain X-Rays, CT, MRI or 
Technetium-99m bone scans. When retrospective questionnaires were used 
there is likely to be under-reporting of ON as only the more severe cases 
may be recalled, particularly if there is a significant delay between treatment 
and survey. 
Prospective studies with MRI screening are more reliable in the reporting of 




In the largest study with prospective MRI screening to assess both 
symptomatic and asymptomatic ON of the hip, the cumulative incidence of 
ON involving at least one hip was 17.1% after 1 year, and 21.7% after 
completion of therapy (4 years) [131]. By the end of therapy, extensive 
femoral head ON affecting ≥30% of the epiphyseal surface had developed in 
6.5% of all patients, and in 24% of those aged over 10 years [131]. An 
earlier report of this study by the St Jude Children’s Research Hospital 
describes results of MRI screening in both hips and knees [132]. They found 
that at one year of therapy, the cumulative incidence for symptomatic ON 
was 14.6%, with an incidence of 35.4% for grade 1 ON (asymptomatic ON). 
At the end of therapy the cumulative incidence for symptomatic ON was 
17.6%, with a cumulative incidence of 53.9% for asymptomatic ON [132]. 
Interestingly, when the same protocol was used for an Egyptian population, 
with prospective MRI screening at the same time points the reported 5 year 
cumulative incidence of symptomatic and asymptomatic ON was only 12%, 
with 38% of those asymptomatic [129]. However, this report was less 
comprehensive, with no information about median length of follow up or 
incidence of ON at each screening visit.  
When assessing the timing of development of ON lesions, study results 
suggest that the majority of patients who develop symptomatic ON do so 
within the first 3 years of treatment [109-111, 115, 119, 127, 150], although a 
number of these studies had a relatively short follow up period, potentially 
missing patients who later developed ON. A large prospective study 
assessing symptomatic ON, with a median follow up of 7.8 years, found that 
only 3% of patients who developed symptomatic ON did so after the 3rd year 
after diagnosis of ALL, with no patients developing ON after the 4th year 
[134]. This study found 41% of patients who developed symptomatic ON did 
so within the first year of diagnosis, with 47% developing it in the 2nd year. 
Cross sectional studies suggest that in ALL ON often resolves 5 years after 
cessation of therapy, with the prevalence of asymptomatic ON falling from 
32% at the end of treatment to 8% 5 years after cessation of therapy [137, 
138]. The prevalence of symptomatic ON also fell, from 14% to 0%, although 
conclusions drawn from these studies must be limited by consideration of 
study size [137, 138].  
For asymptomatic ON, the prospective studies suggest that the bone lesions 
develop early in the course of ALL therapy, with 38.7% of patients having 




A recent study with early MRI screening for ON performed screening MRI 
scans at a median of 12.5 days (range 1-70 days) after ALL/LBL diagnosis 
[151]. It was found that of the 76 patients, 7 (9.2%) presented with an 
osteonecrotic lesion, with an average of 2 joints/patient affected. Of note, 
this study found that leukaemic infiltration of bone at diagnosis was not 
associated with osteonecrotic lesions [151].  
In applying these results when considering management strategies for 
patients it is important to recognise that the majority of studies were not 
based in the UK. The population demographics and differences in treatment 
protocols may therefore make the results of these studies less applicable to 
our patient population.  
The only UK study with prospective MRI screening was a pilot study, with 
results presented in an abstract [152]. This identified features of ON in 62% 
of patients when they had an MRI scan of hips, knees and pelvis at the start 
of maintenance chemotherapy [152]. This study looked only at patients over 
9 years of age, and hence the prevalence is higher than would be expected 
if all paediatric patients with ALL were to be screened. Prior to the analysis 
described in this thesis, the largest retrospective UK study found a 
prevalence of symptomatic ON of 4% [128] but there was no information 
about how or when ON was diagnosed. 
2.1.4 Current classification systems for osteonecrosis 
Any classification system of musculoskeletal conditions should be 
consistent, logical, reproducible, all-inclusive, sensitive and clinically useful. 
It should organise and categorise a problem to guide decision making, and 
should stratify the natural progression or resolution of disease process [153]. 
A successful classification system should also be both reliable and valid. 
Reliability reflects the precision of a classification system, indicated by inter-
observer reliability. Validity reflects the accuracy with which the classification 
system describes the true pathological process. To quantify validity the 
classification system must be compared with a gold standard, which is often 
difficult to establish due to observer bias [153]. Because of the difficulties 
with establishing validity, it is crucial that classification systems have a high 
degree of reliability. The kappa value is a measure to assess agreement 
between observers occurring above and beyond chance alone [154], and is 
the most accepted method of measuring observer agreement for categorical 





Most classification systems for ON are joint specific, and few have been 
validated for children and young people with ALL. The most common joints 
affected by ON in children and young people with ALL are hips, knees and 
ankles [155], but ON in other joints is also well recognised. Most widely used 
classification systems were developed for adults with ON affecting the 
femoral head, and there is no universally accepted classification method for 
assessing severity and prognosticating about the condition.  
One of the first classification systems for ON of the femoral head, before the 
advent of routine clinical MR imaging, was described by Ficat and Arlet 
[156]. Subsequent modifications allowed inclusion of symptoms and MRI 
findings. The modified Ficat and Arlet classification system is currently the 
most commonly used classification system for ON of the femoral head in the 
literature [157] and most surgeons use the four-tiered method (Table 4).  
Table 4. Modified classification system of Ficat and Arlet 
 
There are a number of limitations to this model of classification. The original 
classification system did not use MRI, and required invasive techniques such 
as core decompression. Further modifications amended these issues, but 
when the modified classification system was assessed to determine inter 
and intra-observer reliability it was found that the mean inter-observer kappa 
reliability coefficient was only 0.46 with a mean kappa value of intra-observer 
reproducibility of 0.59 [158], indicating a lack of reliability. The other major 
limitation is that the system did not allow quantification of size of lesion, 
making subtle degrees of progression difficult to assess.  
The second most commonly used classification system for ON of the femoral 
head is the University of Pennsylvania staging system [159], and this was 
the first major classification system to incorporate size of lesion. It is 
described in Table 5 and this classification system defines 7 stages using 
radiographs or MRI to stratify lesion size.  
 
 
Stage Radiographic findings 
1 None (only evidence of ON on MR images) 
2 Diffuse sclerosis, cysts (visualised on radiographs) 
3 Subchondral fracture (crescent sign; with or without head collapse) 





Table 5. Classification system of the University of Pennsylvania 
 
One study assessed the classification system of the University of 
Pennsylvania to determine inter and intra-observer reliability [160]. Sixty five 
hip radiographs with confirmed ON were reviewed by 6 clinicians, including 
surgeons and radiologists. Stage specific kappa values for inter-observer 
variation were lowest for stage 3 (kappa value 0.21) and highest for stage 6 
(kappa value 0.80). For intra-observer variation, kappa values were lowest 
for stage 5 (kappa value 0.27) and highest for stage 6 (0.78). 
The presence of the crescent sign in stage 3 and joint space narrowing in 
stage 5 markedly diminished the overall reliability of the classification 
system, with 30% of intra-observer errors involving stage 3. Intra-observer 
kappa values for stage 3 and 4 were 0.46 and 0.59 respectively.  
Stage Radiographic findings 
0 Normal radiograph, bone scan and MR images 
1 Normal radiograph. Abnormal bone scan/MR images. Subcategories: 
A: Mild (<15% of femoral head affected) 
B: Moderate (15-30% of femoral head affected) 
C: Severe (>30% of femoral head affected) 
2 Cystic and sclerotic changes in femoral head 
A: Mild (<15% of femoral head affected) 
B: Moderate (15-30% of femoral head affected 
C: Severe (>30% of femoral head affected) 
3 Flattening of femoral head 
A: Mild (<15% of articular surface) 
B: Moderate (15-30% of articular surface) 
C: Severe (>30% of articular surface) 
4 Flattening of femoral head 
A: Mild (<15% of surface and <2mm of depression) 
B: Moderate (15-30% of surface or 2-4mm of depression) 
C: Severe (>30% of surface or >4mm of depression) 
5 Joint narrowing or acetabular changes 
Grade average of femoral head involvement, as determined in stage 4, and estimated 








A further attempt to develop a classification system for ON of the femoral 
head occurred after a meeting of the Association Research Circulation 
Osseous (ARCO) in 1991 [161]. The system is based on the University of 
Pennsylvania staging system and is the third most commonly used 
classification system [157]. The ARCO system that is most commonly used 
is described in Table 6.  






























Surface collapse and dome 
depression:  
A: <15% and <2mm 
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As stage 1 As stage 1 
3 Crescent sign 
and/or flattening 
of articular surface 





Radiographs only n/a n/a 
 
An additional classification system was developed by the Japanese 
Orthopaedic Association, which included location of lesion to aid 




Table 7. Japanese Investigation Committee classification 
Stage Radiographic findings 
Type 1A Demarcation line appears in the femoral head 
The outer end of the demarcation line is located at the medial one third of the 
weight-bearing surface 
Type 1 B The outer end of demarcation line is located at the middle one third of the 
weight-bearing surface 
Type 1C The outer end of demarcation line is located at the lateral one third or more of 
the weight-bearing surface 
Type 2 Shows early flattening of the weight-bearing surface, but does not reveal 
demarcation line 
Type 3 Has cystic radiolucent lesion without demarcation line 
surface 
 
This system was the basis of the MRI classification system by Sugano et al 
categorising necrotic lesions into Types A-C.  Classification of the lesions is 
based on location as demarcated by a low intensity band on the central 
coronal plane of T1 weighted image [163]. Type A lesions occupy the medial 
one third or less of the weight bearing portion, Type B the medial two thirds 
or less and Type C greater than two thirds of the weight bearing portion. This 
simple classification system aimed to aid prognostication, with hips with type 
C lesions having a higher incidence of progression to collapse. However 
these systems assume lesions start medially and extend and there is no 
method of classifying lesions in which the acetabulum has become involved. 
The importance of MR imaging was described in an article correlating MR 
results with radiographs [164]. MR images can distinctly demarcate 
ischaemic bone from normal bone within the femoral head. It was found that 
the agreement between plain radiographs and MR imaging was 80.6% for 
staging the disease, 71.2% for recording the location of the osteonecrotic 
lesion, 67.1% for evaluating the size of the lesion, 79.2% for the presence of 
collapse of the articular surface and 56.3% for the degree of collapse [164]. 
This highlights the value of MR imaging in the classification of ON, and 
indicates that the above classification systems could miss important 
information without MR imaging that could alter clinical management.  
One of the few classification systems specifically designed for children with 
leukaemia and lymphoma was described by investigators at St Jude 
Children’s Research Hospital (SJCRH), Memphis, USA, who developed a 
system specifically for diagnosis and grading of ON affecting the knee [165, 




Table 8. St Jude Children's Hospital categorisation for osteonecrosis 
Category Radiographic findings 
1 osteonecrotic lesion absent 
2 osteonecrotic lesion present but not extending to the articular surface 
3 osteonecrotic lesion involving less than 25% of the articular surface 
4 osteonecrotic lesion involving more than 50% of the articular surface 
5 osteonecrotic lesion involving more than 50% of the articular surface 
 
This categorisation system was developed specifically for use with MRI, and 
had a kappa value of 0.66 (CI 0.58-0.75) in locations where observers only 
had to record presence or absence of a lesion, and a weighted kappa value 
of 0.65 (CI 0.59-0.72) where extent of the lesion needed to be specified. 
Intra-observer agreement was also high, with weighted kappa values of 0.65 
and 0.8 for presence of osteonecrotic lesions in the epiphysis. The presence 
of marrow oedema, punctate foci of altered signal, and mottled marrow 
changes were associated with a higher level of disagreement between 
observers.  This study was conducted with two observers for validation of 
the proposed classification system, with review of only 36 imaging studies. 
Both observers were very familiar with ON of the knee, and their familiarity 
may have contributed to the high levels of agreement in categorising lesions. 
The most recent categorisation system by developed by Niinimäki  et al 
aimed to validate a MRI based radiological classification system which was 
suitable for any joint or bone, and in all patients with cancer [167]  (Figure 6). 
In cases with multiple areas of ON, the grade is based on the most severe 
lesion. This classification system takes into account the mechanical 
properties of the bone, location of the lesion, and involvement of the articular 
surface. It was validated by assessment of MRI scans of 36 patients with ON 
(median age 27.5 years). Four independent observers reviewed the total of 
72 MRI images. Inter-observer agreement for location of ON was determined 
to be very good, with kappa values from 0.93-0.98. Intra-observer 
agreement for classification of ON was good or very good, with kappa values 
from 0.79-0.86. Inter-observer agreement for classification of ON was lower, 
but still good, with kappa values from 0.62-0.77.  
The validation of this classification system has a number of weaknesses. 
Only a total of 72 MRI scans from 36 patients were assessed, and all 
patients were likely to have been symptomatic, limiting assessment of 
asymptomatic lesions. This article also did not assess clinical prognostic 




years, and whilst the youngest patient assessed was 11 years of age, the 
majority of patients were adult patients. Only 16 of the patients had ALL, and 
of those only 13 were under 24 years of age. However, this appears to be 
the system that fulfils the greatest number of criteria initially described for a 
clinically useful classification system in our patient population and further 
validation of this would be of value. 
Figure 6. Niinimäki osteonecrosis classification system 
 
                             Weight bearing bones:                                    Non-weight bearing bones: 
                      Long bone                        Short bone                               Long bone                Short bone 
Grade     
0 No ON No ON No ON No ON 
1   Diaphysis or metaphysis 
(0%) 
Body (0%) 
2 Diaphysis or metaphysis 
(0%) 
Body (0%) Epiphysis (<30%) Surface (<30%) 
3 Epiphysis (<30%) Surface (<30%) Epiphysis (≥30%) Surface (≥30%) 
4 Epiphysis (≥30%) Surface (≥30%)   
5 Deformation of joint Deformation of 
joint 
Deformation of joint Deformation of 
joint 
Area of articular involvement presented in brackets 
The lack of a consensus definition for the classification of ON in ALL has been 
recognised internationally, and the Delphi method has been used by the Ponte di 
Legno working group (which consisted of 15 international childhood ALL study 
groups) to develop a consensus definition that aims to allow reliable comparisons of 
frequency and severity of ON across treatment protocols [168]. 
This classification system, presented in table 9, combines both radiological and 
clinical features of ON, and states that the disorder should be confirmed by MRI.  
Table 9. Ponte di Legno consensus classification of osteonecrosis 
Grade Radiological and clinical features 
1 Asymptomatic, with findings only by MRI. 
2 Symptomatic, not limiting or only slightly limiting self-care activity of daily living. 
Lesions only outside joint lines in non-weight-bearing joints.  
3 Symptomatic, not limiting or only slightly limiting self-care activity of daily living. 
Lesions in weight-bearing bones or affecting joint lines in non-weight-bearing bones.  
4 Symptomatic with deformation by imaging of one or more joints and/or substantially 





2.1.5 The natural history of osteonecrosis in young patients with 
acute lymphoblastic leukaemia 
When assessing and managing a patient with ON, it is crucial to understand 
the natural history of both symptomatic and asymptomatic osteonecrotic 
lesions, as this will influence how patients are counselled and managed.  
2.1.5.1 Asymptomatic osteonecrosis  
In the prospective study by the SJCRH team looking at ON in children with 
ALL, it was found that patients who were diagnosed with asymptomatic ON 
at initial screening were more likely to develop symptomatic ON (26%, 
compared with 14% of patients who were initially negative for ON, p=0.008) 
[132]. Of the 141 patients identified in the initial screen as having 
asymptomatic ON, follow up scans were available for 130 patients. Of these 
patients, 14 (11%) had lesions that resolved, 82 (63%) maintained their 
grade and 34 (26%) had worsening of their ON to grade 2 and 4 [132]. In the 
comparable study based in Egypt, of the 25 patients who were 
asymptomatic, (of whom 24 patients had grade 1 ON), follow up MRI scans 
were available for 16 patients. In these patients there was progression of ON 
in 4 patients (25%), resolution in 1 patient (6%), and a stationary course in 
11 patients (69%) [129]. 
Another study by SJCRH retrospectively reviewed 109 patients with 
haematological malignancies who had routine MRI of knees, and confirmed 
ON [169]. In this study, reported by Karimova et al (2010), those who were 
asymptomatic at diagnosis of ON were less likely to have collapse and pain 
than those who were symptomatic (6% versus 37%) [169]. This study did not 
describe in detail the natural history of patients who were asymptomatic at 
first MRI.   
The OPAL trial (Osteonecrosis in Pediatric patients with Acute lymphoblastic 
Leukemia and Lymphoblastic Lymphoma) is an ongoing German trial using 
prospective MRI screening at diagnosis and after 6 months [133]. Of 76 
patients, 7 patients (9.2%) had asymptomatic ON at diagnosis, and at time 
of publication 5 had their follow up 6 month scan. All patients remained 
asymptomatic and in these 5 patients, the number of osteonecrotic lesions 
increased in one patient, decreased in 2 and remained constant in 2 others. 
At diagnosis, 5 of the 7 patients had grade 1 ON, and in 2 patients this 
increased to grade 2 (using the ARCO grading). One patient had grade 3 




2.1.5.2 Symptomatic osteonecrosis 
In a prospective study looking at long term outcomes of symptomatic ON, 
with a median follow up time of 4.9 years after diagnosis of ON, in 40% of 
cases symptoms resolved completely [141]. There were 24 patients who 
were available for analysis of radiological outcome, and in these patients 
25% had partially or completely reversible lesions, 54% showed stable 
lesions, and 21% had progressive lesions. The study reported by Ali et al 
found that in the symptomatic group of patients, extensive (grade 4-6) ON 
developed in 14% of patients, and age>10 years was an independent risk 
factor for development of extensive ON [129].  
In the study reported by Karimova et al (2010), 42 patients had symptomatic 
ON, with clinical information available for 36 patients. Joint collapse was 
experienced by 22% after the diagnosis of ON and the median time between 
the diagnosis of ON of the knee and collapse was 12 months, with a range 
of 2.1-97.1 months [169]. Of the 2 patients who had core decompression, 
one patient had collapse of the articular surface 3.5 years following surgery. 
In an Italian study of 99 cases of ON, 19.4% underwent arthroplasty, with 
50% of patients undergoing one or more alternative interventions [122].  
2.1.6 Risk factors for development and progression of 
osteonecrosis in young people with acute lymphoblastic 
leukaemia 
2.1.6.1 Patient demographics  
All studies found age at primary diagnosis to be a significant risk factor for 
the development of symptomatic ON. Patients aged <10 years at diagnosis 
were at much lower risk than older patients [109-112, 114-116, 119-122, 
127, 128, 132, 145]. The study by Patel et al [123] found that adolescents 
younger than 20 years of age at diagnosis of ALL were at higher risk  of ON 
compared with older patients. Taken together, these suggest that patients 
aged between 10 and 20 years at diagnosis of ALL are the group most 
prone to developing symptomatic ON, compared with any other age group.  
Age also appears to be a risk factor for developing more extensive ON 
lesions [129, 131]. In a study by the SJCRH, of patients identified with 
extensive lesions of the femoral head, 83% were older than 10 years(n=40), 
and of those, 48% (n=19) progressed to joint collapse requiring total hip 
arthroplasty [131]. A number of studies found the highest risk in the later 
teenage years (aged >15 years) [111, 134], but this was not a consistent 




looking at extensive hip ON, patients aged 11-15 years had the same 
incidence of extensive ON as those older than 15 years of age[131], while in 
the NOPHO ALL 2008 study [142] where patients aged 1-45 years were 
treated, it was found that the highest risk group was patients 10-14 years of 
age. Older age at primary diagnosis was found to be associated with more 
frequent collapse, with one study finding 40% of adolescent patients with 
knee ON experienced collapse, compared with less than 4% of younger 
patients [169]. 
Despite age being almost universally accepted as a risk factor for 
development of ON, it should be noted that in the St Jude’s prospective 
study, age was not found to be a risk factor for the development of 
asymptomatic ON [132]. This could suggest that all patients have the same 
risk of developing early ON lesions, but only older patients are at risk of 
these progressing to form extensive symptomatic lesions.  
It has been suggested that female sex is a risk factor for the development of 
ON, but the literature around this topic is far from conclusive. A number of 
studies found female sex to be a risk factor [100, 109, 117, 119, 120, 134-
136, 141, 144], whilst many others found it not to be [110, 111, 114, 123, 
125, 127, 131, 140, 170], even when similar treatment regimens were used 
[109, 111]. One study found that female sex was a risk factor for 
development of ON only in the 10-18 year age group[120]. Even in groups 
with the highest rates of ON there are disparate results- the CCG study 
reported the disorder more frequently in females [119], whilst no gender 
differences were found in the DFCI ALL consortium [127] and studies at 
SJCRH [140]. In the study by Mattano in 2000 [119] the gender difference 
was greatest in the 10-15 year age group, with 3 year rates of 19.2% for 
females and 9.8% for males. However, among the smaller group of 16-20 
year olds with ON, the incidence of ON was higher in males than in females 
(20.7% v 13.2% respectively). This could indicate the importance of pubertal 
stage, as males will typically have later onset and completion of puberty than 
females. It may also be that the specific treatment regimen influences the 
importance of sex as a risk factor in development of ON.  
BMI was found to be a risk factor in only one study [136] where patients with 
a BMI >95th percentile at the end of treatment were found to have a higher 
risk of ON, but BMI at diagnosis was not found to be a risk factor in a 
number of other studies [110, 120, 131, 140, 141]. It is possible that the 
thresholds used for statistical analysis could influence whether or not BMI 




White race was found to be a risk factor in a number of studies [117, 119, 
146], but this was not a consistent finding [131, 132]. Ethnicity as a risk 
factor is a difficult area to study due multiple confounding factors, variation in 
terminology and differences in how ethnic groups are categorised. A number 
of studies separated patients only into White and non-White, whilst others 
had Black and Hispanic groups. Few studies commented on Asian patients 
and most studies where race was commented upon were composed of 
predominantly White patients.  
2.1.6.2 Treatment for acute lymphoblastic leukaemia  
Glucocorticoids are recognised as a causative factor in the development of 
ON in children and young people with ALL. Therefore, it is logical to consider 
whether dose, type and timing of corticosteroid in ALL treatment affects the 
prevalence of ON.  
Not all studies described the cumulative corticosteroid dose received by 
patient, and there are often differences depending on treatment arm. 
Additionally, steroids may be used outside of the ALL treatment protocol: in 
some centres dexamethasone was used as a treatment for nausea and 
vomiting or as prophylaxis during cranial radiation therapy [136]. There were 
also considerable variations in time schedule of steroid administration. In 
some regimens steroid administration was restricted to induction and 
intensification, whilst other regimens have steroids administered during 
maintenance therapy, making the duration of steroid exposure considerably 
longer. A number of studies did describe the treatment regimen and 
cumulative corticosteroid dose in detail. In two studies with similar age 
distribution and patient population, the study with the higher corticosteroid 
dose found a significantly higher prevalence of ON [127] compared with the 
study where corticosteroid doses could be up to 3 times lower [111]. 
However, these were both retrospective studies, with different 
methodologies used for confirming diagnosis of ON. In the prospective study 
by Niinimaki it was found that patients with ON had received significantly 
more dexamethasone compared with those without ON [136], but the odds 
ratio was only 1.01, with confidence intervals (CI) of 1.00-1.01, and the study 
by Ribeiro et al  [140] found no difference in cumulative dose of 
corticosteroids and risk of ON.  
Type of steroid used also varies between protocols and could have an 
impact on the incidence of ON. It has been suggested that dexamethasone 
increases the likelihood of developing ON compared with prednisolone [114], 




meta-analysis looked at the use of dexamethasone versus prednisolone for 
induction therapy in childhood ALL [171] and found that whilst there was 
clear evidence that dexamethasone was protective against CNS relapse, the 
incidence of ON did not significantly differ between the two corticosteroids. 
There were some limitations to this meta-analysis, namely that inclusion of 
older studies could result in underreporting, as accurate ascertainment of 
ON was limited, and there was no subgroup analysis to assess the role of 
age at primary diagnosis in influencing the impact of steroid formulation on 
incidence of osteonecrosis. It was also not possible to remove confounders, 
such as chemotherapy intensity and differences in patient population. US 
studies have found that the risk of ON increased in patients treated with 
dexamethasone compared with prednisolone [105]. Of UK studies, only  the 
study looking at skeletal morbidity in patients treated in trials UKALL97, 
UKALL97/01 and UKALL2003 [114], found an increased incidence of ON 
when patients were treated with dexamethasone compared with use of 
prednisolone. The much larger prospective study looking at results from 
UKALL97 and UKALL97/99 [100] found no excess of ON in the 
dexamethasone arm of the trial.   
A number of trials found ALL risk group to be a risk factor for development of 
ON, with more patients in high risk or moderate risk arms developing ON 
than those in low risk arms[109, 111, 118, 132], although a number of 
smaller studies found no significant difference between treatment arms [110, 
127, 146]. Initial risk stratification can vary between treatment regimens, but 
as described previously, the current UK ALL study, UKALL 2011, which uses 
the NCI risk stratification, high risk at diagnosis is defined as patients ≥ 10 
years of age and/or white cell count of ≥50 x 109/L, and all T-cell ALL and 
lymphoblastic lymphoma patients. In a large prospective study patients in 
the standard/high risk treatment arm were at higher risk of developing 
symptomatic ON compared with low risk patients (odds ratio 2.5), although 
there were wide CIs of 1.2-4.9 [132]. Patients in the standard/ high risk 
group received more intensive therapy, with dexamethasone at 
12mg/m2/day and 20 weeks of continuous ASP, compared with 8mg/m2/day 
of dexamethasone and only 6 weeks of ASP in the low risk arm.  
A number of studies noted that certain components of the treatment regime 
other than steroids also increased the risk of development of ON. It is 
possible that ASP may increase risk of development of ON due to a number 
of different mechanisms, including increasing lipid abnormalities [172], 




dexamethasone. [132, 174].  In a study by Karol et al [117] patients with 
ASP allergy (and hence reduced exposure to ASP) were less likely to 
develop ON, and it is possible that ASP treatment potentiates steroid 
induced necrosis [174]. Hypoalbuminaemia is a marker of ASP treatment, 
which could explain why low serum albumin levels at week 7 were found to 
be a risk factor for development of ON in the study by SJCRH [132]. 
However, murine models have found that discontinuous dexamethasone has 
synergistic anti-leukaemic activity with ASP, without increasing incidence of 
ON [175]. One study found the use of pegylated ASP, versus E.coli or 
Erwinia ASP, was a significant risk factor for development of ON [110], but 
this was a small study and the significance of this finding is unclear. A study 
of 625 patients compared the use intermittent versus continuous pegylated 
ASP, and found no significant difference in hazard rate or cumulative 
incidence of symptomatic ON [176]. However, patients in this study had a 
median age of 4.2 years, with only 29 patients in total affected by ON. There 
was a trend towards a reduction in ON in the experimental (intermittent) arm, 
hence statistical significance may have been achieved in a larger study.  
The specific treatment regimen used is an important factor in development of 
ON. The CCG1961 trial evaluated components of therapeutic intensification 
in high-risk patients (white cell count ≥50x109 and/or age ≥10 years) [106, 
134]. It was found that use of alternate week rather than continuous 
dexamethasone during DI in high risk ALL patients results in a 2-fold 
reduction in the relative risk of symptomatic ON among rapid responders 
aged ≥10years at diagnosis of ALL.  There was a four-fold reduction among 
those randomised to intensified therapy, despite those with alternate week 
dexamethasone having a higher total dexamethasone exposure. The 
incidence of ON was lower among slow responders age ≥ 10 years assigned 
to double DI with alternate-week dexamethasone when compared with a 
similar cohort on the CCG1882 trial [119] who were assigned to two DI 
phases with continuous dexamethasone (11.8% versus 23.2%). The results 
of this study could indicate that dosing manner supersedes cumulative 
exposure.  
2.1.6.3 Radiological risk factors  
After diagnosis of ON in a patient with ALL, it is important to understand 
what the likely prognosis is for a specific lesion, in order to provide 
information for family and clinicians.  
A number of classification systems emphasised the clinical importance of 




have found involvement of the articular surface is associated with risk of 
progression [118], and femoral epiphyseal lesions extending to the articular 
surface were associated with a higher frequency of collapse [169]. 
Size of lesion has also been shown to influence the clinical course of the 
lesion, with larger size associated with risk of progression [118]. One team 
looked at the natural history of ON of the femoral head in 80 patients with a 
primary diagnosis of haematological malignancy [177]. In multivariable 
analysis it was found that the outcome of ON was solely predicted by lesion 
size at diagnosis, with worst prognosis associated with lesions occupying 
more than 30% of the femoral head volume. Of this group of patients, 80% 
of hips collapsed within 2 years of diagnosis, and 50% required arthroplasty. 
A study assessing radiological features of ON in paediatric and adolescent 
(age <21 years) leukaemia patients, found that bone marrow oedema was a 
sign of progressive ON and eventual bone collapse [178]. In this 
retrospective study MRI images of 15 patients with epiphyseal ON in weight 
bearing joints were assessed, with 47 lesions evaluated. There were 17 
cases of eventual bone collapse, and presence of bone marrow oedema had 
a sensitivity and specificity of 94% and 77% respectively, with significant 
association between presence of oedema on imaging and eventual disease 
progression. However, it should be noted that bone marrow oedema was 
only found in patients with lesions extending over 30% of the articular 
surface, which as discussed, is itself likely to be a poor prognostic factor, 
and 70% of patients with bone marrow oedema also had a subchondral 
fracture. 
2.1.6.4 Genetic risk factors  
A number of studies looked at genetic risk factors influencing development 
of ON. Earlier studies used a candidate gene approach to determine 
genotypes for common polymorphisms in genes likely to affect development 
of ON in a patient undergoing ALL treatment [144, 146]. A disadvantage of 
this approach is that suitable candidate genes are selected using existing 
knowledge about known or theoretical mechanisms of development of ON, 
and results are dependent on the selection of appropriate genes. The 
approach has been shown to produce a high rate of false positives [179], 
with results often failing to be replicated in follow up studies.  
One study using the candidate gene approach reported by Relling et al  
found that low thymidylate synthase activity 2/2 (TYMS 2/2) enhancer repeat 




genotype were independent risk factors for ON of the hip in children 
undergoing treatment for ALL [146]. It found that the four risk factors of age 
over 10 years, White race, the TYMS 2/2 genotype and the VDR Fok1 CC 
genotype together have a sensitivity for predicting the development of ON of 
96%, and a specificity of 82%. These gene products affect the 
pharmacodynamics, rather than the pharmacokinetics, of anti-leukaemic 
medications. Methotrexate inhibits thymidylate synthase activity by 
interfering with the ability of the enzyme dihydrofolate reductase to replenish 
intracellular stores of reduced folates, which is required by thymidylate 
synthase to act, and methotrexate polyglutamates also directly inhibit 
thymidylate synthase [180]. Cells that are TYMS 2/2 have increased 
sensitivity to methotrexate and patients with this allele may be more 
susceptible to methotrexate induced toxicity. The relationship between 
thymidylate synthase activity and ON was validated in a separate larger 
study (n=615) [181], but the association with VDR Fok1 genotype was not 
replicated. In this study TYMS 2/2 genotype was only associated with an 
increased risk of ON in patients younger than 10 years of age, with 10.7% of 
those with this genotype developing ON, compared with 4.1% those without. 
This may be because of the different treatment protocols used for those 
under and over 10 years of age, with patients under 10 exposed to more 
methotrexate in the first year of treatment [181]. In a different study looking 
at 12 candidate polymorphisms TYMS 2/2 and VDR Fok1 were not found to 
be risk factors for the development of ON [144]. These differences may 
again be due to differences in study protocols, with patients in the study by 
Relling et al receiving more anti-metabolites than those in other studies [144, 
146]. These results could suggest that genetic risk factors depend upon the 
specific treatment therapy used.   
Later genome wide association studies (GWAS) were used to identify 
genetic variants associated with development of ON in young people with 
ALL. GWAS studies have the advantage that they investigate the entire 
genome, but whilst they can identify single-nucleotide polymorphisms 
(SNPs) and other variants in DNA associated with a disease, they cannot 
specify causal genes.  
In the largest GWAS of glucocorticoid-induced ON in children with ALL a 
number of genetic variants were identified as risk factors for development of 
ON [117]. Meta-analysis was performed by combining GWAS results from 
both the discovery cohort and the two validation cohorts. 197 SNPs with P 




glutamate receptor signalling pathway, including three genes GRIN3A, 
GRIK1 and GRM7, was the top canonical pathway (P = 4.8 x 10-4), 
suggesting its involvement in the pathogenesis of ON in childhood ALL. It is 
possible that glutamate and variations in glutamate receptors may contribute 
to a proximal vascular event that increases the risk of ON in patients 
exposed to steroids, as genetic variation in GRIN3A has previously been 
associated with the severity of vascular complications in Kawasaki disease 
[182].  
The same team looked at genetic risk factors for the development of ON in 
children under the age of 10 years treated for ALL [145]. The genes for BMP 
(bone morphogenic protein) 7 and PROX1-AS1 variants met the genome-
wide significance threshold of <5 x 10-8. BMP7 is released in response to 
bone damage in osteoarthritis and spondyloarthritis, and its release is 
increased by mechanical stress [183, 184]. BMPs can induce mesenchymal 
precursor cells to differentiate into osteoblasts and inhibit the formation of 
osteoclasts [185]. Variants affecting this gene could contribute to 
development of ON by altering bone metabolism and formation both prior to 
and during ALL therapy. BMP7 is also known to be toxic to vascular smooth 
muscle [186], and therefore could contribute to local arteriopathy resulting in 
ischaemia, and hence ON. BMP7 expression in the absence of vitamin D 
induces osteoblast differentiation and mineralization, but this is reversed in 
the presence of 1,25(OH) vitamin D [187]. BMP7 was not identified in 
previous genome wide studies looking at associations with ON. This may 
reflect differences in the populations studied, with BMP7 a specific ON risk in 
younger patients.  
PROX1 has been shown to control the differentiation of lymphatic 
endothelial cells from vascular endothelial cells [188], and has also been 
noted to be down-regulated in familial combined hyperlipidaemia [189]. This 
could result in reduced clearance of plasma lipids, which would increase the 
risk of development of ON.  
The top 92 validated SNPs were enriched for locations within enhancers 
active in tissues closely related to ON, specifically mesenchymal 
progenitors[145]. These cells can differentiate into either osteoblasts or 
adipocytes. SNPs significantly associated with ON were linked to 7 genes in 
the adipogenesis pathway, supporting the importance of genes affecting 
mesenchymal differentiation in ON.  
In pathway analysis, there were 3,271 SNPs with significant (p<0.05) 




were significantly enriched within 8 canonical pathways. Of these, 7 
contained glutamate receptor genes, with the glutamate receptor signaling 
pathway most overrepresented. Variants in 6 genes in the glutamate 
receptor pathway were associated with the development of ON in this 
cohort, including the top validated non-synonymous variant (rs34144324 in 
GRID2). This signaling pathway was also the top pathway represented by 
genetic variants in a cohort of high risk patients of all ages. The 
adipogenesis pathway was the only overrepresented pathway whose genes 
did not overlap with glutamate receptor signaling.  
An alternative method of assessing genomic variation in development of ON 
is the Projection Onto the Most Interesting Statistical Evidence (PROMISE) 
integrative analysis technique, which uses data defining the biological inter-
relationships of phenotypes with one another. This was used to determine 
genetic variants associated with pleotropic dexamethasone phenotypes 
(where genetic variation at a single locus has an effect on more than one 
phenotype). The focus was on ON and thrombosis, and results were 
compared with single phenotype GWAS [190]. This identified more risk 
variants for glucocorticoid effects in regulatory regions than single phenotype 
analysis, and 5 of the top 10 SNPs were chromosome 12 near keratin 
genes, with 4 of these 5 in linkage disequilibrium with SNPs in a 
glucocorticoid receptor-binding site. When the SNPs were prioritized the top 
scoring SNP was one downstream of F2RL1 (rs6453253), which was near 
another selected SNP in the intron of F2RL1(rs2243057). Both of these 
SNPs were in the regulatory region in osteoblast cell lines, and rs6453253 
was also in a glucocorticoid receptor binding site. The G allele of this SNP 
was associated with an increased risk of osteonecrosis, increase in 
cholesterol and higher dexamethasone exposure. The A allele of rs2243057 
was associated with an increased risk of ON and thrombosis, with lower 
albumin level and a greater increase in cholesterol and triglycerides from 
week 7 to week 8 of continuation therapy. The advantage of this method of 
analysis is that by accounting for pleotropic effects the probability of 
selecting variants that exert their effect through common mechanisms (e.g. 
glucocorticoid responsive transcriptional machinery) is enhanced.  
In the prospective study by the SJCRH team [132] SNP genotyping was 
performed. 423 SNPs were associated with symptomatic ON, and of these 
the top 4 SNPs were in the SH3YL1-ACP1 gene locus. Of the 423 SNPs, 27 
were associated with low albumin or high cholesterol. ACP1 is associated 




differentiation [192]. Higher serum cholesterol and lower serum albumin 
were associated with grade 2-4 ON.  This study suggested that ACP1 may 
act via multiple mechanisms to affect bone homeostasis. A study by French 
et al [144] found a polymorphism in SERPINE 1 to be associated with 
development of ON, but this was not found to be the case in the more recent 
study [132], and other studies have found ON to be associated with SNPs 
located within the BCL211 gene, which may affect osteoblast and osteocyte 
apoptosis [147, 193]  
2.1.6.5 Additional findings 
There are a number of additional findings in singular studies.  
In the patients recruited into the prospective study conducted by SJCRH a 
significant association between development of bacteraemia and 
subsequent development of symptomatic ON (p=0.038, CI 1.03-3.41) was 
found [194]. Although this association remained significant after adjustment 
for race and gender, it did not remain so after adjustment for age, which is 
one of the most significant risk factors for development of ON. Nonetheless, 
there was found to be an association between increased number of 
episodes of bacteraemia and development of symptomatic ON, which 
remained after adjustment for race, gender and age (p=0.04) [194]. This 
finding has not been assessed in other studies, and hence it is difficult to 
draw any firm conclusions. However, that episodes of bacteraemia could 
compromise the integrity of the vascular supply to vulnerable areas of bone 
is biologically plausible.  
One study looked at the association between development of ON and 
changes in BMD during treatment for ALL [130]. It was found that lumbar 
spine and total body BMD were not different at baseline between patients 
who did or did not develop ON, but at cessation of treatment and one year 
after cessation of treatment, patients with ON had significantly lower mean 
BMD than patients without. Patients with ON were also more likely to have 
BMD <-1SDS and -2SDS at cessation of treatment (lumbar spine BMD 
(LSBMD) SDS <-1 in 90% of patients with ON, versus 60% of patients 
without ON, and <-2 in 62% of patients with ON, versus 25% of patients 
without ON). This reduction in BMD may be due to a combination of 
avoidance of weight bearing activities and the ON itself. This suggests that 
patients who develop ON during treatment for ALL may be in need of extra 




An important negative finding in a large prospective study looking at both 
asymptomatic and symptomatic ON of the hip is that risk of ON was not 
associated with patency of the epiphysis [131]. One might expect that the 
association of ON with age is due to lack of physeal patency of older 
patients, but this study did not suggest this to be the case.  
As development of ON is due to an interruption of the vascular supply to an 
area of bone, it is plausible that patients with increased likelihood of clot 
development would be at increased risk of development of ON. A 
conference abstract described how induction therapy related alterations in 
coagulation may be associated with development of ON [56], with levels of 
antithrombin (AT) and protein S significantly less in ON positive than in ON 
negative patients after 4 weeks of treatment, including dexamethasone. (161 
paediatric patients). The study by Badhiwala et al [110] found that 
thromboembolism during treatment was a significant predictor of ON, and 
supports a role for hypercoagulability in the pathogenesis of ON. However 
these results are difficult to interpret due to lack of detail provided in the 
reports described.  
Hypertension in patients with ALL may also be postulated to increase 
likelihood of development of ON, due to potential increased pressure within 
the bone marrow. A recent conference abstract presented at sociéteté 
international d’oncologie pédiatrique (SIOP) 2018 found that in an 
assessment of 60 patients over the age of 10 years, hypertensive children 
were at greater risk of developing ON [195]. A murine model found that use 
of quinapril to reduce blood pressure reduced the development of ON [195].    
2.1.7 Summary 
Osteonecrosis is increasingly recognised as a common cause of morbidity in 
patients being treated for ALL. Prospective studies suggest that 
asymptomatic ON affects up to 54% of patients, whilst symptomatic ON 
affects around 18% of patients [132]. Most patients who develop 
symptomatic ON do so within the first 3 years after diagnosis, but 
asymptomatic lesions are likely to develop earlier, and studies suggest they 
develop within the first year of treatment [131, 132].  
A significant proportion of young people affected by ON will have lesions that 
will spontaneously resolve. Patients who have asymptomatic ON early in 
treatment appear to be more likely to go on to develop symptomatic ON, but 
although some risk factors are well elucidated, the specific reasons for 




symptomatic and progressive ON is more likely if there is involvement of the 
articular surface and a larger osteonecrotic lesion, and the presence of bone 
marrow oedema may also increase likelihood of progression of ON. 
It is clear that older age at diagnosis of ALL is an important risk factor for the 
development and extension of symptomatic ON lesions, but studies have 
shown inconsistencies in other risk factors. It is not clear if incidence of ON 
increases with dexamethasone or prednisolone, and other chemotherapeutic 
agents such as ASP are also likely to have a role in development of ON. The 
manner of steroid dosing has been shown to affect likelihood of development 
of ON, with alternate week rather than continuous dexamethasone during DI 
in high risk ALL patients resulting a reduction in risk of development of ON.  
A number of genetic factors have been highlighted as increasing the risk of 
development of ON, and genes affecting the glutamate receptor pathway, 
osteoblast regulation and adipogenesis may be of particular importance. 
A crucial difficulty in discussions about radiological features of ON is that 
whilst multiple grading systems for ON exist, the majority have limitations 
when used in the context of paediatric patients with ALL. The classification 
system devised by Niinimaki et al [167], which was developed specifically for 
patients with cancer, and is applicable to all areas of ON, may have clinical 
relevance in our patient population but needs further validation, particularly 




2.2 Bone mineral density changes in children and young 
people with acute lymphoblastic leukaemia 
Bone fragility is an important aspect of bone health, and this section reviews 
the medical literature around BMD and fracture risk of young people with 
ALL.  
2.2.1 Research questions 
Within this review I aim to cover the following questions:  
1. What is the BMD of ALL patients at diagnosis and during treatment of ALL, 
when compared with healthy peers? 
2. What is the BMD of patients treated for ALL after completion of therapy, 
when compared with healthy peers? 
3. What are the risk factors associated with low BMD in patients with ALL? 
4. What is the fracture risk of patients during and after treatment for ALL? 
5. What are the risk factors associated with increased fracture rate in patients 
with ALL? 
6. What is the natural history of vertebral fractures in patients with ALL? 
2.2.2 Search Strategies 
Medline 1996-2017, Embase 1996-2017, EBM databses, Journals @Ovid, 
Books@Ovid were searched. In addition I searched the reference lists of 
relevant studies.  
Keywords were osteoporosis OR fractures OR bone mineral density, which 
was combined with AND ‘leukaemia’ as a MeSH term.  
Duplicate references were manually removed and eligibility judgements were 
made on the basis of information found in the article abstract and full article 
when appropriate.   
My initial search had a yield of 501 articles. Of these 26 were found to be 
relevant to my study question. During the research period weekly reports 
from Ovid and Embase with any of the above terms in the abstract, title or as 
a keyword were reviewed and added, and the literature review was last 
updated in May 2019. 
Studies which were presented only as abstracts were included only if 





The tables below summarise the most pertinent studies. Table 10 presents 
data from studies in which patients had an assessment of BMD during ALL 
treatment, Table 11 presents data from studies in which patients were 
assessed after completion of ALL therapy, and Table 12 summarises the key 





Table 10. Studies assessing bone mineral density of patients during treatment for acute lymphoblastic leukaemia 










Study design, timing, BMD assessment 
(method) 
Bone mineral density  




Newly diagnosed ALL 
aged 1 month-17 
years 
188 Treatment protocol: 9 
sites COG, 1 site DFCI 
protocol 
(2005-2007) 
Prospective screening of asymptomatic 




Baseline LS-BMD Z score -1.2 (SD 1.3), change at 12 





Newly diagnosed ALL 
aged 1 month-17 
years 
188 Treatment protocol: 9 
sites COG, 1 site DFCI 
protocol  
(2005-2007) 
Prospective screening of asymptomatic 
patients at diagnosis then annually for 4 years  
LSBMD (DXA) 
 
Baseline LSBMD Z score -1.2 +/-1.3, (P<0.001 
compared to healthy average), increased to -1.1 at 
1 year, -0.7 at 4 years  




Newly diagnosed ALL 
aged 4-18 years 
466 DCOG-ALL9 
(1997-2004) 
Prospective screening of asymptomatic 
patients at diagnosis, 32 weeks, end of 
treatment and 1 year after cessation of 
therapy  
LSBMD (DXA) 
At cessation of treatment mean LSBMD -1.28 SDS; 





Newly diagnosed ALL 
aged 0-17 years 
40 DFCI 87-01 
(not documented) 
Prospective screening of asymptomatic 
patients at diagnosis and at 6 monthly 
intervals for 2 years 
LS BMD (DXA) 
 
Compared with status at diagnosis, Z scores for 
BMD and BMC were not statistically significantly 
different throughout therapy 




 2018 [198]  
 
New diagnosis of ALL 
aged 1-18 years 
363 Total XV therapy 
(2000-2007) 
 
Prospective screening of asymptomatic 
patients at diagnosis, completion of therapy 
and 2 years after completion of therapy 
LSBMD (QCT) 
Diagnosis: median BMD Z score 0.06 
End of therapy median BMD z score -1.08 
2 years after therapy: BMD z score -0.72 
No indication of statistical difference between 














Study design, timing, BMD assessment 
(method) 






treatment, age> 4 
years 
39 UKALL 2003 
(not specified) 
Cross-sectional study of patients compared to 
healthy controls. BMD assessed at 100±45 
weeks since diagnosis 
Femoral neck and LSBMAD (DXA) 
Radial and tibial volumetric BMD (pQCT)  
48.6% of ALL patients had femoral BMAD <-2.0 
SDS, 18.4% had LS-BMAD <-2 SDS. BMAD 
significantly lower in ALL patients than controls 
Radial and tibial trabecular vBMD reduced 
compared to controls (p=0.03) but cortical vBMD at 





Newly diagnosed ALL 
aged 4-18 years 
109 Not specified 
(2009-2013) 
BMD assessment of asymptomatic patients at 
diagnosis of ALL 
LSBMD (DXA)   
LS-BMD mean SD -0.45 at diagnosis p=0.01 when 





Newly diagnosed ALL, 
aged 10-21 years 




BMD assessment of asymptomatic patients at 
diagnosis and end of induction 
LSBMD,  femurs and tibias BMD (QCT) 
Whole body BMD (DXA) 
No difference at diagnosis in aBMD (TBLH) 
between patients and controls (z-score 0.28). 






ALL in consolidation   
Aged ≤18 years 
124 (46 patients 
had diagnosis 
DXA) 
DFCI 91-001, 95-001, 20-
001, 05-001 
(1995-2006) 
BMD assessment of asymptomatic patients at 
diagnosis and during consolidation phase of 
therapy 
Lumbar spine BMD (DXA) 
Median change in LS BMD Z score -0.08 




Newly diagnosed ALL.  
age over 4 years 





BMD assessment of asymptomatic patients at 
diagnosis, after 32 weeks, after 2 years (at 
cessation of therapy) and 3 years.   
LSBMD (DXA) 
At diagnosis:  
mean LSBMD -1.1 SDS 
8 months: LSBMD -1.1  
24 months: LSBMD -1.27 













Patient inclusion criteria Number of 
patients 
Protocol  
(treatment/ recruiting period) 
Study design, timing, BMD assessment 
(method) 










BMD assessment median 8 years after 
cessation of therapy (range 2-20 
years); 
LSBMD and femoral neck BMD (DXA) 
No significant difference in BMD compared 





Survivors of ALL; age 1-16 
years 
22 NOPHO protocols 
(1995-1997) 
Cross sectional; 
BMD assessed at cessation of 
chemotherapy; 
LSBD and femoral neck BMD (DXA) 
Significant reduction in BMD compared with 
healthy controls 
LS volumetric BMD mean Z score -0.77, CI -
1.3—0.23, femoral volumetric mean Z score -





Survivors of childhood ALL 
and NHL; >5 years after 
remission; 
age 16 -32 years 
89  
(74 patients with 
ALL) 
FRALLE protocols, ALCL 
protocol for NHL 
(not documented) 
Cross sectional;  
BMD assessed mean 15±4.5 years after 
cessation of chemotherapy; LSBMD, 
femoral neck, hip BMD (DXA) 
40% of patients had LSBMD ≤-1 (10% ≤-2). 






Male survivors of childhood 
ALL  
 
31 UKALL I-X or Memphis V. All 
patient had cranial irradiation  
(not documented) 
 
Cross sectional; BMD assessed median 
17.8 years after cranial irradiation (6.8-
28.6 yrs); LSBMD (QCT); 
LSBMD and right femoral neck (DXA) 
Reduced BMD compared with healthy peers. 
QCT: median Z-score -1.25 (range -3.51-0.95, 
p<0.001), DXA: LS-BMD median Z score -0.74, 
range -2.1-1, p=0.001 
Brennan  
UK 
2005 [208]  
 
Survivors of childhood ALL 53 UKALLXI 
(not documented) 
Cross sectional;  
BMD assessed median 4.6 years after 
cessation of treatment (range 1.2-8.3 
years); 
LSBMD and TBBMD (DXA) 
Distal and mid-radial sites (pQCT)  
No difference in total body or LS BMAD 
compared to controls.   




Survivors of childhood 
cancer> 5 years after end of 
chemotherapy 
142 patients 
with ALL (346 
patients in total) 
Varying protocols, not 
specified (Patients treated 
between 1965-2003, enrolled 
2003-2008)  
Cross sectional;  
BMD assessed median 16.7 years after 
cessation of chemotherapy; 
LS and whole body (DXA) 
Lower LSBMD and TBBMD compared to 
healthy peers.  










Patient inclusion criteria Number of 
patients 
Protocol  
(treatment/ recruiting period) 
Study design, timing, BMD assessment 
(method) 






Survivors of childhood ALL ≥ 
10 years post diagnosis;  
age >18 years 
845  Varying protocols, not 
specified. (Sept 2007-Oct 
2012) 
Cross sectional;  
BMD assessment median 26 years 
after cessation of chemotherapy; 
LSBMD (QCT) 
BMD Z score ≤-2: 5.7%, 






Survivors of childhood ALL; 
<18 years at diagnosis of ALL; 
>2 years from completion of 
chemotherapy 
65  ALL therapy MCP-841 or BFM-
95 
(treated between 1996 and 
2008) 
Cross-sectional; BMD assessment 
median 4.3 years (range 2-14.8 years) 
after cessation of chemotherapy; 
LSBMD and TBBMD (DXA) 
No significant difference in height adjusted 
lumbar or whole body BMD between patients 
and age and sex matched controls 








for ALL, 29 for 
AML) 
Various non-specified French 
multicentric protocols.  
Treated from 1980-2011 
(2007-2008) 
Cross sectional; BMD assessment mean 
14.66±0.44 years after diagnosis of 
malignancy; 
LSBMD, femoral neck BMD (DXA) 
Mean femoral neck Z score -0.19±0.08. 





Male survivors of childhood 
ALL (>10 years post 
diagnosis) 
49 Protocol not specified. ALL 
treatment between 1970-
1998, (not specified) 
Cross sectional;  
BMD assessment 10-38 years after ALL 
diagnosis; 
LS, total body, hip, femoral neck BMD 
(DXA) 
 
Reduced whole body BMD Z score in ALL 
survivors. No significant difference in lumbar 







Survivors of childhood ALL, 
within 2 years of completing 
therapy. Age 5-18 years 
45 Children’s Oncology Group 
Consortium 
Prospective longitudinal study; BMD 
assessment median 0.8 years after 
cessation of chemotherapy and 12 
months later; 
LSBMD, TBBMD, hip, forearm BMD 
(DXA) 
Tibia (pQCT) 
No difference in TBLH/ LS BMD at baseline 
compared with reference data.  






Survivors of childhood ALL, > 
5 years from completion of 
therapy 
424 in baseline 
study 
Total Therapy XI, XII and XIII. 
(treated between 1984-1997) 
Cross sectional study; Average age of 
BMD assessment not documented. 
LSBMD (DXA and QCT) 
 
Median age- and gender-specific LS-BMD Z-
score was −0.3 








Table 12. Studies assessing fractures in patients with acute lymphoblastic leukaemia 




Patient inclusion criteria n Protocol 
(recruiting period) 





Newly diagnosed ALL aged 1 
month-17 years 
155 9 sites COG, 1 site DFCI  
(2005-2007) 
Prospective screening of asymptomatic patients at diagnosis and 1 
year. 
VF (lateral spine radiographs) 





Newly diagnosed ALL aged 1 
month-17 years 
188 9 sites COG, 1 site DFCI 
(2005-2007) 
Prospective screening of asymptomatic patients at diagnosis then 
annually for 4 years  
VF (lateral spine radiographs) 





Newly diagnosed ALL, aged 0-
17 years 
40 DFCI 87-01 
(not documented) 
Prospective screening of asymptomatic patients at diagnosis and at 6 
monthly intervals for 2 years 





Newly diagnosed ALL aged 1 
month-17 years 
186 9 sites COG, 1 site DFCI 
 (2005-2007) 
Prospective screening of asymptomatic patients within 30 days of ALL 
diagnosis. VF (lateral spine radiographs) 




ALL in consolidation   
Aged ≤18 years 
124  DFCI 91-001, 95-001, 20-
001, 05-001 
(1995-2006) 
Assessment of symptomatic fractures during chemotherapy.  
No description of method of fracture assessment.  
18.5%  
te Winkel  
Holland  
2014 [203] 
Newly diagnosed ALL, age > 4 
years 
672  DCOG-ALL9 protocol 
(1997-2006) 
Assessment of symptomatic fractures from diagnosis to one year after 
cessation of treatment.  
Radiological assessment of symptomatic areas.  
17.8% cumulative 




Newly diagnosed ALL aged 1 
month-17 years 
186 9 sites COG, 1 site DFCI 
(2005-2007) 
Prospective screening for asymptomatic VFs at baseline then annually 
for 6 years.  
VFs (lateral spine radiographs) 
Symptomatic low trauma non VFs confirmed by radiology 
VF: 32.5% cumulative 
incidence 





2.2.3 Bone mineral density at diagnosis and during treatment of 
acute lymphoblastic leukaemia   
There are 3 main studies which address the question of bone mineral 
density of patients with ALL at diagnosis and during treatment, compared 
with the healthy population. The largest is a Dutch study, with results 
presented by den Hoed et al [130] and te Winkel et al [203]. In this study 
LSBMD was assessed by DXA in 399 patients with ALL. BMD was 
measured at diagnosis, after 8 months, after 2 years (which was after 
cessation of therapy) and after 3 years. At diagnosis, BMD was significantly 
lower than that of healthy peers, with a mean lumbar spine SDS of -1.1 
(p<0.001). At 8 months, LSBMD remained at -1.1 SDS (p<0.001). By 24 
months this reduced to -1.27 SDS (p<0.001) but recovered slightly by 36 
months (BMD= -0.95 SDS), although it still remained significantly lower than 
the BMD of the healthy population (p<0.001) [130, 203].  
Consistent with this, a Canadian study, presented variously in papers by 
Alos et al [196], Cummings et al [41] and Halton et al [215], also found lower 
baseline BMD Z-scores at diagnosis of ALL when compared with healthy 
peers. This study, known as the Steroid Associated Osteoporosis in the 
Paediatric Population (STOPP) research program, assessed LSBMD by 
DXA within 30 days of diagnosis and every 6 months for 4 years. There were 
186 patients recruited at baseline, which reduced to 136 by 4 years. 
Baseline Z-scores were lower than that of healthy peers, with a Z-score of -
1.2 ± 1.3 (p<0.001) [41]. The score increased after the baseline assessment, 
with a Z-score of -1.1 ±1.1 at 1 year, increasing to -0.7±1.2. at 4 years [41]. 
However, numerical data, with level of statistical significance compared with 
the healthy population, was not reported for each time-point [41].  
The other main study, conducted by SJCRH, used QCT to assess lumbar 
spine vertebral trabecular BMD [198]. As previously discussed in Chapter 
1.2.2, QCT assesses volumetric BMD, and is independent of bone size. 
Trabecular bone is the more metabolically active area of the bone, and 
hence is considered a more sensitive indicator of skeletal metabolism than 
cortical bone. Patients were assessed at diagnosis, week 120 of 
continuation therapy (end of treatment for females), week 146 of 
continuation therapy for male patients (end of treatment for males) and 2 
years after completion of therapy. BMD data was available for 340 patients 
at diagnosis, and 232 patients by 2 years off therapy. The median BMD Z-
score was 0.06 (range -3.27 to 3.56) at diagnosis, which decreased to -1.08 




2.46) at 2 years after therapy. This was the only large study where BMD at 
diagnosis was not lower than healthy controls, with patients ≥10 years of age 
found to have a median BMD Z-score of 0.5, which was higher than normal 
controls, whilst those aged 2-9.9 years had a median Z-score of -0.09, which 
was comparable with controls [198]. This may be a reflection of the method 
of BMD measurement, or of the specific population assessed.  
Other smaller studies using DXA assessment also found that at diagnosis of 
ALL, patients had a lower BMD than healthy controls [200], although this 
was not consistently the case [201], and the reduction in BMD during 
therapy was also replicated [202].  
2.2.4 Bone mineral density of patients treated for acute 
lymphoblastic leukaemia after completion of therapy 
One of the challenges of comparing studies assessing BMD of patients who 
have completed therapy for ALL is the heterogeneity between patient groups 
arising from differences in treatment regimens. However, the most robust 
studies, which used an appropriate control group and adjusted for height, 
found that after completion of chemotherapy, there was no difference in the 
LSBMD of patients compared with healthy peers [40, 204, 208, 211, 213]. 
The timing of bone density assessment in these studies ranged from 2 years 
to 38 years after completion of chemotherapy. However, one large Dutch 
study by den Hoed et al [209] found that patients who had treatment for ALL 
had lower height adjusted LSBMD than healthy peers at a median of 16.7 
years after cessation of chemotherapy (mean LSSDS -0.3, p<0.001) [209]. It 
should be noted that in this study the treatment protocols for patients with 
ALL were not specified, and patients were treated between 1965 and 2003, 
over which time treatment regimens changed considerably. 
The study by Gurney et al [210] was the largest study to look at BMD in long 
term survivors of childhood ALL. The median age of evaluation of BMD, 
using QCT, was 31 years, with a median age of leukaemia diagnosis of 5 
years. The overall prevalence of patients with a BMD Z-score of ≤ -2 was 
5.7%. In a normally distributed healthy population it would be expected that 
2.3% of the population would have a Z-score below -2, but there was no 
statistical analysis in this study to determine if the result was significantly 
different to the healthy population. Of the 845 patients assessed in this 
study, 400 had a previous BMD assessment, with a median time between 
tests of 8.5 years. The mean difference between BMD Z-scores was not 
statistically significant (Z score -0.086, CI -0.2 to 0.031, p=0.15), but 67% of 




subsequent assessment. Of the 845 patients assessed, 518 (61%) had 
cranial radiotherapy, and 21 (2.5%) were HSCT recipients. 
When change in BMD after cessation of ALL therapy was assessed it was 
found that on average DXA Z-scores at all sites increased over time [40], 
and gains in bone mineral content and density were most pronounced in the 
cohort shortly after completion of therapy. This may suggest that there is a 
period of time shortly after ALL therapy is completed during which BMD 
rapidly recovers.  
2.2.5 Risk factors for low bone mineral density 
In the largest studies to assess risk factors for low BMD, younger age was 
significantly associated with lower BMD Z-score both at diagnosis of ALL 
[198, 203] and after cessation of therapy [209]. Low BMI was also found to 
be an independent risk factor for low BMD in a number of studies [203, 209, 
214, 217, 218].  
A low BMD at diagnosis has been shown to persist through ALL treatment 
[198]  with larger declines in BMD during treatment found in older patients 
(age >10 years [198, 203]), those with a lower BMD Z-score at diagnosis 
[198] and those with a larger dexamethasone area under the curve [198]. 
Lower albumin levels, which can be caused by the administration of ASP, 
and older age are associated with a larger dexamethasone area under the 
curve (reflecting an increased actual body exposure to dexamethasone) 
[132]. However, there are varying methods for calculating dexamethasone 
area under the curve, and hence results can vary depending on the 
methodology [219].  
Although older patients had a greater decline in BMD during treatment, after 
cessation of therapy patients aged ≥10 years at diagnosis had significantly 
greater increases in BMD Z-score from end of therapy to 2 years off therapy 
[198] compared with those < 10 years of age at diagnosis of ALL.  
Factors not associated with a greater decline in BMD were sex, white cell 
count at diagnosis, B or T lineage, BMI Z-score change, and presence or 
absence of CNS involvement [198]. Being on a high risk protocol arm was 
found to be significantly associated with a greater decline in BMD in the 
Dutch study [203], but this was not replicated in a US study [198]. In the 
Dutch protocol, the high risk arm contained lower steroid doses than the 
non-high risk arm, suggesting that factors other than steroid dose are likely 




Methotrexate has been shown to result in increased osteoclast formation, 
with increased bone loss [220]. It may be anticipated that higher 
methotrexate doses would result in lower BMD. However, in long term 
survivors of ALL treatment methotrexate dose was not found to be 
associated with lower BMD [210] and a Finnish study found no single 
chemotherapeutic agent showed an independent relationship with BMD 
[205]. 
A genome-wide association study looking at the association between BMD 
and ALL treatment was reported by Inaba et al [198]. In this study 481,281 
SNP genotypes were studied and genotypes were evaluated for 
associations with BMD Z-score changes from diagnosis to week 120 of 
maintenance treatment, using significance levels of p<1 x 10-4. Genomic 
analysis found the strongest association SNPs with BMD Z-score changes 
from diagnosis to week 120 was in a SNP in the collagen gene COL11A1 
and a SNP in the neural epidermal growth factor-like 1 (NELL1) [198]. These 
are both genes important in osteogenesis and bone mineralisation. 
COL11A1 encodes the α-1 chain of type XI collagen, and there is significant 
phenotypic variation in individuals with COL11A1 mutations [221]. NELL1 is 
a secreted protein whose expression promotes osteoblast cell differentiation 
and terminal mineralisation, with inhibition of osteoclast-induced bone 
resorption. Decreased NELL1 expression leads to skeletal under-
mineralisation [222]. However, none of the SNPs reached genome-wide 
significance (<5 x 10-8), which may be related to the sample size of the 
study.  
A number of studies found that patients who required cranial or craniospinal 
irradiation had lower BMD after treatment [209, 210], with female survivors 
appearing to be more susceptible to craniospinal radiation effects [210]. This 
is now rarely used as therapy for ALL in the UK, so these results are less 
applicable to our current patient population.  
2.2.6 Fracture risk of patients during and after treatment for acute 
lymphoblastic leukaemia 
Fractures are an important indicator of skeletal fragility, and the significance 
of diagnosing vertebral fractures and low trauma fractures is increasingly 
recognised [223]. Vertebral fractures often go undetected as children with 
vertebral fractures are frequently asymptomatic, and in the past there has 
been no routine screening of at-risk children [223]. Patients with ALL would 
be categorised as ‘at-risk’ due to the use of extensive glucocorticoid therapy 




The Canadian STOPP study was most robust prospective study to look at 
vertebral fracture prevalence in young people being treated for ALL. Results 
have been described in a series of papers authored by Halton et al (2009) 
[215], Alos et al (2012) [196], Cummings et al (2015) [41] and Ward et al 
(2018) [216]. In this study 186 patients were recruited for prospective 
screening for asymptomatic vertebral fractures at baseline, and then 
annually for 6 years. Fractures were graded using the Genant semi-
quantitative method for vertebral morphometry [47].  Data about 
radiologically confirmed, symptomatic, low trauma non-vertebral fractures 
was also collected.  
Halton (2009) [215] found that in vertebral radiographs taken within 30 days 
of chemotherapy initiation, 16% of patients had prevalent vertebral fractures. 
Of these patients (n=29), 52% had one prevalent vertebral fracture, 27% had 
2 to 5 fractures and 21% had between 6 and 10 fractures. In patients with 
vertebral fractures 48% of patients had grade 1 fractures, 31% grade 2 
fractures and 21% grade 3 fractures as their highest grade. The majority of 
fractures occurred in the mid thoracic (T6/T7) and thoraco-lumbar region 
(T12-L2).  
Alos et al [196] described that at 12 months, there were incident vertebral 
fractures (defined as a new fracture in a previously normal vertebral body, or 
worsening of an existing VF) in 16% of study patients (n=25)  who completed 
12 month data collection (n=155). A total of 61 incident VFs were detected. 
85% of these (n=52) were in previously normal vertebral bodies. A single VF 
was found in 52% of affected patients, 28% had 2 to 3 fractures, and 20% 
had 4 to 10 incident fractures. Again fractures were clustered around the 
mid-thoracic region and thoraco-lumbar region. At 4 years the study 
assessed VFs in 136 patients. A total of 105 incident VFs were identified in 
38 children in the 4 years following diagnosis [41]. The 4 year cumulative 
incidence was 26.4%, with an unadjusted VF incident rate of 8.7/100 person-
years.  
At 6 years 102 patients were assessed for VFs, with results reported by 
Ward et al (2018) [216]. In the 5th year, 38 patients (37%) had incident VFs, 
but all of those patients had at least one incident VF in the first 4 years. 
There were no incident VFs in the 6th year, and 6 year cumulative incidence 
of VF was found to be 32.5%, [216] with 39% of patients with incident VF 
reported to be asymptomatic. The final paper also reports the 6 year non-VF 
cumulative incidence as 23% [216], with an incidence 2.5 times higher than 




baseline, with peak annual incidences occurring at 2 years (5.4%) and 5 
years (4.8%) [216].  
Additional smaller studies have also assessed vertebral and non-VF 
incidence in paediatric patients with ALL. In one study male survivors of 
childhood ALL were assessed between 10 and 38 years after diagnosis and 
vertebral compression fractures were found in 20% of survivors [213]. 
However, in this population 73% of patients had cranial irradiation and 35% 
of patients had testicular irradiation, potentially limiting the applicability of 
these results to our patient population.  
The Dutch study of 672 patients reported by te Winkel et al assessed 
cumulative symptomatic fracture incidence during ALL therapy and found 
similar results to that of Ward et al, with an estimated cumulative incidence 
of 17.8% at 3 years [203]. This is similar to the study by Rayar et al, which 
found 18.5% of patients developed symptomatic fractures during ALL 
treatment [202].  
2.2.7 Risk factors associated with increased fracture rate in 
patients with acute lymphoblastic leukaemia 
In the Canadian STOPP study it was found that glucocorticoid exposure and 
VFs at baseline were significantly associated with increased vertebral and 
non-VF risk (p<0.01, HR 6.25, CI 3.22-12.15 and p<0.01, HR 4.52, CI 2.01-
10.15 respectively) [216]. LSBMD Z-score was found to be significantly 
reduced in children with prevalent and incident VFs (p=0.01, HR 1.55, CI 
1.12-2.13) [41, 196, 215] and this was also found to be the case in patients 
with symptomatic non-VFs [202, 203, 216].  
Decreased age at baseline was also found to be a risk factor for 
development of incident VFs (p=0.01, HR 1.09, CI 1.02-1.16), but not for 
non-VFs (p=0.27) [216].  
There was no significant difference in age, gender, leukaemia sub-diagnosis, 
white blood cell count, leukaemia risk category, height, weight, bone age or 
family history of osteoporosis in likelihood of development of VFs at baseline 
[215]. Calcium, vitamin D intake and physical activity were not related to VF 
development, and there was no evidence of an independent effect of puberty 
on VF risk [215].  
This correlates with the results of the study by te Winkel et al, which 
assessed symptomatic fractures, and found age at diagnosis of ALL, gender, 
pubertal stage and anthropometry parameters were no different between 




related bone loss was similar in patients with and without fractures, 
indicating that it is low values of LSBMD at diagnosis and during treatment, 
rather than treatment related decline, that determines fracture risk in children 
with ALL [203]. 
2.2.8 The natural history of vertebral fractures in patients with 
acute lymphoblastic leukaemia 
It is important to recognise the wide spectrum of recovery from fracture-
induced vertebral deformity in children with ALL. Some patients have 
spontaneous vertebral body reshaping with no treatment, whilst others have 
debilitating back pain with bisphosphonate therapy used to facilitate 
reshaping [225, 226]. Vertebral body reshaping is a growth-dependent 
phenomenon that results from bone modelling, and hence can only occur in 
childhood.  
The 6 year results of the STOPP study found that 77% of children with VFs 
had complete vertebral reshaping (n=34), 18% had incomplete reshaping 
(n=8) [216] and two patients (4.5%) had no change. However, only 44 
children (23.7%) met the inclusion criteria for evaluating reshaping of 
vertebral bodies, and so the results need to be interpreted with care. Those 
with incomplete/ absent reshaping were older at diagnosis (median age 8.0 
versus 4.8 years) and had more frequent and severe VFs at baseline [216, 
226]. The reduction in vertebral reshaping in older patients may be due to 
lack of remaining linear growth potential for “catch-up” modelling. Vertebral 
reshaping was not associated with LSBMD Z-score or with change in BMD 
Z-score from baseline to last visit [216].  
2.2.9 Summary  
In patients with ALL, studies suggest that BMD is lower at diagnosis of ALL 
than in healthy peers, and this is more marked in younger patients and those 
with a low BMI. This is perhaps unsurprising, given the gross infiltration of 
the bone marrow with proliferating leukaemic cells at the point of diagnosis 
of leukaemia, and the corresponding increased cytokine activity. BMD 
appears to reduce or remain low during ALL treatment, particularly in older 
patients, but subsequently recovers after completion of chemotherapy. The 
most rapid period of recovery is likely to be shortly after the completion of 
therapy, with older patients showing greater increases in BMD after 




There are likely to be genetic factors which have significant influence over 
BMD in patients with ALL. Thus far there has only been one GWAS, which 
implicated genes affecting osteogenesis and bone mineralisation.  
Ultimately, the relevance of BMD of ALL patients and survivors is to 
determine if the disease or its treatment has had a detrimental effect on 
bone fragility, with a resultant increased risk of fractures. The high rate of 
fractures in paediatric patients with ALL is being increasingly recognised. 
One study found VFs affected 16% of patients at diagnosis of ALL, with a 6 
year cumulative incidence of 32.5% [216]. The critical period for 
development of VFs appears to be in the first 2 years of chemotherapy with 
no fractures occurring by 6 years after ALL diagnosis [216]. Peak incidence 
of VFs was found to be 12 months after diagnosis. Low trauma non-VFs are 
also more common than in the general population, occurring in about a fifth 
of patients. It is possible that vertebral bodies are more affected than other 
areas of the skeleton because vertebral bodies are largely composed of 
metabolically active trabecular bone, whilst bone turnover in cortical bone is 
lower and hence less easily affected [227]. The main risk factors for 
development of vertebral and non-VFs were higher glucocorticoid exposure, 
presence of VFs at baseline and a lower spine BMD Z-score at baseline.  
Although the VF incidence is relatively high, 39% of patients with VFs were 
asymptomatic. Thus it is imperative to understand the natural history of 
these fractures, particularly to prevent over-management of patients. It 
appears that the majority of children with VFs will restore normal vertebral 
dimensions. However, older patients who are likely to have limited remaining 
growth potential, or those with more severe vertebral collapse, are at greater 





2.3 Potential therapeutic strategies 
From the preceding literature review, it is clear that the bones of young 
people who are treated for ALL suffer from numerous insults, resulting in 
many patients suffering with ON and/or increased bone fragility. Despite this 
knowledge, within the haematology community there is currently no 
consensus on how to manage these conditions, and an uncertainty about 
how to optimise the bone health of young patients with ALL [228].  
The final part of this chapter focusses on potential therapeutic interventions. 
For the purpose of this thesis, I have focussed on the use of 
bisphosphonates for the management of ON in young people with ALL, and 
the role of vitamin D. These therapeutic interventions were chosen as both 
have been proposed as potentially beneficial for patients with ON or bone 
fragility, but their explicit role in young people with ALL remains 
controversial. The review of the role of vitamin D in children and young 
people with ALL was conducted as a full systematic review, with planned 
meta-analysis.   
2.3.1 Bisphosphonate therapy in the management of young 
patients with osteonecrosis and acute lymphoblastic 
leukaemia 
2.3.1.1 Background 
Bisphosphonates are widely used in clinical practice to inhibit bone 
resorption. Their main use is in the management of hypercalcaemia, 
osteoporosis, osteogenesis imperfecta, metastatic bone disease and Paget 
disease.  
Structurally, bisphosphonates are chemically stable derivatives of inorganic 
pyrophosphate, which is a naturally occurring compound of 2 phosphate 
groups linked by esterification [229]. Bisphosphonates inhibit osteoclastic 
bone resorption by attaching to hydroxyapatite binding sites on bony 
surface, with a predominance on surfaces undergoing active resorption. 
When osteoclasts begin to resorb bone that is impregnated with 
bisphosphonates, the bisphosphonates inhibit hydroxyapatite breakdown, 
thus suppressing bone resorption [230]. Bisphosphonates also reduce 
osteoclast activity by decreasing osteoclast progenitor development and 
recruitment and by promoting osteoclast apoptosis [231]. Moreover, 




mouse models finding bisphosphonates prevent osteocyte and osteoblast 
apoptosis [232].  
First generation bisphosphonates are non-nitrogen containing and include 
agents such as etidronate, clodronate and tiludronate. They have a different 
mechanism of action to second and third generation bisphosphonates (e.g. 
pamidronate and zolendronate respectively), which have nitrogen containing 
side chains. The presence of a nitrogen group increases the 
bisphosphonates anti-resorptive potency by 10-10,000, with zoledronic acid 
being 10,000 times more potent than etidronate and 100 times more potent 
than pamidronate [233]. 
It has been hypothesised that the suppression of necrotic bone resorption 
could help in maintaining the spherical shape of the femoral head, allowing 
revascularisation and preventing femoral head collapse in ON [234] and 
bisphosphonates have been considered to be a promising medical 
intervention for osteonecrosis [235]. However, the actual benefit of 
bisphosphonates in ON is unclear, and this review aimed to answer the 
following question: 
 In a patient with osteonecrosis and childhood acute lymphoblastic 
leukaemia, what is the evidence for use of bisphosphonates versus no 
bisphosphonates in reducing pain or improving functional or radiological 
outcomes? 
2.3.1.2 Search Strategy 
Primary Search  
EMBASE and Medline were searched using the Ovid Medline database 
(1946 to present) in November 2018. The following terms were used (subject 
headings=SH): (‘osteonecrosis’ (SH) OR ‘avascular necrosis’ OR ‘aseptic 
necrosis’) AND (‘glucocorticoids’ (SH) OR steroids OR leuk*emia) AND 
(‘diphosphonates’ (SH) OR ‘alendronate’ (SH) OR ‘bisphosphonates’ OR 
‘pamidronate’ OR ‘zoledronic acid’ OR ‘risedronate’). The search was 
restricted to studies conducted on human beings and limited to publications 
in English.  
Secondary Search 
A search of EBM Reviews - Cochrane Database of Systematic Reviews 
2005 to June 2018, EBM Reviews - ACP Journal Club 1991 to July 2018, 
EBM Reviews - Database of Abstracts of Reviews of Effects 2nd Quarter 




2018, EBM Reviews - Cochrane Methodology Register 3rd Quarter 2018, 
EBM Reviews - Health Technology Assessment 3rd Quarter 2018, EBM 
Reviews - NHS Economic Evaluation Database 2nd Quarter 2018 found no 
new articles for review.  
During the research period weekly reports from Ovid and Embase with any 
of the above terms in the abstract, title or as a keyword were reviewed and 
added, and this review was last updated in May 2019. 
2.3.1.3 Inclusion criteria 
Studies involving patients diagnosed with ALL under 25 years of age, and 
use of bisphosphonate therapy for the management or prevention of 
radiologically identified ON.  
2.3.1.4 Outcome measures 
Outcome measures assessed were: 
 Pain 
 Development of symptomatic ON 
 Functional ability 
 Radiological changes of ON 
Reported adverse drug reactions and adverse drug events were also 
considered.  
2.3.1.5 Results 
524 articles were identified. Only studies looking at the effect of 
bisphosphonates in osteonecrosis were included, leaving 11 articles. There 
were only 3 relevant comparative studies described in full text articles [236-
238], none of which were relevant to paediatrics. Three conference abstracts 
of interest were identified [239-241]. Of these, only two included patients 
who were less than 25 years of age [239, 241], one of which included a 
randomised control group [239]. There were full text articles of 8 non-
comparative studies, of which 5 were relevant to paediatrics [234, 242-245]. 
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Table 13 highlights the significant heterogeneity between studies. There is 
only one randomised study, which was described in an abstract [239]. The 
studies all had small sample sizes, with variable duration, type and dose of 
treatment, and different intervals between onset of ON and use of 
bisphosphonates. All of these may result in considerable variation in any 
efficacious effect of bisphosphonates. There were also considerable 
differences in study design, with one study categorizing patients into low, 
medium and high risk, and allocating treatment accordingly [243]. It is known 
that the size of necrotic lesion, and involvement of articular surface is 
particularly important in predicting outcome [118], so there is an inherent 
difficulty in grouping all patients with ON together. The majority of patients in 
the studies were diagnosed with ALL, but one study also included patients 
with lymphoma (n=6) and benign haematological disorders (n=2) [242]. 
Patients both between and within studies were managed with different ALL 
treatment regimens, with a number of patients receiving cranial or total body 
irradiation, or stem cell transplantation (which is usually conditioned with 
total body irradiation). These differences could also significantly alter the 
progression of osteonecrotic lesions. The general management of patients 
with ON also varied between and within studies, particularly with regards to 
cessation of steroids and use of vitamin D and calcium supplementation. 
When looking at outcome measures it should be noted that there are no 
universal scales for outcome measures such as pain, mobility or level of 
function, resulting in difficulties comparing studies. Due to the above issues, 
no meta-analysis was possible and a narrative summary of results is 
provided below.  
2.3.1.5.1 Pain  
The results suggest that pain was reduced in all or most patients with ON 
and ALL who were given pamidronate or zolendronate therapy [234, 241-
243]. Results from 1 study suggests oral alendronate therapy is less 
efficacious in reducing pain [243]. The largest case series of patients who 
received zolendronic acid then alendronate was described by Agarwala et al, 
and found that mean pain score reduced from 5.82 at the start of therapy to 
2.72 in a mean duration of 5.2 weeks [234]. The pain score was statistically 
lower than at presentation at all time points following initiation of 
bisphosphonates, regardless of Ficat-Arlet stage of ON. There was also a 
corresponding reduction in mean analgesic requirement [234]. It is known 
that a significant number of patients with ON have spontaneous resolution, 




spontaneously resolve in these non-randomised studies. Despite this, the 
speed of improvement in pain does suggest a positive effect of 
bisphosphonate therapy. A few studies compared patients who were given 
bisphosphonates with those who were not. They found that in the patients 
who were not treated with bisphosphonates, within the study follow up time, 
there was no, or minimal reduction in pain [243, 244]. However, comparator 
groups were not clinically equivalent to treated groups in either of these 
studies.  
2.3.1.5.2 Development of symptomatic ON 
Only one study looked at the use of prophylactic bisphosphonate therapy in 
reducing development of symptomatic ON. This was reported in an abstract 
by Bostrom et al, and was a retrospective study using prophylactic 
pamidronate therapy within the first year of therapy for ALL patients aged 
between 10 and 28 years who were developing symptomatic ON [239]. In 
the 23 patients who were given prophylactic pamidronate, the incidence of 
development of symptomatic ON was significantly lower than that in the 
control group (14% versus 43%, p=0.049). Within the control group of 39 
patients, only 14 were developing symptomatic ON at the start of the study. 
Although this means the control group is not directly comparable with the 
treatment group, it would be expected that the direction of bias would be 
towards an increase in development of symptomatic ON in the treatment 
arm, yet the opposite was seen. The method of selecting patients who were 
‘developing symptomatic ON’ was not defined in this abstract, and the study 
is described as retrospective, making results less robust than those of a 
prospective randomised control trial [239].  
2.3.1.5.3 Functional ability of patients 
The functional outcome of patients was assessed in 5 studies. The study by 
Leblicq et al found 9 of 12 patients treated with bisphosphonates had an 
improvement in motor function [244]. This is similar to the findings by 
Nguyen et al where 4 of 6 patients had improved mobility at 1 year [245], 
and in the 4 patients treated in the study reported by Shaw et al, all patients 
had increased range of movement and ambulation [241]. In the study by 
Kotecha et al, all 6 high risk patients who were given pamidronate had 
improvement in function and range of movement, whilst in the intermediate 
risk group who were given alendronate, only 2 of 6 patients had 
improvement in function [243]. In the low risk group who were treated 
conservatively only 1 of 8 patients showed improvement in function and 




there was a statistical improvement in Harris Hip Score for all stages of ON 
after treatment with bisphosphonates, compared with the start of the study 
[234]. The Harris Hip Score is a clinician-based outcome measure and 
covers the domains of pain, function, absence of deformity and range of 
motion. However, it should be noted that the Harris Hip Score was 
developed in 1969 for the assessment of the results of hip surgery in an 
adult population [246], which calls into question its use in this population. 
Again, the lack of a control group in these all of these studies limits the 
strength of these findings.  
2.3.1.5.4 Radiological changes of ON 
As previously described, the natural history of osteonecrosis is far from 
clear, particularly in the paediatric population. We are aware that some 
patients will have reversal of osteonecrotic lesions, whilst other will have 
lesions that progress and result in joint collapse [131, 141]. In the study by 
Kotecha et al, it was found that regardless of therapeutic intervention, all 
patients showed a reduction in total volume of ON with time, with no 
statistical difference between patients treated with pamidronate and 
alendronate [243]. Nguyen et al found no improvement in MRI features of 
ON in patients treated with pamidronate [245] and this was also found to be 
the case in the report by Shaw et al [241]. The study by Agarwala et al found 
radiological progression in 38% of hips (n=13) at a median follow-up time of 
50 months, with radiological collapse in 26% of hips (n=9) [234].  
There are few relevant prospective natural history studies, and the natural 
history may vary depending on size/ site of lesion at the start of the period of 
observation. In the earlier literature review the SJCRH study was described, 
which found that in 130 patients with asymptomatic ON, 11% had lesions 
that resolved, whilst in 26% the grade of lesions worsened [132].  
2.3.1.5.5 Adverse effects 
In all studies, definitions and methods of data collections for adverse events 
were rarely published, and therefore adverse events were likely to be 
detected opportunistically.  
The most commonly described adverse event was the classical acute phase 
reaction to bisphosphonates, which is a non-specific physiological and 
biochemical reaction that typically includes fever and mild myalgias and 
arthralgias [247, 248]. Other adverse events that have been reported in 
studies assessing safety of bisphosphonate therapy include hypocalcaemia, 




and gastric irritation secondary to oral bisphosphonate use [249]. 
Osteonecrosis of the jaw, atrial fibrillation and atypical femoral fractures are 
rare complications of bisphosphonate therapy, but these have never been 
described in paediatric patients [249].  
Pamidronate was the most commonly used bisphosphonate, used in the 
studies reported by Bostrom [239], Kotecha [243], Leblicq [244], Nguyen 
[245] and Shaw [241]. The acute phase reaction was reported in 50% of 
patients in the study by Lebliq et al [244], and by ‘most patients’ in the study 
by Nguyen et al [245], with ‘no untoward side-effects from pamidronate’ 
reported in the abstract by Bostrom et al [239]. The studies reported by 
Kotecha et al and Shaw et al made no mention of any side-effects of 
pamidronate treatment.  
Zolendronic acid was used in the studies reported by Padhye and Agarwala 
[234, 242]. An acute phase reaction was reported in 10% (n=2) of patients 
included in the study by Agarwala et al [234] whilst in the study by Padhye et 
al, 35% of patients (n=7) experienced an acute phase reaction after the first 
dose [242].  
After the first dose of intravenous bisphosphonate, subsequent doses were 
uneventful, with no patients experiencing clinically significant hypocalcaemia 
or bisphosphonate related osteonecrosis of the jaw. 
Two studies used oral alendronate therapy. One of 6 patients (17%) who 
used alendronate in the study described by Kotecha et al reported recurrent 
gastrointestinal upset whilst on treatment [243]. In the study by Agarawala et 
al, mild dyspeptic symptoms were reported in 3 patients (15%), which 
resolved within one month of starting therapy [234].  
2.3.1.6 Conclusion 
In conclusion, there are methodological flaws in all of the studies described, 
but in selected cases there is limited evidence that pamidronate and 
zolendronate may be beneficial for pain management. There is also a 
suggestion that functional ability of patients improves with use of 
pamidronate or zolendronate, but there is no clear evidence to suggest that 
bisphosphonates alter radiological progression of osteonecrosis in 
childhood. In these small studies, bisphosphonates appeared to be well 
tolerated, with an acute phase reaction after the first dose of pamidronate or 
zolendronic acid the most common adverse event. Individual patient 
characteristics would need to be considered before use, and the optimum 




2.3.2 Efficacy and safety of vitamin D in children and young 
people with acute lymphoblastic leukaemia: a systematic 
review  
2.3.2.1 Background 
Vitamin D plays a pivotal role in calcium and phosphate metabolism, and is 
an important variable in bone health. It has also been shown to have anti-
cancer and immunomodulatory effects: in some cancers vitamin D and its 
derivatives inhibit proliferation, induce apoptosis, reduce angiogenesis and 
sensitise cells to chemotherapy [250]. In a meta-analysis of adult patients 
with any haematological malignancy, it was found that low serum 25-
hydroxyvitamin D (25OHD) levels were significantly correlated with reduced 
overall survival and relapse free survival time [251]. However, this meta-
analysis did not include paediatric patients, who are affected by different 
haematological malignancies compared with adult patients [252].  
The endocrine regulation of bone metabolism has been described in the 
introductory chapter, highlighting the importance of Vitamin D in the 
maintenance of calcium homeostasis. Vitamin D exists as 2 forms: 
ergocalciferol (vitamin D2), and cholecalciferol (vitamin D3). Following 
intestinal absorption both are metabolised to 25OHD at the liver, which 
undergoes subsequent conversion in the kidney and other tissues 
possessing 1-α hydroxylase activity to 1, 25-dihydroxycholecalciferol 
(1,25(OH)2D), the biologically active form. Calcitriol is the synthetic 
physiologically active analogue of 1,25(OH)2D, specifically the vitamin D3 
form. Typically 1,25(OH)2D will bind to the nuclear vitamin D receptor (VDR) 
to induce a conformational change in the protein, which permits binding to 
the retinoid X receptor. The heterodimer then acts as a transcription factor, 
causing transcription or repression of target genes [250] (see Figure 7). 
The VDR is expressed in at least 30 different target tissues including bone, 
kidney, blood, breast, prostate, gut, activated B and T-lymphocytes, 
monocytes and keratinocytes [253, 254]. In some cells, such as intestinal 
cells,  a membrane receptor for 1,25(OH)2D has also been shown to exist, 
but it is unclear if this receptor is present in other types of cells [255, 256]. 
VDRs have also been found in breast cancer [257], human melanoma [258], 
neuroblastoma [259], prostate cancer [260] and myeloid leukaemia cells 
[261]. However, in a small study of 4 ALL cell lines, no ALL cells had 
detectable levels of VDR [262], although in vitro calcitriol was found to inhibit 









Vitamin D has both genomic and non-genomic effects, and facilitates active 
calcium and phosphate transport in the intestine, resulting in a net increase 
in serum calcium and phosphate [263]. It also acts to increase reabsorption 
of calcium in the distal renal tubules and stimulates phosphate reabsorption 
at the proximal tubule [264]. In bone, 1,25(OH)2D has both anabolic and 
catabolic actions, but appears to facilitate bone formation at physiologically 
optimal concentrations, while higher levels promote resorption and limit 
mineralisation to sculpt bone [264]. In vitamin D deficient states there is a 
corresponding increase in parathyroid hormone (PTH), which can result in 
pathological resorption in bones and increased bone fragility. Vitamin D also 
maintains phosphate homeostasis via its interaction with FGF23, a key 
phosphate regulator. 1,25(OH)2D induces the release of FGF23 from bone, 
resulting in phosphaturia, a process which is independently stimulated by 
high phosphate levels. 
The most widely used preparation for treatment of vitamin D deficiency is 
cholecalciferol. Activated vitamin D preparations, such as calcitriol or 
alfacalcidol, are not generally used for the treatment of simple vitamin D 
deficiency due to the risk of serious adverse effects, including 




Optimal vitamin D levels in blood are highly debated. Current UK practice, as 
recommended by the British Paediatric and Adolescent Bone Group, defines 
a blood level of 25OHD <10ng/ml (25nmol/L) as deficient, with insufficiency 
defined as between 10-20ng/ml (25-50 nmol/l) [265]. The Endocrine Society 
defines vitamin D deficiency as a 25-OHD level below 20ng/ml (50nmol/l), 
and vitamin D insufficiency is defined as a 25OHD level of 21-29ng/ml (52.5-
72.5nmol/l) [266].  These cut-off values were set with regards to prevention 
of rickets and/ or symptomatic osteomalacia, however it should be 
recognised that in determining risk of development of rickets, other crucial 
factors need to be taken into consideration, including serum phosphate and 
dietary intake of calcium, both of which can affect serum PTH. The 
prevalence of vitamin D deficiency varies considerably depending on the 
geographic latitude of the population studied, time spent outdoors, 
fortification of food, age of the population, ethnicity and time of year samples 
are obtained [267, 268]. The seasonality of vitamin D deficiency is illustrated 
by a study which reported that between January and March 40% of UK 
children aged between 11-18 years have a 25OHD level below 25nmol, 
which falls to 13% between July and September [269].  
At present, there is no consensus on how best to manage patients who have 
newly diagnosed ALL with concurrent vitamin D deficiency, and the benefits 
and risks of doing so are unclear. This review aims to determine if treatment 
with vitamin D provides any evidence of clinical benefit or holds any specific 
risks in this vulnerable patient population. 
2.3.2.2 Methods 
This review was undertaken following a pre-specified protocol registered on 
PROSPERO (the international prospective register of systematic reviews): 
CRD42018092553 April 2018 [270]. The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines were also 
followed [271].  
2.3.2.3 Inclusion criteria 
Studies involving patients under 25 years of age with ALL with low levels of 
vitamin D (defined as vitamin D deficient with levels of 25OHD < 10ng/ml 
(<25nmol/L) or vitamin D insufficient with levels of 25OHD 10-20ng/ml (25-
50nmol/L)), treated with any dosing schedule of cholecalciferol, 
ergocalciferol or calcitriol during treatment for ALL.  
Randomised and non-randomised controlled trials were assessed for 




as randomised and non-randomised controlled trials were included for safety 
analysis.  
2.3.2.4 Exclusion criteria 
Patients who received haematopoietic stem cell transplant as treatment for 
ALL were excluded, due to previous chemotherapy exposure and significant 
differences in treatment received by patients.  
2.3.2.5 Outcome measures 
Primary outcome(s) 
1. Bone health: 
a. Prevalence of low impact fractures 
b. Prevalence of osteonecrosis  
2. Acute lymphoblastic leukaemia: 
a. 1, 2, 3, 5, >5 year survival estimates and median survival time from 
diagnosis of ALL 
Secondary outcome(s) 
1. Bone health: 
a. Bone mineral density 
b. Calcium, phosphate, PTH levels 
c. Vitamin D levels 
2. Acute lymphoblastic leukaemia: 
a. Cumulative incidence of relapse 
b. Response to treatment (as defined by bone marrow minimal residual 
disease at end of induction chemotherapy)  
Reported adverse drug reactions and adverse drug events were also 
considered. 
2.3.2.6 Search methods for identification of studies 
Database searches of Embase (1996-2018), Medline (1996-2018), The 
Cochrane library and Web of Science were undertaken with the following 
search strategy:  
(Leukemia, lymphoid (MESH term) OR leuk?emia (keyword)) 
 AND  
(Vitamin D (MESH term) OR Vitamin D Deficiency (MESH term) OR vitamin 





Reference lists of identified articles and key review articles, abstracts from 
major conferences and hand searches of journals that comprise the most 
frequent venues for publications in this area were included.  
Searches were performed without language restrictions and attempts were 
made to obtain a translated copy where possible. Grey literature was also 
searched.  
During the research period weekly reports from Ovid and Embase with any 
of the above terms in the abstract, title or as a keyword were reviewed and 
added, and this review was last updated in May 2019. 
2.3.2.7 Study selection 
Study selection and data extraction was conducted using the following 
method: 
Two reviewers independently assessed the title and abstract of all studies 
for possible inclusion. Inclusion or exclusion was verified by assessment of 
the full text of potentially included studies.  
Discrepancies between reviewers were resolved by discussion. Unresolved 
discrepancies were referred to an independent assessor.  
2.3.2.8 Data extraction and management 
Data were extracted using a standardised form (Appendix 2) which was 
independently checked by the second reviewer. The author(s) of the paper 
were contacted when additional information was required, including 
information on methodological criteria. If no further information was available 
the criteria was rated as ‘unclear’.  
The quality of randomised studies was assessed by the Cochrane risk of 
bias [272] to assess adequacy of methods for sequence generation, 
concealment of allocation, completeness of outcome data or handling of 
incomplete outcome data, and blinding of assessors.  
Risk of bias in non-randomised studies was assessed using the ROBINS-I 
(risk of bias in non-randomised studies of interventions) [273].  
The Loke method was used to assess quality of studies investigating 
adverse events [274]. 
Extracted data was checked for agreement between review authors, and 
disagreements in methodological assessments were resolved by consulting 




2.3.2.9 Data synthesis 
A meta-analysis of survival outcomes was not possible due to the lack of 
appropriate studies, and a narrative summary undertaken instead. A 
narrative synthesis was undertaken for the safety analysis, including 
reporting of adverse events/ reactions occurring within single arm studies. 
Due to insufficient data, we were unable to perform random effects meta-
analysis of logit-transformed proportions experiencing that adverse event/ 
reaction.  
2.3.2.10 Analysis of subgroups or subsets 
Subgroup analyses according to age, sex, timing of therapy and vitamin D 
level at diagnosis was not possible due to lack of sufficient data. 
Assessment of evidence of between group interactions and qualitative 
assessment of differences between groups was undertaken. As there were 
insufficient studies, meta-regression was not performed. Due to lack of 
sufficient high quality data we were unable to perform a sensitivity analysis, 
based on risk of bias and study design.  
2.3.2.11 Results 
We identified 1939 unique articles, of which 22 were eligible for full text 
review. Of these only 5 studies were found to be appropriate for full review 
(Figure 8). Only 2 studies were randomised [275, 276] with 3 cohort studies 
reviewed [277-279]. Indications for exclusion of articles is summarised in 
Figure 8. Tables 14 and 15 outline the characteristics of the studies included 
in the subsequent analysis.  
One randomised study [275] and one cohort study [278] treated all patients 
with the vitamin D supplements, regardless of vitamin D status, and the 
other two cohort studies treated all patients, but with varying doses of 
cholecalciferol depending on vitamin D status [277, 279]. Although they do 
not completely fulfil the inclusion criteria for study selection, these studies 
were selected for inclusion due to their value for the safety analysis, and due 
to the high prevalence of vitamin D deficiency in the population [269]. The 
cohort study by Claar et al was only published as an abstract, and 









Figure 8. Study flow diagram of search and selection process 
 
Due to the variability between studies, the results were not able to be pooled 
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Table 15. Characteristics of studies included for analysis: cohort studies 
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*conversion factor for 25 hydroxyvitamin D: 1ng/ml=0.4nmol/l 
**Unpublished data, received upon e-mail correspondence with author.  
*** full details of Claar et al Vitamin D supplementation guidelines (received upon correspondence with author) 
Vit D deficient:cholecalciferol 2000IU/day, recheck levels within 6-8 weeks, if sufficient treat as per sufficient guideline. If remains deficient, increase to 
4000IU/day if over 1 yr (refer to endo if age <1yr) 
Vit D insufficient: 1000IU/day, recheck levels within 6-8 weeks, if sufficient treat as per sufficient guideline. If remains insufficient: increase to 2000IU/day, 
recheck in 6-8 weeks 
Vit D sufficient: age 0-1yr: 400IU/day, age >1yr: 600-1000IU/day 




2.3.2.11.1 Risk of bias assessment 
Tables 16 and 17 summarise the risk of bias assessments for the 
randomised studies and cohort studies respectively. Judgement was made 
as per the Cochrane risk of bias assessment tool for the randomised 
controlled studies, and using the ROBINS-I for the non-randomised studies. 
Only one study, the randomised study by Orgel et al, was found to have an 
overall low risk of bias in all domains- despite lack of blinding the objective 
methods of assessment minimises risk of bias [276]. Although the study by 
Diaz et al had a high risk of bias, the magnitude of bias is likely to be small 
due to the objective nature of outcome measures, although the confidence in 
the estimate is reduced [275].  The ROBINS-I identified serious risk of bias 
in all of the cohort studies assessed, predominantly due to the lack of use of 












Blinding of participants and personnel Blinding of outcome assessment Incomplete 
outcome data 





Low risk Low risk Low risk- no blinding but outcome not 
likely to be influenced by lack of blinding 
Low risk- no blinding but outcome not 
likely to be influenced by lack of blinding 





High risk High risk Low risk- no blinding but outcome not 
likely to be influenced by lack of blinding 
Low risk- no blinding but outcome not 
likely to be influenced by lack of blinding 




Table 17. Risk of bias for non-randomised studies  
First Author, Year Bias due to 
confounding 
Bias due to 
participant selection 




Bias due to deviations 
from intended 
interventions 
Bias due to 
missing data 
Bias due to 
measurement of 
outcomes 
Bias due to selection 
of reported results 




Serious Low Low No information No information- no 
protocol  
Low No information- no 
protocol 
Serious  
Young, 2018 [277] Serious Low Low No information No information- no 
protocol 
Low Risk of selective 
reporting 
Serious 
Claar, 2014 [279] Serious No information Low Yes (results of adherent 
patients presented) 







Adherence to medication was only addressed fully in one study, which 
highlighted the likelihood of low levels of adherence for prescribed 
medication. This study, reported by Orgel et al, was initially opened as a 
double-blinded, placebo controlled prospective trial testing a daily 
combination of vitamin D3 and calcium citrate [276]. At interim analysis after 
one-third of target accrual only 23% of patients were adherent by report and 
tablet count, and a median of 7% of doses were delivered. It was 
subsequently amended to an open-label trial testing directly observed 
therapy of high dose vitamin D3 (100,000IU) administered in clinic at the 
start of each chemotherapy phase, and calcium supplementation was 
changed to a flavoured, chewable calcium carbonate. With this alteration 
there was 100% adherence to vitamin D3 and 61% adherence to taking 
≥75% of prescribed calcium carbonate. In the abstract presented by Claar et 
al it was reported that 71% of patients were adherent to supplementation, 
but no further details were given regarding methods of assessing adherence 
[279].  
2.3.2.11.3 Primary outcomes 
1a: Prevalence of low impact fractures 
There were no studies with the outcome of prevalence of low impact 
fractures. 
1b: Prevalence of osteonecrosis 
There were no studies assessing impact of vitamin D therapy on prevalence 
of osteonecrosis.  
2a: 1, 2, 3, 5, >5 years and median survival from diagnosis of ALL  
There were no studies assessing impact of vitamin D therapy on survival 
after diagnosis of ALL.  
2.3.2.11.4 Secondary outcomes 
1a: Bone mineral density 
There were 2 small randomised studies [275, 276] looking at BMD following 
vitamin D supplementation, with considerable variability between the studies. 
Neither study found an overall difference in final BMD between groups who 
did and did not have vitamin D supplementation.  The highest quality 
randomised study was that by Orgel et al, in which patients aged over 10 




30ng/ml were treated with cholecalciferol after completion of induction 
chemotherapy [276]. Volumetric bone density was assessed using QCT, and 
no significant differences were observed for trabecular volumetric BMD of 
the lumbar spine, cortical volumetric BMD of the femur, or bone structure 
and geometry between randomised groups [276]. The study by Diaz et al 
assessed pre-pubertal patients with newly diagnosed ALL who were 
randomised to calcitriol treatment or no treatment after completion of 
induction therapy. DXA imaging was used to assess LSBMD, hip BMD, total 
body BMD and total body mineral content, with no difference in BMD found 
between groups [275].  In a subset analysis, with no a priori description of 
planned analysis, a correlation study reported a greater LSBMD increment in 
the children with lower initial BMD in the calcitriol group.  
In the cohort study by Demirsoy et al, 11 patients with newly diagnosed ALL 
had DXA imaging within a week of starting induction therapy and then 
approximately 8 months later. Despite low dose cholecalciferol and calcium 
supplementation in all patients there was a significant reduction in total body 
BMD Z-score, TBLH and L1 to L4 BMD Z-score [278]. When final BMD was 
compared with that of ALL survivors who were 8 to 24 months post-
diagnosis and who had not received supplementation, the BMD was lower in 
the group who had not received supplementation. However, this was a 
historic control group, with BMD measured at a wide range of time-points 
post initiation of treatment. Patients in this historic control group were also 
treated with different chemotherapy protocols, one of which included the 
administration of prophylactic radiotherapy in the medium risk group, making 
the 2 groups essentially incomparable.   
1b: Calcium, phosphate, parathyroid hormone levels 
The study by Orgel at al assessed changes in calcium, phosphate and PTH 
after vitamin D supplementation in young people with ALL, and found that 
after cholecalciferol therapy there were no significant differences in 
corrected calcium, phosphate or PTH levels between treatment and control 
groups [276].  
A small increase in calcium was reported in one cohort study which provided 
patients with calcium supplementation as well as low dose vitamin D 
supplementation, with a reported increase in median calcium level from 9.0 






1c: Vitamin D levels 
All of the 4 studies which assessed vitamin D levels found increases after 
supplementation. Reported results from studies are presented in the Table 
18 below. Specific results were not reported in the abstract by Claar et al, 
but it was reported that with supplementation 92% of adherent patients 
achieved vitamin D sufficiency within 8-12 weeks [279].  
The study  by Orgel et al was the only randomised study assessing changes 
in vitamin D level after supplementation, and found there was a significant 
increase in vitamin D level after directly observed cholecalciferol treatment 
[276].  
Table 18. Changes in vitamin D level after supplementation 
Author, year Baseline median 
vitamin D level 
(ng/mL)  
End of study median 
vitamin D level 
(mg/mL) 
P value Confidence 
intervals 
Young, 2018 [277] 24.7 47.8 Not reported Not reported 
Orgel, 2017 [276] 19.45 26.5 0.026 Not reported 
Demirsoy, 2017 [278] 17.9 23.5 0.01 Not reported 
 
As seasonality will clearly have an effect on vitamin D levels, the papers 
were assessed to determine when each study was conducted to help 
ascertain impact on vitamin D levels. In the paper by Young et al, patient 
recruitment started in November 2014, with 35 patients recruited in winter 
and 34 recruited in summer [277]. However, 53 patients ended the study in 
summer, compared with 16 who ended the study in winter. This could 
potentially result in bias towards an increase in end of study median Vitamin 
D levels. In the study by Orgel et al, patients were enrolled between May 
2011 and November 2014, with a median length of follow up of 6.7 months 
(range 5.5-8.7 months) [276] but numbers of patients recruited in different 
seasons was not documented. If more patients ended the study in summer 
this could result in bias towards an increase in end of study median vitamin 
D levels, but without a full breakdown of patient start and end dates this was 
not possible to determine.   
The timing of recruitment of de novo ALL patients was not clearly 
documented in the study by Demirsoy et al or in the abstract by Claar et al.  
2a: Rate of relapse of ALL 





2b: ALL response to treatment 
There were no studies assessing impact of vitamin D on ALL response to 
treatment. 
 
2.3.2.11.5 Safety analysis  
In the 5 studies included within the safety analysis comprising a total of 191 
patients, there were no reported adverse events as a consequence of 
vitamin D supplementation other than supra-therapeutic, but non-toxic, 
levels of vitamin D. The Loke method has been used for quality assessment 
for the reporting of adverse events (Table 19). It can be seen that definitions 
and methods of data collections for adverse events were rarely published, 
implying adverse events were likely to be detected opportunistically.  
The main adverse events that may be anticipated are hypercalcaemia, 
nephrolithiasis and supra-therapeutic levels of vitamin D. Of these, levels of 
vitamin D over 150ng/ml were reported in 4 of 69 patients (6%) in the study 
by Young et al [277]. This study also reported 8 episodes of nephrolithiasis 
in 7 patients (10%), none of which were in the setting of elevated 25OHD 
levels or hypercalcemia. There were no toxicity or adverse events attributed 
to cholecalciferol or calcium supplements in the studies by Orgel, Demirsoy 
or Claar et al, although the latter 2 studies did not clearly record methods of 
adverse event data collection. The study by Diaz et al was the only study to 
use calcitriol as the intervention of choice. This was reported to be well 
tolerated, with plasma and urinary calcium levels remaining within the 















Which categories of 
adverse effects do the 
investigators report 
How were these defined Method of adverse event 
data collection 
Did the report give 
numerical data by 
intervention group 
Did the investigators 
report on all 




RCT No Hypercalcaemia 
Hypercalciuria 
Not defined Plasma and urine calcium 









Not defined Not reported Yes Yes 
Demirsoy, 
2017 [278] 
Cohort No  Hypercalcaemia 
Symptomatic 
nephrolithiasis  
Not defined Not reported Yes Yes 
Young, 
2018 [277] 





Communication with author: 
Hypercalcaemia (mg/dL): Age 8 weeks 
to 2 years:> 10.5, age 2-10 years:>10, 
age 10-18 years: >10.2, age 18-150 
years:>10.1 
Nephrolithiasis not defined 
Retrospective chart review. 
Vitamin D levels measured 
every 3 months, calcium and 
vitamin D measured at each 









2.3.2.12 Quality of evidence 
Using the Grading or Recommendations, Assessment, Development and 
Evaluations (GRADE) approach to rating quality of evidence [280], (Table 
20), there was moderate to low quality evidence that cholecalciferol 
supplementation at a dose of 100,000IU given 2 monthly for 3 doses has no 
impact on BMD, with low quality evidence that calcitriol supplementation also 
does not impact upon BMD. There was moderate quality evidence that 
cholecalciferol supplementation at a dose of 100,000IU 2 monthly for 3 





Table 20. Grading of recommendations, assessment, development and evaluations evidence profile: vitamin D for children 
with acute lymphoblastic leukaemia 
Outcome of interest  Risk of bias Inconsistency Indirectness Imprecision Publication bias Quality  
Bone mineral density 
        Orgel (RCT) 
        Diaz (RCT) 



























        Orgel (RCT) 
        Demirsoy (cohort) 
 

















Vitamin D levels 
         Orgel (RCT) 
         Young (cohort) 
         Demirsoy (cohort) 


































2.3.2.13 Discussion  
The purpose of this review was to evaluate the safety and efficacy of vitamin 
D in children and young people with ALL. Five studies were included for full 
analysis (2 randomised studies and 3 cohort studies), with a total of 191 
included participants. The studies suggest that in the short term 
cholecalciferol supplementation does not impact upon BMD of patients with 
ALL, despite increasing vitamin D levels. Although one randomised study 
reported a greater LSBMD increment in the children with lower initial BMD in 
patients who received calcitriol, due to lack of clarity over the analysis, and 
despite biological plausibility, there were insufficient data to draw any 
conclusions from this [275].   
Meta-analysis of study results was not possible due to marked statistical 
heterogeneity of reported outcomes and lack of studies with adequate 
sample sizes. Between the studies there was marked variability in patient 
populations, therapeutic intervention and duration of follow up, preventing 
pooling of results and subgroup analysis. All studies were limited by the 
short duration of follow up, which could reduce both detection of adverse 
events and any long-term benefits from treatment.  
Several methodological approaches were used to assess risk of bias in the 
included studies. For RCTs the Cochrane risk of bias was used and study 
protocols were searched for. There was one high quality RCT with a 
published protocol, but with only 29 patients, conclusions drawn from this 
study must be limited [276]. There was a high risk of bias in the one other 
RCT, and their use of calcitriol, rather than cholecalciferol, together with lack 
of assessment of initial vitamin D status in patients, makes it difficult for the 
results of this study to be used in clinical practice [275]. In both of the RCTs 
supplementation to patients was only after induction chemotherapy was 
completed. The study by Orgel et al cited the in vitro results by Antony et al 
[281], as the reason for this delay. This study assessed proliferation of 
leukaemic cell lines in response to dexamethasone alone, and then 
dexamethasone with varying concentrations of calcitriol. However, there 
were a number of important limitations to this study, including lack of 
complete reporting of results, the in vitro nature of the study and lack of 
discussion of the relevance of the concentrations chosen in comparison with 
in vivo concentrations of therapeutic cholecalciferol. Therefore delaying 
treatment purely on the basis of these results may not be warranted.  
For the cohort studies the ROBINS-I was used to assess risk of bias. The 




ethnicity limited the quality of results and led to serious risk of bias in all 
cohort studies included.  
The lack of adherence monitoring in all but one of the papers may have 
limited the likelihood of significant findings. When adherence was assessed 
in one study, it found that less than 10% of prescribed doses were delivered 
[276]. This suggests that in studies with no assessment of adherence, the 
true adherence was likely to be limited, reducing the likelihood of any 
therapeutic benefit.   
The Loke method for quality assessment of safety of vitamin D 
supplementation identified that the majority of studies were unclear on 
definitions and reporting methods of adverse event data collection.  
However, given these limitations, cholecalciferol appeared to be well 
tolerated, with no adverse events reported that would impact on patient 
safety. 
2.3.2.14 Summary 
This systematic review demonstrates that there is currently insufficient 
evidence to conclude that vitamin D supplementation in children and young 
people with ALL has any benefit on fracture incidence, BMD, incidence of 
osteonecrosis, survival time, quality of life, or response to ALL treatment. 
There were no studies which assessed use of vitamin D with respect to any 
of our patient centred primary outcomes. The studies that were included in 
this review did suggest that in young patients with ALL cholecalciferol has a 
good safety profile, although there were limitations with the adverse event 





Chapter 3 A retrospective national study of osteonecrosis in 
children and young people with acute lymphoblastic 
leukaemia 
3.1 Introduction 
Within haematology departments there has been an increasing awareness 
of ON as a significant consequence of ALL treatment, yet many aspects, 
including management and long term outcomes, remain unknown. For the 
UK population of young people being treated for ALL it is important that we 
accurately determine the prevalence and chronology of ON, identify risk 
factors and understand the management and long term consequences of the 
condition. This will enable clinicians to more accurately inform and 
prognosticate for patients who are at risk or who have developed ON during 
ALL treatment.  
The primary aims of this study were to:  
 Report the UK prevalence of symptomatic ON in young people with 
ALL recruited into UKALL 2003 
 Describe the chronology of development of symptoms of ON and 
diagnosis 
 Identify risk factors for the development of ON 
 Determine joints affected by ON and methods of diagnosis of ON in 
patients with ALL 
 Describe medical and surgical management of patients diagnosed 
with ON  
 Establish long-term outcomes of patients affected by ON  
This was undertaken in a cohort of patients enrolled to the national ALL trial 
for children and young adults, UKALL 2003, that ran from 2003 to 2011.  
The methodology and results will be presented in this chapter, with a 
discussion of the results in Chapter 5.  
3.2 Methods 
3.2.1 Patient population 
The patient population assessed in this study were the 3113 patients aged 




national ALL study which aimed to assess whether treatment intensity could 
be adjusted for children and young adults according to MRD risk 
stratification. Patients were recruited in 45 centres in the UK and Ireland 
between Oct 1, 2003 and June 30, 2011 and all patients had a diagnosis of 
ALL which was diagnosed with standard morphological and flow cytometric 
criteria [128, 282]. An outline of treatment regimens is presented in Figure 9.  
Initial risk stratification occurred at presentation, which was subsequently 
reviewed at day 15 and 28 of induction, with day 8 rather than day 15 used 
for patients on regimen B aged 1-15 year. At these points risk stratification 
incorporated cytogenetics and early response to induction therapy, assessed 
by bone marrow blast counts. Patients who started treatment on regimen A 
were aged < 10 years at diagnosis of ALL, with a highest WCC before 
starting treatment of less than 50x109/L. Regimen B was for patients defined 
at high risk of relapse because of their age (>10 years) or presenting white 
cell count (≥50x109/L).  
Patients were put onto regimen C if they either had a slow early response in 
regimen A or B, had MRD positive day 28 bone marrow and were 
randomised to regimen C, or had unfavourable cytogenetics (hypodiplidy, 
t(4:11), t(9;22), iAMP21, E2A-HLF) [128]. Patients with Philadelphia-
chromosome-positive ALL were transferred onto other protocols once their 
Philadelphia chromosome status was known. 
MRD low risk patients were randomly assigned to 1 (reduced treatment) or 2 
(standard treatment) blocks of DI and MRD high risk patients were randomly 
assigned to standard treatment or regimen C, a more treatment intensive 
schedule. Patients with indeterminate MRD status at day 28 received 2 
blocks of DI. An outline of risk groups and randomisations is presented in 
figure 10.  
In 2009 the randomisation of MRD low risk patients to 1 or 2 blocks of DI 
was closed due to accrual of the target number of patients, and subsequent 
patients received a block of single delayed intensification.  
Dexamethasone doses: 
All patients received a daily dose of 6mg/m2/day oral dexamethasone during 
induction for 28 days with a maximum dose of 10mg. Patients on regimen A 
and B received dexamethasone during interim maintenance, at a daily dose 
of 6mg/m2 oral dexamethasone on days 1-5 and days 29-33 in regimen A, or 
days 2-6 and days 30-34 in regimen B. In those who received 2 blocks of DI, 




patients received 10mg/m2 dexamethasone daily for two weeks, on alternate 
weeks, with no cap on the dose. Maintenance therapy was run in 12 week 
cycles, and in each cycle patients were given 6mg/m2/day oral 
dexamethasone on days 1-5, 29-33 and 57-61 of each cycle. 
In UKALL 2003 the upper age limit of entry was 18 years at the start of the 
trial, but increased to 20 years in February 2006, and to 24 years from 
August 2007. This was due to retrospective studies showing improved 
outcomes in young adults when treated on paediatric protocols. In June 
2008 the overall treatment intensity for patients with Down syndrome was 
reduced due to excess treatment-related mortality. From June 2008 Down 
syndrome patients were registered on the trial but did not undergo 
randomisation and were treated as clinical standard-risk patients, with 









Figure 10. Treatment and randomisation algorithm in UKALL 2003 
 
3.2.2 Questionnaire development  
In UKALL 2003 long-term monitoring of patients who developed ON was not 
a routine part of data collection, although there was reporting of patients with 
severe ON. I therefore developed a questionnaire in collaboration with the 
Consultant Paediatric Haematologists at Leeds Children’s Hospital to 
understand more about the prevalence, management and outcomes of 
patients with ALL who developed symptomatic ON (Appendix 3). A 
questionnaire was felt to be the most appropriate method of data collection 
as it is a practical method of data collection from a large cohort of people. It 
was important to carefully consider the design of the questionnaire, to 
ensure readability, ease of use, and ease of analysis. Key areas for data 
collection were identified from the literature review (Chapter 2.1), with a 
focus on areas of insufficient or inconclusive data, such as time to diagnosis, 
medical and surgical management and long term outcomes. It was important 
to include questions on the chronology of the development of ON, including 
when symptoms were first reported, and timing of diagnosis. The aim of this 
was to establish if there were significant delays in diagnosis of ON in this 
population. Method of diagnosis and reports of all diagnostic imaging were 
requested, to enable us to verify the diagnosis. The feasibility of requesting 
imaging directly was considered. This would allow grading and true 
confirmation of ON, but at the time of initial data collection it was felt that 
there was not sufficient technical expertise within the team for this to be 
appropriately utilised.  
There is limited information about the medical and surgical management of 




understanding of patient care across the country. Specific information 
regarding cessation of steroids, use of bisphosphonates, vitamin D and 
surgical interventions was requested. These were chosen as all have been 
previously been considered as potential therapeutic interventions in the 
management of ON, although as previously discussed, evidence is limited.   
Throughout the questionnaire closed questions were used when possible, 
providing the respondent with a rapid method of indicating their response, 
and increasing ease of analysis. There were areas where open questions 
were felt to be more appropriate, including symptomology and types of 
surgery. This was to prevent ‘suggestion’ of answers for symptoms felt to be 
attributed to ON, and to allow data collection on the full range of surgical 
procedures undertaken.   
Prior to distribution of the questionnaire the data manager at Leeds 
Children’s Hospital, together with other data managers working in the UK, 
assessed readability and clarity of the questionnaire. This helped to ensure 
that questions were as objective as possible, with minimal ambiguity. I 
subsequently piloted this on 10 patients in Leeds Children’s Hospital. Our 
data manager also tested the questionnaire separately on a sample of these 
10 patients. Success of the pilot was assessed by appraising ease of data 
collection and questionnaire use, time taken to complete the questionnaire 
and readability of the questionnaire. This included consideration of factors 
such as layout of the questionnaire, and avoiding bias in questions. It was 
important that the questionnaire was as clear, concise and as direct as 
possible, with avoidance of redundant questions. After piloting the 
questionnaire, minor changes were made to layout and wording of 
questions, prior to national distribution.  
In the final questionnaire, areas of data collection included: 
 Patient demographics 
 Joints affected by ON 
 Timing of onset of symptoms 
 Timing of diagnosis of ON 
 Fracture history 
 Method of diagnosis of ON 
 Medical management of ON  
 cessation of steroids  
 bisphosphonate use 
 vitamin D supplementation 




 Long term effects: 
 no long term effects  
 minimal disability (able to carry out activities of daily living) 
 significant disability (unable to carry out activities of daily 
living) 
 requires a wheelchair 
 death (any cause) 
 
3.2.3 Data Source 
The central trial unit (Clinical Trials Service Unit) for UKALL 2003 was 
notified of patients who developed bone toxicity (including ON, osteopenia 
and fractures) during their leukaemia treatment. Reporting was via toxicity 
reporting forms (Appendix 5), which specifically requested data regarding 
ON, or serious adverse event forms. A serious adverse event was defined 
as any adverse event that was life-threatening, required unexpected 
hospitalisation or prolongation of a hospital stay, resulted in persistent or 
significant disability or incapacity, or resulted in death.  
After receiving approval from the Chief Investigator of UKALL 2003 a list of 
these patients from the Clinical Trial Service Unit was obtained, together 
with demographic and treatment details, including age at diagnosis of ALL 
and ethnicity data. Ethnicity was determined by self-report, and categorised 
into the following groups: Black, White, Asian, Oriental, Middle Eastern, 
Mediterranean, mixed, other, unknown.  
3.2.4 Questionnaire distribution 
Between 08/04/2015 and 20/04/2015 each of the 40 primary treatment 
centres (PTCs) were contacted via NHSmail, a secure e-mail service 
authorised for sending sensitive information. Contact was made with the 
data manager, research nurse and consultants caring for these patients, 
listing patients identified by the central trial unit who were reported to have 
suffered from bone toxicity in their centre, based on information from toxicity 
reporting forms. The questionnaire could be completed by any of these 
people. A questionnaire was attached to the e-mail for completion for each 
patient, together with a supplementary form developed to identify and gain 
further information on those patients who were not previously reported to 




3.2.5 Managing returns and data collection 
Up to 5 reminders were sent out to centres over the course of 8 months to 
improve questionnaire uptake. All completed questionnaires were sent back 
to myself, together with imaging reports.  
3.2.6 Statistical analysis  
An Access database was developed in order to store and collate 
questionnaire data. Access was chosen as the most appropriate format for 
this as it readily allows data cleaning, data validation and development of 
data searches and reports. Seven tables were constructed to allow thematic 
collation of data, based on the main sections of the questionnaire. Free text 
responses were coded to allow ease of data analysis. Once data entry was 
complete, queries were generated to allow further analysis. Height and 
weight variables had to be dropped from analysis as data were missing for 
over 80% of patients.  
Descriptive analysis, including medians, cumulative incidence, and 
interquartile range (IQR) was used to describe the prevalence of ON in the 
cohort of patients and chronology of development of symptoms of ON and 
time to diagnosis. Percentages were used to describe the joints affected by 
ON, the management of ON and long term outcome of patients affected by 
ON. Sub-analysis was undertaken for those patients who received 
bisphosphonates and those who had surgical interventions for ON.  
Univariable and multivariable logistic regression analyses were used to 
identify significant differences in the prevalence of ON according to age 
group at diagnosis (age < 10, 10-15 and 16+ years), sex, ethnicity (White, 
Black, Asian, other), and treatment (1 or 2 rounds of DI). Ethnic groups other 
than Black, White and Asian were combined due to the small numbers of 
patients in these groups. Odds ratios and 95% confidence intervals were 
reported as measures of association.  
The minimal sufficient set of confounders adjusted for was based on a 
causal inference framework identified by the drawing of a DAG [283, 284] 
(Figure 11, model code in Appendix 7). A DAG is a graphic model depicting 
a set of hypotheses about the causal process, which in turn generates a set 
of variables of interest. The use of DAGs is a mathematically rigorous 
method for minimising bias and determining true confounders [284]. The 
causal diagram is developed as a graphic model by explicitly defining the 
theoretical causal relations between each covariate (including the main 




arrows represent assumed direct links from cause to effect. Causal paths 
start at the exposure, contain only arrows pointing away from the exposure, 
and end at the outcome. Biasing paths are all other paths from exposure to 
outcome. Emphasis is placed on assuming a theoretical relationship exists 
between every pair of covariates unless there is convincing evidence of a 
null relationship. Each covariate in turn can be considered as the main 
exposure variable so that bespoke model adjustment can be made thus 
avoiding the table 2 fallacy [285], whereby multiple adjusted effect estimates 
from a single model are presented in a single table.  
Figure 11. Directed acyclic graph for causal effect identification in 
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Using the DAG from Figure 11, the results suggested that the minimal 
sufficient adjustment sets for estimating the effect of number of DI blocks on 
development of ON were age, sex and ethnicity. No adjustment was 
necessary to estimate the total effect of ethnicity, age or sex on development 
of ON. The model suggests that the total effect of treatment regimen cannot 
be estimated by covariate adjustment, hence further analysis of this was not 
undertaken.  
Multivariable logistic regression was therefore only performed for 
assessment of the impact of number of DI blocks, which was adjusted for 
age, sex, and ethnicity, with univariable logistic regression used for age, sex 
and ethnicity.  
Statistical analysis was undertaken using Stata version 14 (StataCorp, 2015) 
(Appendix 6 for Stata code). The directed acyclic graph (DAG) was 
developed and analysed using DAGitty version 2.3, a web-based software 
program for analysing causal diagrams. 
3.2.7 Ethical permission 
Consent for this work was covered by existing consent for UKALL 2003, 
ISRCTN07355119. 
3.3 Results 
A total of 292 patients were reported by the Clinical Trials Service Unit as 
having some form of bone toxicity (which included symptomatic severe 
osteopenia, fracture and avascular necrosis) and questionnaires were 
completed for 90% of these patients. There was no explanation given for the 
lack of questionnaire completion in 25 of the 28 cases where there was no 
response (23 centres), and notes were not available for the remaining 3 
patients (Appendix 8 provides details of questionnaire responses according 
to centre). The median duration of follow-up for patients from time of ALL 
diagnosis was 70.5 months (range 24-127 months, IQR 54-86 months). 
3.3.1 Prevalence of osteonecrosis in UKALL 2003 
In the cohort of 264 patients for which results were obtained, 170 patients 
were reported to have ON (Figure 12). This is 55 more patients than were 
formally reported via toxicity reporting alone [128]. Given the total number of 
patients recruited to UKALL2003 was 3113, the overall prevalence of ON in 





Figure 12. Questionnaire response rate for patients with bone toxicity 
Demographic details of the 29 patients with no questionnaire response, 
compared with all patients enrolled into UKALL 2003 and patients with 
radiographically confirmed ON, are provided in Table 21. Patients for whom 
no questionnaire response was received were not included in the overall 
analysis of patients, as ON was not able to be confirmed. The p-value 
(calculated using a Chi-squared) represents the comparison between 
columns 2 and 3. Although there were significantly more patients aged over 
10 years for whom questionnaire responses were not available, the absolute 
number of patients was small (n=26). There were no other areas in which 
the patients with no questionnaire responses differed significantly from those 
for whom we were able to confirm a diagnosis of ON.  
Table 21. Demographic details of patients  










P-value All trial patients 
(n=3113) (%) 
Age (years)at diagnosis of 
ALL 
                     <10 
                     10-15 






















                  White 
                  Asian 
                  Black 



























                  Male 

















3.3.2 Chronology of symptomatology and diagnosis of 
osteonecrosis in patients with acute lymphoblastic 
leukaemia  
In this cohort of patients, symptoms of ON were reported in 139 patients, 
and were typically pain and/ or reduced range of movement. Symptoms of 
ON presented in lower limbs for 118 patients (85%), both upper and lower 
limbs for 6 patients (4%) and upper limbs for 12 patients (9%). Back pain 
was the presenting symptom of ON in 2 patients (1%).  
Symptoms of ON were reported at a median of 14 months after diagnosis of 
ALL (IQR 10-19 months). The date of diagnosis of ON was not available for 
6 patients. Of the remaining 164 patients, ON was diagnosed at a median 
time of 16 months after diagnosis of ALL (IQR 12-22 months).  
In patients who presented with upper limb symptoms, the median time from 
diagnosis of ALL to development of symptoms of ON was 17 months (range 
9-32 months, IQR 14-21 months), compared with 13.5 months for those who 
presented with lower limb symptoms (range 1-72 months, IQR 10-19 
months), but there was not found to be a significant difference between the 
groups (p=0.60, CI -8.58 to 5.00).   
In the 1st year after diagnosis of malignancy, 35 patients were diagnosed 
with ON (21% of all patients diagnosed with ON), with 91 patients diagnosed 
during the 2nd year (55%), and 25 diagnosed during the 3rd year (15%). Eight 
patients were diagnosed between 3 and 5 years after diagnosis of 
malignancy (5%), and only 2 patients were diagnosed with ON after 5 years 
(1%). The longest time to diagnosis of ON was 6.26 years after diagnosis of 
ALL. The cumulative incidence of ON diagnosed in all patients was 1.1% at 
1 year, 4.0% at 2 years, 4.9% after 3 years, 5.1% at 5 years and 5.2% at 7 
years. For patients over the age of 10 at diagnosis of ALL, the cumulative 
incidence of ON was 3.3% at 1 year, 12.5% at 2 years, 15.1% at 3 years, 










Figure 13. Cumulative incidence of osteonecrosis in UKALL 2003 
 
 
3.3.3 Risk factors associated with development of osteonecrosis 
Age, ethnicity, sex and 1 versus 2 blocks of DI were assessed as risk factors 
in development of ON. Univariable and multivariable analysis was 
undertaken using the results of the DAG assessment described previously 
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Table 22. Results of univariable logistic regression analysis of age, sex and ethnicity, and association with osteonecrosis in 
patients with acute lymphoblastic leukaemia 
  Univariable logistic regression 




Odds ratio 95% Confidence intervals P-value 
Age (years)       
 <10 22 (1) 2257 (99)    
 10-15 111 (18) 496 (82) 22.96 14.38-36.64 <0.001 
 16-20 32 (17) 154 (83) 21.31 12.09-37.57 <0.001 
 21+ 3 (7) 38 (93) 8.10 2.32-28.22 0.001 
Ethnicity       
 White 141 (6) 2384 (94)    
 Black 3 (4) 71 (96) 0.73 0.23-2.35 0.60 
 Asian 15 (6) 217 (94) 1.20 0.69-2.07 0.05 
 Other 11 (4) 271 (96) 0.91 0.52-1.59 0.73 
Gender       
 Male 96 (5) 1671 (95)    
 Female 74(5) 1272 (95) 1.04 0.76-1.43 0.79 
No. of blocks of delayed intensifications       
 2 138 (6) 2142 (94)    





Table 23. Results of multivariable logistic regression analysis of number of blocks of delayed intensification and association 
with osteonecrosis in patients with acute lymphoblastic leukaemia 
  Univariable logistic regression Multivariable logistic regression 












No. of delayed intensifications          
 2 138 (6) 2142 (94)    1.00   






It is clear that age at diagnosis of ALL was an important risk factor for the 
development of ON, with the highest risk of developing ON in the 10-20 year 
age group. Patients over 20 years of age at diagnosis of ALL were still at 
greater risk of developing ON compared with those under 10 years of age, 
but at a lower risk than those aged between 10 and 20 years at diagnosis. 
The full distribution of age of patients who developed ON is illustrated by 
Figure 14, with the x-axis representing the age at which ALL was diagnosed 
[286].  
Figure 14. Age of patients in UKALL 2003 with symptomatic 
osteonecrosis. 
 
A contingency table was used to assess if there was any age by gender 
interaction for development of ON. The results in Table 24 suggest the lack 
of significance, which was confirmed in a likelihood ratio test, where the 
addition of age by gender interaction for categorical variables showed no 
significance (p=0.96). 
Table 24. Age by gender interaction for development of osteonecrosis 
Age Females Males 








<10 1005 (98.82) 12 (1.18) 1252 (99.21) 10 (0.79) 
10-15 207 (81.18) 48 (18.82) 289 (82.10) 63 (17.90) 
16-20 51 (83.61) 10 (16.39) 103 (82.40) 22 (17.60) 




3.3.4 Method of diagnosing osteonecrosis  
MRI was the most common method of imaging to confirm the diagnosis of 
ON in UKALL 2003, used in 140 (82%) patients. Plain X-rays were used for 
diagnosing ON in 27 patients (16%) across 10 centres. There appeared to 
be centre specific variation in method used to diagnose ON, with two large 
centres diagnosing around 40% of cases of ON using X-ray. The diagnostic 
imaging modality was unknown in 3 patients (Figure 15). Of those that had 
X-rays to diagnose ON, 16 patients subsequently had MR imaging (59%). All 
of the imaging reports were reviewed to verify the diagnosis, with no 
inaccurate diagnoses made. 
Figure 15. Imaging modality used for diagnosis of osteonecrosis  
 
3.3.5 Joints affected by osteonecrosis  
Of the 170 patients who developed ON, there were a total of 480 joints with 
confirmed ON. Fifteen percent of patients (n=26) had unifocal ON. In those 
under the age of 10 years at diagnosis of ALL, of those who developed ON 
(n=22), 5 patients had unifocal ON (23%). 











Figure 16. Number of joints affected in patients with osteonecrosis 
   
In the 170 patients, hips (34%, n=165), knees (32%, n=154), shoulders 
(14%, n=67) and ankles (10%, n=46) were the most commonly affected 
joints (Figure 17). A total of 99 patients (58%) had at least 1 hip affected, 
and of these 59 people (35%) had 2 affected hips.  
A total of 41 (24%) people had at least one shoulder affected by ON, with 35 
(21%) of these having both shoulders affected. There were 87 people (51%) 
who had at least one knee affected by ON, of which 76 patients (45%) had 
both knees affected. Of the 99 patients who had at least one hip affected by 
ON, 32 patients (32%) also had at least one knee affected, and 29 had at 
least one shoulder affected (29%). Only 18 patients (11%) with ON had no 
hips or knees affected.  
Figure 17. Joints affected by osteonecrosis  
 
3.3.6 Medical management of patients 
There was significant variation in the medical management of patients 
































3.3.6.1 Steroid management 
In the UKALL 2003 protocol there was initially no specific guidance about 
continuation or cessation of steroids after a diagnosis of ON. From 2009, 
centres were advised to contact the Trial Coordinators if ON developed 
before maintenance therapy, and for further steroids to be omitted if ON 
developed during maintenance. In 60% of cases steroids were stopped 
(although the specific timing of stopping steroids was not collected). In 32% 
of cases steroids were continued, and in 8% of cases it was unknown 
whether steroids were stopped due to ON. There were 3 centres in which all 
the patients who developed ON had their steroids stopped (Addenbrooke’s, 
Sheffield, North Staffordshire), others where the vast majority of patients had 
steroids stopped (Bristol, Manchester, Southampton), and others where the 
majority of patients continued on steroids after diagnosis of ON (Our Lady’s 
Children’s Hospital in Ireland, Leeds Children’s Hospital). The date and 
rationale for cessation of steroids was not requested. In 3 of the patients it 
was reported that dexamethasone was changed to prednisolone subsequent 
to the diagnosis of ON.  
3.3.6.2 Use of bisphosphonates 
Bisphosphonates were used in 27% of patients with ON (n=43). In the 
majority of centres intravenous pamidronate was used as the 
bisphosphonate of choice, although in one centre (Christie Hospital, 
Manchester, which is a teenage/ adult institution) all patients received oral 
alendronate. In Birmingham the 2 patients that were given bisphosphonates 
were given zolendronate, and in Manchester Children’s Hospital of the 9 
patients that were given bisphosphonates, 6 were given oral risedronate. 
Figure 18 illustrates frequency of different forms of bisphosphonate used 
across all centres. Of the 40 centres involved in this study, 13 used 
bisphosphonates in some of their patients with ON. Information regarding 










Figure 18. Type of bisphosphonates given to patients with 
osteonecrosis 
 
In the 170 patients reported to have ON, 35 were reported to have fractures 
(21%). Of the 43 patients who were given bisphosphonates, 12 patients 
were reported to have fractures (28%), and 13 were reported to have had an 
assessment of their BMD. Of these 13 patients we were able to obtain the 
initial DXA reports for 9 patients, and 7 out of 9 patients had a lumbar spine 
Z score of <-2 SDS.  
3.3.6.3 Vitamin D use in patients with osteonecrosis  
Vitamin D supplementation was provided to patients in 32% of cases. 36% 
of patients received no supplementation, whilst provision was unclear in the 
remaining 32% of cases. Details regarding vitamin D sufficiency, treatment 
modality or date of initiation of treatment were not requested.  
3.3.7 Surgery in patients with osteonecrosis   
Of the 170 patients who were diagnosed with ON, 65 were reported to have 
had surgery related to their ON (38%). These 65 patients underwent a total 
of 99 surgical procedures, with a number of centres reporting that patients 
were awaiting further surgical events [286]. The surgical procedures 



















Table 25. Surgical procedures reported in patients with osteonecrosis 
Type of surgery Number of patients (%) 
Hip replacement 33 (19) 
Core decompression 22 (13) 
Knee replacement 2 (1) 
Shoulder replacement 2 (1) 
Arthroscopy 10 (6) 
Hip fixation 2 (1) 
Other 10 (6) 
 
Total hip replacements (THR) were the most common surgical procedure 
described in our cohort of patients. Core decompression, which involves 
drilling into the area of ON, was the second most common surgical 
procedure reported. In the 10 patients who had arthroscopy, only 3 received 
arthroscopy alone. Additional procedures undertaken included synovial 
debridement, meniscotomy, correction of osteochondral defects, reshaping 
of the femoral head, removal of loose bodies and joint stabilisation. Multiple 
joint replacements were required in 16 patients, with 12 patients requiring 
bilateral THR. The 2 patients who needed shoulder replacements also 
needed a hip to be replaced, and 1 patient needed a knee and hip to be 
replaced. There was 1 patient who had 3 joints replaced (bilateral THR and 
one knee replacement). The median age at which joint replacement was 
performed was 19.25 years. The youngest age at which a joint was replaced 
was 12.9 years.  
Of the 22 patients who were under 10 years of age at diagnosis of ALL and 
who developed ON, only 4 (18%) had any form of surgical management (2 
had core decompression, 2 had joint replacements). The youngest age of 
joint replacement was 8 years.  
When affected hips, knees, ankles and shoulders were assessed in turn, the 
following results were found:  
3.3.7.1 Hips 
Of the 165 hips affected by ON, there were 47 THRs reported (28% of all 





Other procedures identified were:  
 Hip fixation: n=4 
 Reshaping of femoral head: n=2 
 Removal of femoral spurs: n=2 
 Osteoplasty: n=1 
 Osteotomy: n=1 
 Articulated distraction: n=1 
3.3.7.2 Knees 
A total number of 154 knees were reported to be affected by ON. Of these, 3 
had knee replacement (2%), and 5 (3%) had core decompression. There 
were arthroscopies performed in 5 knees (3%) affected by ON.  
3.3.7.3 Shoulders 
There were 67 shoulders affected by ON, and of these, 3 (4%) went on to be 
replaced, and 2 core decompressions were performed (3%).  
3.3.7.4 Ankles 
Of the 46 ankles reported to be affected by ON, 3 (6.5%) had core 
decompression performed.  
3.3.8 Long-term outcomes of patients affected by osteonecrosis 
In the questionnaire distributed to centres, the long term effects of ON were 
defined as the effect of ON at the most recent follow-up consultation.  
Despite the high incidence of surgery in patients affected by ON, at the time 
of data collection (median 70.5 months follow-up) the majority of patients 
who had ON were reported to have either no long term effects (39%, n=66), 
or minimal disability (38%, n=64). Significant disability was reported in 9% of 
patients (n=16), and 5 patients required a wheelchair (3%). Six percent of 
patients had died at time of data collection, and information was not 
available for 9 patients (5%). These results are illustrated in Figure 19. This 
distribution was similar for patients both under and over 10 years of age at 








Figure 19. Long term outcomes of patients affected by osteonecrosis 
who had surgical intervention 
  
 
Of the patients who had surgery, 54% (n=35) were reported to have minimal 
disability and 29% reported no long term effects. Despite surgical 
intervention 7 patients (11%) still described the presence of significant 
disability. 3 patients who had surgical intervention (arthroplasty in 2 patients, 





















3.4 Detailed analysis of surgical and radiographic outcomes 
in children and young adults in UKALL 2003 affected by 
osteonecrosis 
3.4.1 Introduction 
The previously described retrospective national study of ON in patients 
recruited into UKALL 2003 highlighted the considerable surgical burden of 
ON [286]. However, in the initial data collection the high prevalence of 
surgery was unanticipated, and detailed information was not requested.  
The primary aim of this additional work was to gain further information about 
surgical procedures used in different joints affected by ON, ascertain the 
timing of procedures and the use of sequential procedures in the 
management of this challenging condition. These results are described in 
part A, whilst part B uses radiographic staging of osteonecrotic lesions to 
assess the effectiveness of core decompression in preventing joint collapse 
for patients with ON affecting the femoral head.  
3.4.2 Methods 
The methodology for identifying patients with ON has previously been 
described in Chapter 3.2.   
A further letter of contact and a questionnaire was developed in collaboration 
with the paediatric orthopaedic team and the paediatric haematology team 
(Appendix 9). Prior to distribution the data manager at Leeds Children’s 
Hospital assessed readability and feasibility of returning the information 
requested. 
All centres who had previously reported patients with ON in UKALL2003 
were contacted again with a short questionnaire for completion. The 
following information was requested for each reported patient: 
 Operation notes 
 Orthopaedic clinic letters 
 Radiographic imaging of areas of ON  
 Current levels of pain 
 Current mobility status 
3.4.2.1 Questionnaire distribution 
Between February 2018 and July 2018 each of the PTCs were contacted via 




centre, and patients were listed according to their trial number and date of 
birth.  
Up to 3 reminders were sent out to centres over the course of the 6 months 
to improve questionnaire uptake.  
3.4.2.2 Analysis 
The initial Access database developed for collection of UKALL2003 
retrospective data was modified to allow input of additional clinical data from 
this work, allowing integration of previously collated data. Pain and mobility 
status were coded to allow ease of data analysis. Pain was categorised into 
no pain/ occasional pain relief required/ regular pain relief required. Mobility 
status was categorised into the following groups: requiring wheelchair; 
requiring crutches; limited mobility; full mobility. Where available, details 
from operation notes were extracted and inputted into the central database.  
For Part A, descriptive analysis, including medians, percentages, chi-
squared test and IQR was used to describe the demographics of the 
population, timing of surgical interventions and surgical procedures used.  
For Part B, radiographs were scored by a tertiary paediatric radiologist as 
per the scoring system developed by Niinimäki et al in order to determine the 
stage and extent of the osteonecrotic lesion [167]. The diagnostic MRI was 
used to grade the lesion. Subsequent imaging was used to determine final 
grade of ON. Plain radiographs were only used to determine the presence or 
absence of collapse of the femoral head (grade 5 ON).  
A Kaplan-Meier failure time plot was used to estimate and graphically 
summarise time from initial diagnosis of ON to the end-point (grade 5 ON 
(joint collapse)/ total hip replacement (THR)). When the end-point was not 
reached the patient was censored. The Cox proportional hazards model was 
used to compare the use of core decompression with no joint preserving 
surgical intervention, with Breslow’s method for ties to adjust for the natural 
clustering of joints within patients [287]. The patients with grade 4 ON at 
diagnosis were analysed as a subset in an ad hoc subgroup analysis. A 
causal inference approach using DAGs was used to determine the need for 
covariate adjustment (Figure 20), showing that no additional adjustment was 
necessary to estimate the total effects for age or sex (DAG code available in 
Appendix 7). The total effect for initial grade of ON could not be estimated by 
covariate adjustment. Statistical analysis was undertaken using Stata 
version 14 (StataCorp, 2015) and dagitty software was used for develop of 





Figure 20. Directed acyclic graph for causal effect identification of 
development of grade 5 osteonecrosis 
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3.4.3 Results: Part A 
Surgical management of patients with osteonecrosis   
Of the 170 patients reported to have developed ON during UKALL2003, 
further information was received for 85 patients (50%) from 14 centres. The 
main reason for lack of supply of further information was insufficient data 
manager capacity, or lack of capacity to supply radiological images on disk. 
Median duration of follow up was 83 months for these 85 patients.  
Sixty surgical operation notes were available for review (64%), and 
additional details regarding the surgery are provided for these patients. 
3.4.3.1 Demographics 
Demographic details of patients for whom information was received, 
compared with all patients with confirmed ON are provided in Table 26. It 





Of the 85 patients with follow-up data, the median age of patients at 
diagnosis of ALL was 13.83 years (IQR: 11.79-15.54 years), with a median 
age at diagnosis of ON of 15.21 years (IQR: 13.17-17.04 years).  
Table 26. Comparison of demographic details for all patients with 
confirmed osteonecrosis with those for whom secondary 
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It was reported that 1 patient of the 85 patients with questionnaire responses 
had bone marrow transplantation- however this information was not 
specifically requested at time of questionnaire distribution. 3 patients had 
died at the time of questionnaire data collection (2 died from relapse, one 




3.4.3.2 Joints affected 
In these 85 patients a total of 206 joints were affected. The most commonly 
affected joints were hips, knees, shoulders and ankles (Figure 21). 
Additional areas affected by ON were long bones (n=1), sacrum (n=1), 
elbows (n=4), wrists (n=2) and metacarpals (n=1).  
 
Figure 21. Joints affected by osteonecrosis in UKALL 2003- surgical 
sub-study analysis 
 
3.4.3.3 Surgical procedures 
Some form of surgical intervention was required in 47% of patients (n=40), 
with 94 surgical procedures were performed in total. At least one surgical 
procedure was performed in 33% of all joints affected by ON (n=69), with 
more than one procedure performed in 8% of joints (n=17). Type of surgery 
is detailed in Table 27.  
Table 27. Surgical procedures performed in joints affected by 
osteonecrosis 
Type of surgery Number of joints 
Hip replacement 36 
Shoulder replacement/ resurfacing 4 
Knee replacement 4 
Core decompression 32 






































A total of 43 joints were replaced, with 21% of all joints affected by ON 
requiring arthroplasty. 
Core decompression was undertaken in 32 joints (15%), and was most 
commonly performed on the femoral head (n=25) (30%). Core 
decompression was also performed on 4 knees, 2 ankles and 1 shoulder 
joint. The specific indication for core decompression was not requested from 
centres, and was not able to be consistently elucidated from clinic letters 
provided.  
There were 30 patients who had arthroplasty as their primary intervention; of 
these 25 were hip replacements, 3 were shoulder replacements/resurfacing 
and 3 were knee replacements.  
3.4.3.4 Timing of surgical intervention 
The median age at first intervention for affected joints was 17.45 years (IQR 
15.30-19.60 years). 
The median patient age for joint replacement was 18.92 years (IQR 17.33 to 
20.17 years), with a median age for hip replacement of 18.38 years (IQR 
16.96 to 19.90 years). Joints were replaced at a median of 3.83 years after 
the diagnosis of ALL (IQR 3.17-4.83 years).  
The median patient age at which core decompression was performed was 
15.25 years (IQR 13.17 to 17.96 years), which was a median of 2 months 
after the diagnosis of ON (IQR 1.00 to 7.00 months). The median time for 
core decompression after the diagnosis of ALL was 20 months (IQR 14.00-
30.00 months).  
3.4.3.5 Joint specific analysis of interventions for osteonecrosis  
3.4.3.5.1 Hips 
A total of 84 hips were affected by ON, with 25 core decompressions 
performed (30% of hips affected by ON).  One patient with core 
decompression had shelf osteotomy at the same time as core 
decompression. The operation notes were available for 16 patients (64%). A 
pre-operative arthrogram was performed in 1 patient. Four hips had 
Osteoset® bone graft substitute (25%), and 2 hips had bone marrow 
aspirate used at the time of the decompression (13%). The most common 
technique used at the time of decompression was 2 cannulated drill passes. 
The number of cannulated drill passes ranged from 1 to 5. Of those that had 




There was a total of 36 THRs (43% of all hips affected by ON), with 26% of 
all patients requiring at least one hip replacement (n=22). Of these patients, 
operation notes were available for 22 patients (61%). Eight different 
prosthesis were used, with one operation note not stating the prosthesis 
used. The most common prosthesis was an Exeter stem with either a 
contemporary acetabular component (n= 5, 23%) or a Trident acetabular 
component (n=5, 23%). The most common fixation technique was a hybrid 
THR (n=9, 41%), followed by an un-cemented system (n=7, 32%) and then a 
cemented system (n=6, 27%). The most common bearing surface was 
ceramic on ceramic (n=14, 64%), followed by ceramic on polyethylene (n=8, 
36%).  
There was no surgical procedure performed in 33 hips (38%). A small 
number of affected hips underwent other procedures, some of which went on 
to THR. These included cheilectomy of femoral head and neck in 1 patient, 
arthroscopy in 2 patients, excision arthroplasty + pelvic osteotomy in one 
patient, and femoral lengthening following excision arthroplasty in one 
patient.  
Results are presented in Figure 22.  
Figure 22. Surgical management of hips affected by osteonecrosis 
  
3.4.3.5.2 Shoulder 
Of the 33 shoulders reported to be affected by ON. Only one had core 
decompression, and in this case there was no further surgical intervention. 
Four shoulders were replaced/ resurfaced (12%). No surgical procedure was 
performed in 28 shoulders. One patient had a hemi-cap fixation and 1 had 























ON affected 66 knees in our cohort of patients, and of these, 4 knees were 
replaced (6%), and 4 had core decompression as the only surgical 
intervention (6%). No surgical procedure was performed in 55 knees 
affected by ON (83%). Other procedures carried out were arthroscopy and 
removal of loose body (n=3, 5%), curettage and bone graft (n=1, 2%) and 
reduction and internal fixation of an osteochondral fracture (n=1, 2%).  
3.4.3.5.4 Ankles 
A total of 14 ankles were affected by ON. Two ankles had core 
decompression, one of which went on to have arthroscopy and debridement, 
with no surgical intervention in the remaining 12 ankles (86%).  
3.4.3.5.5 Other areas affected 
Of the other areas affected, no surgical procedure was performed in an 
affected metacarpal (n=1), long bone (n=1), sacrum (n=1), or wrist (n=2). 
Four patients were reported to have ON affecting the elbow. Of these 
patients, 1 patient had arthroscopy and removal of a loose body and 1 had 
open reduction and internal fixation of an intra-articular fracture.  
3.4.3.6 Long term outcomes 
The outcomes of pain and mobility were assessed by analysis of 
questionnaire results and data taken from the most recent clinic letters.  
3.4.3.6.1 Mobility 
Figure 23 illustrates the reported mobility status of patients at a median 
follow up time of 83 months.  



















The patient requiring crutches had ON affecting both hips and knees, with no 
surgical intervention undertaken at the time of data collection.  
Of the 17 patients reported to have limited mobility, 8 had had no surgical 
intervention (47%). Of those with limited mobility, 5 patients were described 
as having regular pain. Two of these patients had hip replacements, 2 had 
no intervention and 1 patient had core decompression of the knee.  
3.4.3.6.2 Pain 
Pain status was also assessed from clinic letters and questionnaire 
responses. Categorisation of analgesia use was planned, but due to sparsity 
of data this was unable to be completed. Results are presented in Figure 24.  
Figure 24. Pain status of patients in UKALL 2003 with osteonecrosis  
 
It can be seen that 41% of patients reported no pain. Occasional pain was 















3.4.4 Results: Part B 
Efficacy of core decompression of the femoral head  
Diagnostic imaging was available for 59 of the 84 hips affected by ON (70%) 
(35 patients). Of these 59 hips, 20 had core decompression of the femoral 
head (34%). Median duration of follow up was 6.9 years (IQR: 5.0-8.5 
years). 
3.4.4.1 Demographics  
The median age at diagnosis of ALL in these patients was 14.61 years (IQR: 
12.56-16.43 years). 18 patients were female, 17 were male. Ethnicity was 
defined as White for 30 patients, mixed for one patient and Asian for 4 
patients. The median age of diagnosis of ON was 16.17 years (IQR: 14.45-
18.09 years), with a median time to diagnosis of ON after diagnosis of ALL 
of 1.17 years (IQR: 0.96 to 1.68 years). In those patients who had core 
decompression, the intervention was performed at a median of 3 months 
after the diagnosis of ON (IQR: 1-7 months).  
Results of grading of hips along with outcomes are presented in Table 28.  
Table 28. Grading of hip osteonecrosis at diagnosis  
Osteonecrosis 
grade at first 
imaging  
Number of hips 
at given grade 
of 
osteonecrosis 
(% of all hips) 
Number of hips 
with core 
decompression (% 






ON/ THR  
(% of hips 
at given 
grade) 
Number of hips to 
reach grade 5 ON/ 
THR after core 
decompression 




2 2 (3%) 2 (100%) 2 (100%) * 
3 7 (12%) 1 (14%) 2 (29%) 0 
4 37 (63%) 13 (35%) 27 (73%) 8 (62%) 
5 13 (22%) 4 (31%) Not 
applicable 
Not applicable 
Total  59 20 44 10 
*although 2 patients had grade 2 ON at initial MRI, the core decompression only occurred 
after the patients had progressed to grade 5 ON.  
 
The majority of hips were grade 4 or 5 at diagnosis of ON (86%).  




At time of decompression there was a median of 2 cannulated drill passes, 
with a range of 1 to 5 drill passes (IQR 1.8-3). 2 hips had Osteoset® bone 
graft substitute used at time of core decompression, and both of these hips 
also had bone marrow aspiration. The two hips where Osteoset® bone graft 
substitute was used were grade 4 at diagnosis of ON, and had a survival 
time of 203 days. 
3.4.4.2 Survival analysis  
A Kaplan-Meier failure time estimates comparing core decompression with 
no early surgical intervention in patients with ON of the hip is shown in 
Figure 25.  
Figure 25. Kaplan-Meier failure time estimates for hips comparing core 
decompression with conservative treatment.  
  
Survival time: time since diagnosis of osteonecrosis to reach grade 5/ total hip replacement 
(whichever sooner) 
Event status: event=THR/collapse, censored=no collapse 
 
The median time to develop joint collapse/ THR for the patients who had 
core decompression (excluding those with grade 5 ON at diagnosis) (n=16) 
was 765 days (IQR 388-1161 days), compared with 522 days for those who 
had no joint preserving surgical intervention (IQR 270-1092, n=30). Cox 




ratio=0.79, p=0.57, 95% CI= 0.34 to 1.82), although core decompression 
was associated with a 20% lower risk of joint failure compared with 
conservative treatment.  
The majority of patients in this analysis had late stage ON (grade 4 or 5) at 
diagnosis. The patients with grade 4 ON were analysed as a subset in an 
ad-hoc subgroup analysis. The Kaplan-Meier survival curve is presented in 
Figure 26.  
Figure 26. Kaplan-Meier failure time estimates for hips with grade 4 
osteonecrosis comparing core decompression with conservative 
treatment. 
  
Survival time: time since diagnosis of osteonecrosis to reach grade 5/ total hip replacement 
(whichever sooner) 
Event status: event=THR/collapse, censored=no collapse 
 
In this subset of patients, the median time to event (THR/grade 5 ON) for the 
patients in whom core decompression was performed was 442 days (IQR 
203-523 days), compared with 410 days for the conservatively managed 
group (IQR 176-629 days). Cox regression indicated no significant difference 
between the groups (hazard ratio= 0.69, p=0.42, CI= 0.28 to 1.69) although 
the hazard ratio suggests core decompression in this patient group was 





Chapter 4 The British OsteoNEcrosis Study  
4.1 Study development 
4.1.1 Introduction 
It is clear from Chapters 2 and 3 that there is a need for a greater 
understanding of the factors affecting the development of ON in children and 
young people treated for ALL and LBL.  
This chapter describes the protocol development for the British 
OsteoNEcrosis Study (BONES), a prospective cohort study developed to 
examine the natural history of ON in older children, teenagers and young 
adults with ALL and LBL. The first part of this chapter describes the 
rationale, feasibility assessment and multidisciplinary involvement in 
developing the study methodology. The second part of this chapter 
describes the final study protocol. The last section reports our preliminary 
results. A discussion of the results will be presented in Chapter 5. At time of 
thesis submission the study is ongoing. 
The complete study protocol is provided in Appendix 10.  










4.1.2 Consultation phase  
This study arose due to an increasing awareness of the significant morbidity 
associated with ON in young people with ALL, both within paediatric 
haematology, and in patient and carer groups [1]. Initial discussions about 
the proposal for a prospective longitudinal study took place within a core 
group comprising of clinicians from tertiary paediatric haematology 
departments, and was further developed by a national toxicity working group 
focussed on ON. There were concerns that there was incomplete 
understanding of the pathophysiology and natural history of osteonecrotic 
lesions, and a consensus view that a UK study specifically targeting young 
people with ALL would be of value. 
Once a decision had been made to develop the study, I was involved in a 
series of meetings with professionals and families, which allowed the formal 
development of the study protocol.  
4.1.2.1 Initial consultations with professionals 
For this part of the consultation phase I discussed different elements of the 
study protocol with a range of health professionals. This included 
representatives from paediatric haematology, endocrinology, orthopaedic 
surgery, radiology, and physiotherapy. In the development stages the study 
concept was also presented at national ALL toxicity working group meetings 
and physiotherapy meetings to allow for discussion of the most appropriate 
methodology. These presentations provided an opportunity to discuss some 
of the issues facing clinical and research departments across the country. 
My initial consultations enabled me to understand feasibility, scientific 
validity and clinical concerns of the different professionals involved in the 
care of patients with ALL. Some important areas for consideration were 
resource capacity, methods of minimising study burden to patients, and 
optimal timing of discussions about study participation with patients and 
families. The outcomes of these meetings facilitated the development of the 
study aims and objectives, as well as the initial protocol and assessment 
processes.  
4.1.2.1.1 Radiology 
The involvement of a paediatric radiologist specialising in musculoskeletal 
radiology was essential. During the consultation phase the main issues 





 Feasibility of MRI in paediatric patients, including length of time of scan and 
need for sedation/ anaesthesia  
 The most relevant body areas to image 
 Frequency and timing of imaging 
 Management of MRI results 
 Incorporation and use of DXA and VF assessment  
4.1.2.1.2 Physiotherapy 
The physiotherapy assessment was developed in collaboration with the 
paediatric physiotherapy team at Leeds Children’s Hospital, who had an 
existing interest in the management of ON in patients being treated within 
the paediatric haematology and oncology service. The plans were also 
discussed at a national physiotherapy meeting. Whilst developing the 
protocol, it became clear that this study provided an opportunity to 
incorporate a physical assessment of the patient which could be correlated 
with radiological and biochemical data. It was important to determine current 
practice both locally and nationally, and to identify methods of patient 
evaluation. The main issue was the lack of a validated paediatric ON 
assessment tool. A range of subjective and objective assessment methods 
were assessed, to identify patient evaluation tools which would be 
acceptable and suitable for our patient population and which would aim to 
identify early signs or symptoms of ON.  
4.1.2.2 Consultation with families  
Once there was broad agreement over the study design and development of 
study literature, I conducted a series of structured discussions about the 
study with patients and families diagnosed with ALL. The consultations 
comprised of informal meetings with individual patients and families to 
review and discuss the proposed study design and study literature.  
Patients and families with ALL were approached in the paediatric 
haematology day unit, and discussions were held in side rooms prior to or 
after their clinical appointment. Six families were contacted, with an equal 
mix of male and female patients, and a range of patient ages. Discussions 
lasted between 30 to 45 minutes, and included the following points: 
 An explanation of the study aims 
 An explanation of study design and patient involvement 
 Review of study paperwork, including patient and parent information leaflets 
 Whether the young person and parents would have felt happy to participate 




There was also the opportunity to discuss additional issues or concerns the 
family had regarding the study.  
4.1.3 Key points emerging from consultations with professionals 
4.1.3.1 Patient population 
Previous research has repeatedly found that patients with the highest risk of 
development of ON were those over 10 years of age at diagnosis of ALL. It 
was felt to be appropriate to target these patients as the group most likely to 
develop significant morbidity from ON, as well as a group of patients likely to 
be able to tolerate imaging without additional sedation or anaesthesia. 
Patients with both ALL and LBL were included within the study as both 
groups currently receive the same chemotherapeutic treatment, and hence 
have the same risks of treatment toxicity. The upper age limit of 24 years 
was chosen as it correlates with the upper age limit for inclusion within the 
current national study for children, teenagers and young people with ALL or 
LBL (UKALL 2011). Although it has been shown that the incidence of ON 
reduces in patients over 20 years of age, it is still significantly higher than in 
patients under 10 years of age at ALL diagnosis [286], and this is a group of 
patients often overlooked in research studies.   
It was decided that the only essential exclusion criteria was an inability to 
tolerate the study investigations.  
The recruitment target was developed using the retrospective data from UK 
centres, described in Chapter 3, which enabled us to predict incidence of 
patients diagnosed with ALL/LBL aged 10-24 years.  
4.1.3.2 Imaging 
MR imaging was chosen as it provides a non-invasive diagnostic evaluation 
of a region of interest, and is more sensitive in the detection of early stage 
focal ON than CT or plain radiographs, even with limited MR imaging 
protocols [288-291]. MRI images clearly depict size of lesions and allows 
sequential evaluation of asymptomatic lesions that are undetectable on plain 
radiographs [164]. Contrary to most other imaging modalities which might 
detect ON, MRI does not use ionising radiation, which is of particular 
significance in the vulnerable growing skeleton. MRI is also capable of 
imaging in multiple planes, and has high spatial and contrast resolution, 
allowing evaluation of morphological features [292].  
Although there was an initial desire to image both upper and lower limbs, a 
more pragmatic approach prevailed. This took into consideration access to 




lower limbs was of greatest value, given the preliminary results presented in 
Chapter 3 highlighting the high prevalence and morbidity associated with ON 
affecting hips and knees. It is possible to scan lower limbs in a single 30 
minutes assessment, limiting both cost and time in scanner for patients. 
Non-contrast coronal T1-weighted spin-echo and short tau inversion 
recovery (STIR) sequences (which nulls the signals from fat) were 
determined to be sufficiently detailed to determine presence or absence of 
osteonecrotic changes in hips, knees or ankles [292]. Although the use of 
intravenous contrast highlights areas of decreased enhancement in the 
necrotic bone and increased enhancement at the reparative surface, this can 
be differentiated without use of contrast as viable tissue exhibits low signal 
intensity on T1-weighted and intermediate or high on STIR MR images, 
whereas necrotic areas are hypo-intense on all sequences [293]. This avoids 
the need for intravenous access and administration of potentially allergenic 
contrast.   
When assessed by MRI, ON is visualised as an area of yellow marrow 
surrounded by a low signal intensity rim on all pulse sequences or a double 
line rim comprising of a low signal line and an adjacent high signal line on 
fluid sensitive sequences. The area of ON may be complex in shape with 
serpentine, crescentic, band-like or undulating outline or represented as 
multiple small lesions [294-296]. It was also decided that non-classical 
abnormalities would also be recorded if encountered, including 
haemorrhagic or cystic change as well as non-specific marrow changes and 
marrow oedema, as these have been previously described and may 
represent a significant prognostic factors for development of ON [294-296].  
In Chapter 2.1.4 the advantages and disadvantages of various ON scoring 
systems were highlighted. After discussion, it was concluded that the 
classification system published by Niinimäki et al to assess ON was the most 
suitable system to use in this study [167]. As this system is not joint specific 
it can be used to assess hips, knees and ankles. A radiology proforma was 
developed by the consultant radiologists involved which enabled them to 
separately record ON seen within the metaphysis and diaphysis of long 
bones. If different scores were seen for two bones comprising a joint (e.g. 
tibial and femoral epiphysis as part of the knee) both scores were captured 
before giving the overall score for the knee, with the aim of assessing the 
overall burden of ON in the lower legs. 
Within the haematology community there were significant concerns 




greatest issue was the need to ensure that there was no change in the 
management of patients recruited to the study, and that clinicians did not 
find themselves in a position where they had information about osteonecrotic 
lesions which they had not solicited.  
Consequently, the protocol was clarified to make it clear that the images 
were not routine MRI scans, and were not for local interpretation. It was 
decided that local reports would simply say “images are for trial purposes 
only”. In line with common study practice, if a significant abnormality other 
than ON, such as a fracture, was found when images were centrally 
reviewed, information was to be fed back to the local centre. In the event of 
the development of locally diagnosed symptomatic ON, the patient was to be 
managed according to local protocols and at the discretion of their own 
consultant. At present, the optimal management of asymptomatic ON is not 
known, and so there would be no benefit for an asymptomatic patient to be 
made aware of osteonecrotic changes. 
Determining the optimal timing of imaging was of considerable importance. 
The first time-point was chosen to be as early as practically possible, to 
assess if there were any early changes that may indicate the likelihood of a 
patient developing extensive ON. It was initially planned that patients would 
be assessed within 2 weeks of the diagnosis of ALL. However, it became 
apparent that there were practical difficulties in consenting patients and then 
organising imaging within this timeframe, resulting in poor recruitment of 
patients. A major amendment was submitted and approved, increasing the 
initial window for consent, imaging and assessment from 2 to 4 weeks of 
diagnosis. This significantly improved study recruitment.  
The end of DI was chosen as the second time point for assessment, as by 
this point patients have had the majority of their high dose steroids, widely 
thought to be a causative agent. Previous studies have shown the majority 
of lesions develop early in treatment [132], and it was hoped that an 
assessment at this point would ascertain the presence of most emergent 
lesions.  
In order to determine the natural history of osteonecrotic lesions there are 3 
further annual assessment points. These provide the opportunity to assess 
progression or regression of lesions, as well as the onset of signs and 
symptoms in patients.  
During the course of the study development there was an increasing 




decision was made to include analysis of annual DXA scans and VF 
assessment as a bone health adjunct. In some centres this has become 
standard of care for patients, but there is significant variability across the 
country. Lateral vertebral assessment of patients using DXA scans was felt 
to be the most suitable method of assessment of vertebral fractures due to 
the low radiation exposure to patients and high level of accuracy in the 
assessment of VFs [44, 45], although lateral spine radiographs are an 
acceptable alternative in centres without DXA imaging facilities.  
Consideration was given to the need to standardise DXA results, and 
following consultation with paediatric endocrinology and radiology it was 
determined that the most valid method for this was using the amalgamated 
reference data for size-adjusted bone densitometry measurements reported 
for UK children and young people in the ALPHABET study [38]. This 
provides a method for calculating size adjusted results, with lumbar spine 
BMAD (g/cm3) and total body less head (TBLH) the most valuable 
measurements for analysis [32].  
In order to reduce observer error a central review panel of paediatric 
radiologists with an interest in paediatric haematology was established. Each 
MRI was to be assessed by the panel in order to agree the grade of ON 
according to the radiology proforma. In addition, DXA and lateral vertebral 
assessments would be assessed centrally using the Genant semi-quantative 
method. This was chosen as at the time of study development it was the 
most widely used method for diagnosis and grading of vertebral fractures 
[47].  
4.1.3.3 Clinical and demographic information 
It was clear from the existing literature that age and sex of patient were 
important demographic details to capture. Height and weight were included 
within demographic data collection to enable calculation of BMI SDS and 
height velocity of patients during treatment. BMI SDS, rather than BMI, was 
chosen for use as BMI was initially developed and applied to adults as a 
correlate of adiposity. For children, BMI varies with age, not only with weight. 
Because of this, BMI values will be compared with reference values that are 
age and sex specific, and transformed into a standard deviation score (Z-
score) [297].  
Following our collection of retrospective data from UKALL2003, and given 
the paucity of high quality literature in this area, the value of collecting 




causative factors for development of vertebral fractures and ON, postcode 
collection was also incorporated into the data collection form to allow 
analysis of deprivation score of participants. The index of multiple 
deprivation (IMD) is calculated using the index of multiple deprivation 2015. 
This ranks every small area in England from 1 (most deprived) to 32,844 
(least deprived) [298].  
4.1.3.4 Pubertal assessment 
Given the increased risk of ON in patients of pubertal age, it was important 
to incorporate an assessment of puberty of patients participating in the 
study. Tanner staging is the most widely used detailed method of pubertal 
assessment, and is an objective classification system that allows tracking of 
the development and sequence of secondary sex characteristics of children 
during puberty [299, 300]. However, it requires considerable user experience 
and is an examination which should only be performed with a chaperone 
present. It was clear from discussions that it is rarely carried out by 
paediatric haematologists, and consultations with clinical staff highlighted 
concerns about this method of assessment. A collective decision was made 
to use the simplified form of pubertal staging which is used by the Royal 
College of Paediatrics and Child Health in the childhood and puberty close 
monitoring growth chart. In this, phase of puberty is assessed by questions 
rather than an intimate examination, and patients are categorised into 3 
phases: pre-puberty (Tanner stage 1), in puberty (Tanner stage 2 and 3) and 
completing puberty (Tanner stage 4 and 5) [301]. Although this provides less 
detailed information than the Tanner stage, it can be ascertained through 
simple questions about the presence of secondary sexual characteristics 
and pubertal milestones.  
4.1.3.5 Biochemical data 
As one of the aims of this work was to identify risk factors for development of 
ON in ALL/ LBL, data collection needed to include diagnostic and prognostic 
indicators for the condition being treated. Therefore data about the 
individual’s immune-phenotype, cytogenetics, molecular results, flow 
cytometry and MRD status were to be collected. 
Previous literature has suggested that changes in the lipid profile and 
albumin levels affect the risk of ON development [132], and these were 
incorporated into our data collection. Initially, we planned to collect 
information on specific markers of bone turnover. These are not routinely 




collagen crosslinks (CTX), bone specific alkaline phosphatase and N-
terminal pro-peptide of type 1 procollagen (P1NP). During ongoing 
discussions with specialists in metabolic bone medicine, it was felt that the 
study would be insufficiently powered to draw meaningful conclusions from 
these results, and as these tests were not routinely used in clinical practice 
there would be little benefit in collection of these data. The tests also placed 
an additional burden on patients, and would potentially prevent patients from 
participating in the study. After consideration, these were removed from the 
study as part of a major amendment, and replaced by collection of PTH, 
vitamin D, calcium and phosphate results. These are tests that are routinely 
performed and used in clinical practice, and hence were felt to be likely to 
provide more clinically valuable data, without placing additional demands on 
the patient.  
4.1.3.6 Physiotherapy assessment 
The physiotherapy assessment facilitates integration of biochemical, 
radiological and clinical information. It was established that in Leeds all 
patients with a new diagnosis of ALL had a baseline subjective assessment 
of pain and current levels of activity, along with gait assessment and 
discussions about maintaining mobility during treatment. When this was 
discussed in national physiotherapy meetings it became clear that such an 
assessment was not universal. In the majority of other centres physiotherapy 
assessments occurred only if a specific referral was made due to physician 
concerns. Once this was recognised, it was clear that a standardised 
approach to patient assessment would be required for this study.  
There was value in collection of both subjective and objective data during 
this assessment. Subjective data allowed an understanding of the patient 
experience, whilst objective data collection aimed to help to determine 
physical signs that may relate to ON development. It was decided that a 
questionnaire would be the best method of subjective assessment. Patient 
questionnaires are a form of outcome measure that are universally 
accepted, and a way of collecting data quickly and efficiently. If correctly 
phrased and formatted they are able to provide a subjective, patient-centred 
approach to outcome evaluation. Using subjective and objective tests in 
combination helps to remove bias that comes from only having a single 
perspective [302]. The areas we wished to assess were activity levels, 
mobility, and pain.  




 Is validated in our population,  
 Is age appropriate 
 Assessed the relevant domains 
 Has internal consistency 
 Is easy to complete and acceptable to patients.  
A number of different questionnaires were evaluated for suitability. These 
included the: 
 Quality of life Evaluation in patients receiving Steroids (QuESt) [303] 
 Lower Extremity Functional Scale (LEFS) [304] 
 Juvenile Arthritis Functional Assessment Scale (JAFAS) [305] 
 Activities Scale for Kids (ASK) [306] 
 Paediatric Outcomes Data Collection Instrument (PODCI) [307] 
 Pediatric Quality of Life Inventory (PedsQL) [308] 
 Childhood Health Assessment Questionnaire (c-HAQ) [309]  
The only questionnaire validated for use our population was QuEST, an 
assessment tool developed to assess the quality of life in patients aged 8-24 
years receiving maintenance therapy for ALL. However, many of the 
questions were not relevant in our setting, with only one of the four domains 
assessing physical health (other domains were appetite and body image, 
emotion and cognitive effects) [303].  
The LEFS was not used in BONES due to the lack of validation in the 
paediatric population, with some questions that were unsuitable for use in 
this setting. The JAFAS is used for patients aged 7-16 years, was 
specifically developed for children with rheumatoid arthritis, and requires 
observation of the child’s performance of activities under standardised 
conditions. This was not a suitable assessment tool for our study due to the 
narrow age range and the training required to administer the test. In addition, 
there is no published evidence that the JAFAS is able to detect change in a 
child’s physical function over time. The ASK and PODCI assess physical 
function in children with chronic health disorders. The ASK is designed only 
for assessment of children aged 5-15 years, and requires a licence for use. 
These factors made the use of the ASK unfavourable for use in our study. 
PODCI is an assessment tool for patients aged 2-18 years, and was 
developed to evaluate problems related to bone and muscle conditions. 
There is no UK version of the questionnaire, and as scoring is calculated 
using knowledge of the general population mean (standardised) score and 
corresponding standard deviations, it was felt not to be applicable for our 




The PedsQL can be completed by young people aged 5-18 years, and 
assesses physical, emotional, social and school functioning. There were a 
number of questions that were too non-specific, particularly those around 
feelings, school and social functioning, and therefore the PedsQL was 
discounted for use in BONES.   
The c-HAQ was developed for children with rheumatoid arthritis [310], but 
has since been validated in a number of different patient populations. One 
comparative study of different measures of paediatric function compared 5 
different measures of paediatric function, including the c-HAQ, JAFAS, 
PODCI and ASK [311]. When these were all compared only the c-HAQ was 
found to have excellent validity and reliability and good responsiveness. 
Although this was in patients with juvenile arthritis and juvenile idiopathic 
inflammatory myopathies, the c-HAQ evaluates health status and physical 
function, and assesses a child’s capability to perform activities in their daily 
environment. It is validated for use in young people with juvenile arthritis 
[310], chronic musculoskeletal pain [312], dermatomyositis [313] and 
systemic lupus erythematosus [314]. It includes the international 
classification of functioning, disability and health components of body 
function and activities and participation, as well as a measure of overall 
health status. It was important to consider the respondent burden and 
usability. The cultural English language version of c-HAQ takes 10-15 
minutes to complete, with language that is simple and easy to read. A 
disadvantage of use of the c-HAQ is its ceiling effect in children with mild 
disease. This means that it is challenging to measure improvements at the 
better end of the functional spectrum (i.e. clinical validity is reduced), but 
given the reliability (internal consistency (Cronbach’s coefficient α) of 0.94) 
and ease of use it was felt to be the most suitable questionnaire for use in 
our study [315]. Further validation of this questionnaire in our specific patient 
population would be of value, but is out of the remit of this study given the 
anticipated sample size.  
Together with the c-HAQ it was felt that a subjective assessment of pain in 
specific areas was required, and the Wong-Baker Faces pain scale was 
used as a self-report measure of pain intensity developed for children [316]. 
This allows the scoring of pain on a widely accepted 0-10 metric. Permission 
was applied to use the scale within our study and was granted by the Wong-
Baker FACES Foundation.  
The objective assessment was developed by paediatric physiotherapists. 




movement and muscle power which could easily be replicated across 
centres.  
4.1.4 Development of study literature 
An essential element of the development of the study protocol and 
submission for ethical review was the design of study literature. This 
included development of patient information leaflets, parent information 
leaflets, consent and assent forms, and data collection forms. Consent and 
participant information sheets were prepared in line with the Health 
Research Authority and Medical Research Council guidance [317]. It was felt 
that the age range of 10-24 years was too broad for a single patient 
information leaflet, and hence different leaflets were developed for patients 
aged between 10-12, 13-15 and over 16 years. These varied in level of 
detail to ensure they were suitable for patients at different developmental 
stages.   
As well as explaining why, how and where the study was being conducted, 
the information sheets included information about the study website and 
details of a local contact for further information. A letter was also developed 
to send to families after their discharge from hospital to thank them for their 
involvement and to remind them of the next stage of the study. A sample of 
study literature is available in Appendix 11.  
Data collection forms were developed in collaboration with the healthcare 
professionals involved in research data collection.  
4.1.5 Study development following consultations with families  
The consultations with families identified overwhelming support for a study 
looking at ON. Patients and families, particularly in the later stages of 
treatment, recognised it as an important complication requiring further 
research.  
Of the 6 families approached, 5 felt they would definitely have participated in 
the study. The sixth family had concerns that their child would not be able to 
tolerate the MRI scans, and hence would not be able to participate.  
Patient and families were generally happy with the study literature, which 
was felt to be age appropriate for the different patient groups. Minor 




4.1.6 Study promotion 
4.1.6.1 Communicating with healthcare professionals 
A website was developed with the assistance of IT support from the 
University of Leeds for use by healthcare professionals and patients. This 
was to act as a gateway to information for healthcare professionals, 
including access to all documents required for the study, as well as a source 
of additional information for patients and families. As the website was built 
on a University of Leeds platform, there were limitations to site design but 
this format had the advantage of on-going IT support. The study was 
discussed at regional, national and international meetings for paediatric 
physiotherapy, haematology and endocrinology. This stimulated significant 
interest in participation and study development. To maintain interest in the 
study I sent regular newsletters to all participating and interested centres 
with updates on study progress and explanations of any developments. 
4.1.6.2 Communicating with families 
The website described above provided patients and families with current 
study information. Families were also sent thank you letters after they 
returned home, to express our gratitude for their participation. 
4.1.7 Data management strategy 
Each patient is allocated a unique identifier at enrolment to the study. A 
Microsoft Access database was developed to use this identifier as the 
primary key, allowing recording and linking of all the socio-demographic and 
clinical data for a study participant with information from their radiology 
assessments. An Access database was chosen as it is a relational database 
management system enabling easy storage of information for reporting and 
analysis.   
In order to comply with data protection regulations it was determined that 
data would be submitted centrally via a secure NHS email address with all 
patient identifiers removed.  At each hospital site local clinicians and 
physiotherapists completed the relevant forms at each time-point, with forms 
anonymized locally. Images of MRI scans and DXA images were 
anonymized locally and placed onto CDs which were sent to the central trial 
unit. 
4.1.8 Statistical analysis  
Data was planned to be collected and analysed in clinically relevant 




The full dataset was to be analysed using Chi-squared tests and 
multivariable logistic regression models, to determine differences between 
groups adjusting for a relevant set of confounders identified using causal 
inference methods [283]. Potential confounders to be assessed include age, 
sex, ethnic group, IMD, treatment arm, highest white cell count, immune-
phenotype, cytogenetics, phase of puberty, body mass index z-score, lipids, 
albumin, VFs, BMD, ALP, PTH and vitamin D status. If numbers are 
sufficiently robust a more sophisticated ordered logistic regression analysis 
was planned to be carried out using an ordered categorical outcome variable 
for severity of ON. 
Discussion with epidemiologists established that the optimal use of data was 
to use an intention-to-treat principle in the analysis. It was decided that if 
data on some subjects were missing at some time points the entire subject 
history will not be excluded from analysis. If the data were missing at rates 
higher than the expected attrition rate the following steps were to be taken: 
 If data regarding independent variables were missing but data for the 
corresponding dependent variables are present, we would do multiple 
imputations for the missing values 
 If some data associated with a dependent variable were missing, such as some 
follow-up data, and the underlying mechanism is random, only the missing 
observations were excluded 
 If some dependent variable data were missing and the underlying mechanism 
was not random, we will estimate group effects according to methods proposed 
by Wu and Bailey [318] and Milliken and Johnson [319] 
4.1.9 Summary of amendments 
After completion of the initial consultation and development phase of the 
study, there have been further discussions with different healthcare 
professionals and families to allow evolution of the study as new issues 
came to light. The main modifications that were incorporated into major 
amendments are as follows: 
 The development and promotion of the British OsteoNEcrosis study website 
 Change of physiotherapy questionnaire to c-HAQs, as discussed above 
 Removal of measurement of P1NP, CTX and bone specific alkaline 
phosphatase 
 Extension of the time to first assessment to 4 weeks, to allow patients longer to 
assimilate and understand the study prior to consent 




The next major amendment, which will be submitted shortly will include the 
following exclusion criteria:  
 Patients diagnosed with mature B-ALL (Burkitt-like, t(8;14), or C-MYC re-
arranged regardless of morphology or phenotype) 
 Patients diagnosed with Philadelphia-positive ALL (t(9;22) or BCR/ABL 
positive) 
 Patients who fail induction treatment. If patients are recruited but 
subsequently fail induction they should be withdrawn, with no further 
assessments 
This is because all of these patient groups will receive significantly different 
treatment regimes, limiting the value of comparison between patients.  
4.2 The British OsteoNEcrosis Study Protocol  
4.2.1 Objectives 
The objective of this study was to establish a prospective, multi-centre study 
for older children, teenagers and young adults to address the following 
questions:  
 What is the incidence of symptomatic and asymptomatic ON in older 
children, teenagers and young adults being treated for ALL or LBL in the UK 
at different time points in their treatment? 
 What are the risk factors for progression and the development of 
symptomatic ON in this population?  
 Are there specific radiological features that predict for either progression or 
regression in those with asymptomatic ON? 
The study also aims to: 
 Evaluate functional ability and explore the correlation of this with MRI 
findings 
 Evaluate changes in BMD and VF incidence during treatment for ALL or LBL 
4.2.2 Study design 
BONES is a prospective longitudinal cohort study.  
4.2.3 Study setting 
The study is being conducted in PTCs and teenage and young adult centres 
for patients with cancer within the UK. It is currently open in Leeds Children’s 
Hospital; St James’s University Hospital, Leeds; Birmingham Children’s 




4.2.4 Study population  
Inclusion criteria: children, teenagers or young adults between the age of 10 
and 24 years 364 days (at the time of diagnosis) with a first diagnosis of ALL 
or LBL (TNHL or SmIg negative precursor B-NHL) diagnosed under 
standard criteria. 
Exclusion criteria: inability to have MRI scans of lower limbs 
4.2.5 Recruitment target 
The recruitment target is 50 patients over a 3 year period, which was based 
on an anticipated participation of 75% of eligible cases. Given the 
observational nature of the study, the emphasis on hypothesis generating, 
and the wide number of potential predictors of interest, a power calculation 
was of limited relevance.  
4.2.6 Study outcomes  
Primary outcome:  
 Cumulative incidence of symptomatic and asymptomatic ON in patients 
aged between 10 and < 25 years being treated for ALL or LBL in the UK at 
multiple time points in their treatment 
Key secondary outcomes:  
 Risk factors for progression and development of symptomatic ON 
 Specific radiological features that predict for either progression or regression 
in those with ON 
 Evaluation of functional ability as measured by c-HAQ and physiotherapy 
assessment and exploration of correlation of with radiological findings.   
 BMD changes as measured by DXA during treatment for ALL or LBL 
 Prevalence and risk factors for development of VFs during treatment for ALL 
or LBL 
 
4.2.7 Patient assessment 
4.2.7.1 Radiology assessment 
Irrespective of symptoms patients were screened for ON via prospective 
MRI of the hips, knees and ankles at the following time-points:  
 Within 4 weeks of diagnosis 
 At the end of DI (typically 6 to 8 months after start of ALL treatment) 




 Two years after the start of maintenance treatment 
 Three years after the start of maintenance treatment 
MRI of the lower limbs comprised of unenhanced coronal T1 weighted and 
STIR (short tau inversion recovery) images of 5mm (or less) slice thickness 
as a minimum protocol.  Scanning parameters varied slightly depending on 
available MR scanners in each participating centre. 
DXA scans and vertebral fracture assessments were performed at diagnosis 
of ALL, and annually for 3 years after diagnosis, and assessed posterior-
anterior lumbar spine (L1-4) and TBLH areal bone mineral density, and 
thoracic and lumbar vertebral fracture incidence.  
4.2.7.2 Clinical and demographic data collection 
Baseline demographic data collection included the child’s age, sex, ethnic 
background (White British; Asian; Black; Mixed; Other), postcode, height and 
weight at diagnosis. Clinical data were provided by the treating clinicians via 
a dedicated clinical report form, which included information on pubertal 
status, highest WCC prior to treatment, immunophenotype, cytogenetics and 
molecular results, along with presence or absence of hepatomegaly, 
splenomegaly, lymphadenopathy and bone pain at diagnosis.   
At each of the time-points outlined above details regarding treatment regime, 
height, weight, phase of puberty, and diagnosis and management of 
symptomatic ON were collected. Data on results of routine blood tests, 
including lipid profile, albumin, bone profile, PTH and vitamin D levels were 
collected. Clinicians collecting these details were blinded to the study MRI 
reports.  
4.2.7.3 Physiotherapy evaluation 
Patients had a subjective and objective physiotherapy assessment at each 
of the same time points as MR imaging (within 4 weeks of diagnosis of ALL, 
at the end of DI and annually thereafter, to a total of 5 assessments). The 
physiotherapy assessment consisted of a paper questionnaire for completion 
by the participant, which included information about activity levels, mobility, 
pain and the c-HAQ, [310] alongside a physical assessment evaluating gait, 
range of movement and muscle power.   






Figure 28. Schema of British OsteoNEcrosis Study procedures 
 
4.2.8 Data analysis  
Data was collected and analysed in clinically relevant categories.  
4.2.8.1 Demographic and clinical data 
Where possible, both demographic and clinical data were analysed as 
continuous variables. 
Cytogenetics and molecular results were coded into 3 groups: high risk; 
intermediate risk; and good risk. These are as follows: 
 High risk - these are cytogenetic and chromosomal abnormalities that have 
been associated with a poor outcome. The abnormalities classified as high 
risk are:  
- iAMP21, t(17;19)(q22;p13), MLL (KMT2A) rearrangement, near haploidy 
and low hypodiploidy 
 Good risk –the cytogenetic and chromosomal abnormalities classified as 
good risk, which are: 




 Intermediate risk- all other patients were categorised as intermediate risk 
cytogenetics, including those with a missing or failed genetic analysis.  
If a patient had high risk cytogenetics and high hyperdiploidy, the 
hyperdiploidy was secondary feature, and they were classified as high risk.  
MRD status was categorised into low risk; intermediate risk; risk; or, no 
result.  
Immunophenotype was categorised into B-ALL; T-ALL; B-LBL; or, T-LBL.  
4.2.8.2 Radiology data 
A central review panel consisting of Paediatric Radiologists with an interest 
in paediatric musculoskeletal imaging reviewed each MRI. The grade of ON 
was assessed using a modified scoring system using a study radiology 
proforma with additional descriptive analysis of MR imaging.   
DXA and vertebral fracture assessment results were also reviewed centrally, 
with adjustments to bone mineral density using BMAD for the spine, and the 
height Z-score for TBLH [38]. The thoracic and lumbar vertebra were 
assessed (T4-L4 where possible), using the Genant semi-quantitative 
method [47].   
4.2.8.3 Physiotherapy assessment 
The physiotherapy assessments was processed as below: 
The subjective assessment, the c-HAQ, was coded using the c-HAQ scoring 
system. The 8 categories within the c-HAQ are: 








Responses for each category were coded: 
Without any difficulty=0 
With some difficulty=1 
With much difficulty=2 




The highest score for any component question determined the score for that 
category. If a component question was left blank/ not applicable, the score 
for that category was determined by the remaining completed questions. If 
devices, aids or assistance were required for a category the minimum score 
was 2.If all components for a category were blank, then the category was not 
included.  
The disability index was calculated by adding the scores for each of the 
categories and dividing by the number of categories answered, which gave a 
score between 0 and 3.  
The disability index was supplemented with two visual analogue scales, one 
for pain and one for global assessment of overall well-being. Both were 
measured on a 0-10 scale, with 0 being no pain or no concerns, and 10 
being severe pain or extremely bad overall well-being.  
Where possible, elements of the objective physiotherapy assessment 
developed for this study were analysed as continuous variables. This 
included activity levels (hours), pain score (0-10) and power (0-5). Range of 
movement was not able to be analysed as a continuous variable as phrases 
such as ‘end of range restriction’ were used, and hence range of movement 
was coded as below: 
Range of movement Score 
No restriction 0 
End of range (<5 degrees restriction) 1 
Moderate restriction (5-20 degrees restriction) 2 
Significant restriction (>20 degrees restriction) 3 
 
Qualitative statements, including gait analysis were analysed and 
categorised accordingly.  
The final frozen dataset for the preliminary analysis was taken on 
20/06/2019.  
4.2.9 Data management and ethical permission 
A Microsoft Access database recorded and linked all the socio-demographic 
and clinical data for a study participant with information from their radiology 
assessments. Data protection regulations (including EU General Data 
Protection Regulation 2016) at each centre were complied with.  
The local clinical team will identify and provide age relevant patient 




will be obtained by the local clinical team, with parental consent obtained for 
patients under 16 years of age. Data was submitted centrally via a secure 
NHS email address with all patient identifiers removed.  At each hospital site 
local clinicians and physiotherapists completed the relevant forms at each 
time-point, with forms anonymized locally prior to being returned to the 
central trial unit.  Images of MRI and DXA scans were anonymised locally 
and placed onto CDs which were sent to the central trial unit.  
Ethical approval for the study was granted by the Yorkshire and the Humber 
Sheffield research ethics committee on the 12th of July 2016. REC reference: 
16/YH/0206 (Appendix 12) 
A substantial amendment was submitted prior to initiation of the study at any 
sites on 12/03/2017, with a REC favourable opinion received on 12/04/2017. 
A further substantial amendment was submitted on 17/01/2018, with REC 
approval granted on 14/02/2018. Details of amendments are available in 
Appendix 13. 
Trial registration number: NCT02598401 
Date of registration: 05/11/2015 
4.3 Results 
4.3.1 Patient demographics  
At time of data freezing, there were 22 potentially eligible patients. 19 of 
these patients consented for inclusion in the study. During the study, 3 
patients were unable to continue to participate. 1 patient was unable to 
tolerate MRI scans, and 2 patients failed induction treatment. 18 patients 
were initially treated on regimen B, with 1 patient treated on regimen A at 
diagnosis. The patient who started on regimen A was unable to tolerate MRI 
scans, and withdrew from the study.  










Table 29. British OsteoNEcrosis Study demographic and biochemical 
data 
 




Age 19 14.1 














         Male 






Multiple deprivation index 19  20475 
(8135 to 27060) 
BMI SDS 19 0.6 
(-1.2 to 1.4) 
Immunophenotype 
           B-ALL 
           T-ALL 
           B-LBL 








Clinical features at diagnosis  
         Duration of symptoms (months)       
         Lymphadenopathy 
         Hepatomegaly 
         Splenomegaly   













Highest white cell count (x109cells/L) 19 13.6 (3.9 to 29.4) 
Cytogenetics/ molecular status 
                High 
                Intermediate 
                Good 








MRD status (end of induction) 
               High risk 
               Low risk 








                Pre-pubertal  
                In pubertal 
                Completed puberty 








Treatment regimen (consolidation)  
                A 
                B 
                C 








Biochemical results at diagnosis  
                Albumin (g/L) 
                HDL (mmol/L) 
                LDL (mmol/L) 
                Cholesterol (mmol/L) 
                Triglycerides (mmol/L) 
                PTH (pmol/L) 
                Vitamin D (nmol/L) 
                Alkaline phosphatase (U/L) 
                Calcium (mmol/L) 













35.0 (31.0 to 38.5) 
1.5 (1.2 to 1.6) 
2.5 (2.3 to 3.1) 
4.8 (4.4 to 5) 
1.4 (0.8 to 2.5) 
5.1 (3.1 to 12.8) 
45.0 (31.3 to 71.3) 
111.5 (86.5 to 150.5) 
2.2 (2.1 to 2.2) 
1.3 (1.0 to 1.5) 
Biochemical results at end of delayed 
intensification 
                Albumin (g/L) 
                HDL (mmol/L) 
                LDL (mmol/L) 
                Cholesterol (mmol/L) 
                Triglycerides (mmol/L) 
                PTH (pmol/L) 
                Vitamin D (nmol/L) 
                Alkaline phosphatase (U/L) 
                Calcium (mmol/L) 















40.0 (36.0 to 42.5) 
1.1 (0.8 to 1.4) 
2.6 (1.7 to 3.5) 
5.0 (3.5 to 5.8) 
1.2 (1.2 to 1.4) 
4.6 (3.2 to 6.6) 
52.3 (39.5 to 66.7) 
97.0 (70.5 to 110.5) 
2.4 (2.2 to 2.4) 




4.3.2 MRI and physiotherapy results  
At time of data freezing, MRI scan results were available for 18 patients, with 
2 or more MRI scans available for 11 patients. Results are presented in 
Table 30.  
The median time to first scan was 20 days after commencement of 
chemotherapy, (IQR 14.5-22 days). The median time to second scan was 








Table 30. Magnetic resonance imaging and physiotherapy results 
Patient 
number 
Timing of MRI 
scan (days 
after start of 
treatment) 
MRI right lower 
limb score 



























(power, range)  
1 20 0 0 Marrow oedema in distal 
femoral and proximal 
tibial metaphysis 
2  0  1.00 Not 
completed 
NAD No limitation 
180 Femur  2  
Tibia 2  
Knee 3 
Femur  2  
Tibia 2  
Knee 3 
Classical ON, not in same 











Hips  (4) 
Knees (4) 









Classic ON lesions, 
prominent in distal tibial 
metaphysis. Marrow 
oedema in medial proxima 
tibia and distal femoral 
metaphysis 
       




Classical ON. Marrow 
changes in distal femoral 
and proximal tibial 
metaphysis have resolved 






NAD Shoulders (4) 
2 4 0 0 Marked marrow changes 10  0 0.00 3.5 
3.5 
NAD Hips (4) 
Knees (4) 






Classical ON 4  Back 5 0.5 3 
0.5 
NAD Hips (4) 
Knees (4) 
Ankles (4) 
442 (extra scan 
of hips - not 
BONES) 
Hip 5 Hip 5         





throughout the femoral 
and lower legs 
4 Wheelchair  
Aids for 














Timing of MRI 
scan (days 
after start of 
treatment) 
MRI right lower 
limb score 



























(power, range)  
250 0 0  2 Wheelchair 
Bath rail 
Back 7 1.63 6 
2 
Out-toeing R hip (4) 





4 11 0 0 Diffuse abnormalities 
throughout all bones, no 
classical ON 
7  0 0 0 
0 
NAD No limitation  






Diffuse changes still 
present. 
6.5  Back 3 0 0.5 
0.3 
NAD Hips (4) 
Knees (4) 
5 22 Femur 2 0 Marrow changes, 
especially over pelvis and 
proximal femur. One area 
of early ON in proximal 
femur 
3  Back 5 
Right hip 8 
Left hip 6 
Right knee 
8 
Left knee 6 
Right ankle 
6 








215 Femur 2 0 Classic ON in femur. 
Atypical patchy changes in 
pelvis 








NAD Hips (3, 1) 
Knees (4) 
Shoulders (4) 
6 27 0 0 Diffuse marrow 
abnormalities 
5  0 0 0 
8 
NAD No limitation  

















NAD Right hip (4) 






Timing of MRI 
scan (days 
after start of 
treatment) 
MRI right lower 
limb score 



























(power, range)  
7 22 0 0 Small hip and knee 
effusions 
6  0 0.5 0 
3 















Classical ON 2 Wheelchair Shoulders 
2 
Back 8 
Right hip 5 





Wide base of 
support, short 
stride, flat foot 
strike  
Right hip (4,1) 





Left shoulder (4) 
8 18 0 0 Small knee effusion 6  Back 6 0 0 
0 













Classical ON 2 Wheelchair, 
raised toilet 
seat 
Back 6 1.75 3.5 
3 
Foot drop with 
peripheral 
neuropathy 




9 30 0 0 Patchy changes 
throughout, no classical 
ON lesions  
4  Back 8 0 0.1 
0 
Slight in-toeing  No limitation  
10 
 
110 0 0     1.75 0 
4 
 No limitation  





NAD No limitation  
11 
 
21 0 0     1.71 Not 
completed 
Antalgic gait Knees (4) 
12 
 
28 0 0 Oedema right femoral 
neck 
   0.88 1 
0.5 
NAD No limitation  
13 
 
11 0 0 Patchy oedema left 
femoral head and mid-
tibia bilaterally. Small knee 
effusions 
8   0.00 0 
0 







Timing of MRI 
scan (days 
after start of 
treatment) 
MRI right lower 
limb score 



























(power, range)  

















NAD No limitation  
14 20 0 0 Marked diffuse marrow 
change throughout, likely 
leukaemic infiltrate 
4 Bath stool  Right knee 
5 
Left knee 5 
1.13 4 
4 
Stiff No limitation  






Classical ON lesions not 
involving joints 







NAD Right hip (1) 
Left knee (4) 
Right knee (4,1) 
15 17 0 0 Marked diffuse marrow 
change throughout 
3.5     NAD No limitation  
236 Pelvis Grade 2, 
Femur Grade 2, 
Knee Grade 3, 
Tibia Grade 2, 
Fibula Grade 2, 
Ankle Grade 3, 
Foot Grade 3 
Pelvis Grade 2, 
Femur Grade 2, 
Knee Grade 4, 
Tibia Grade 2, 
Fibula Grade 2, 
Ankle Grade 3, 
Foot Grade 3 





16 21 0 0 Marked diffuse marrow 
change throughout  







NAD No limitation 
17 12 0 0 Marked diffuse marrow 
change, soft tissue and 
muscle oedema 




NAD No limitation  
18 28 0 0 Diffuse marrow changes 7   0 0 
0 
NAD No limitation  
For ON score: If all areas score the same, only one score is documented. If there is no specific score for an area, it has scored 0. NAD=no abnormality detected, ROM=range of 
movement.  
αFor pain score: Only areas with scores over 0 documented.  
*For joint movement: if not specified, no limitation in power or range of movement. Power scored 1-5. R=right, L=left. ** Patient had full passive range of movement in ankles, but 




It can be seen that only two patients (Patients 3 and 5) had changes 
consistent with ON at the time of their first scan. These changes had 
resolved by the end of DI for Patient 3, but the patient continued to require 
the use of a wheelchair, possibly indicating that their functional limitations 
were unrelated to the osteonecrotic changes. Patient 5 had on-going 
changes in the femur, with persistent pain reported in hips and knees.  
All other patients who had a second MRI scan developed at least one 
osteonecrotic area by the end of DI, with more than one area involved in the 
majority of patients. All patients who developed osteonecrotic areas by the 
end of DI had a reduction in self-reported hours of activity (median activity 4 
hours at diagnosis (IQR: 3.5 to 6.5), which reduced to 2 hours (IQR: 1.9 to 4) 
by the end of DI). However, this was also the case for patient 3, whose 
osteonecrotic changes had resolved by the end of DI.  
The most common aid used by patients was the wheelchair, used by 5 out of 
10 patients by the end of DI.  
The overall pain score increased from a median score of 0 (IQR: 0 to 3) at 
diagnosis of ALL (n=14), to 3.5 (IQR: 2.4 to 4.5) by the end of DI (n=12). The 
overall score of well-being stayed constant in patients, with a median score 
of 1.5 at the start of treatment and by the end of DI.  
There were 3 patients who developed ON of one or more of their hips, 
(Patients 2, 6 and 7). Hip pain was reported in one of these patients, with 
limitation in power noted in 2 patients. Due to development of symptoms, 
Patient 2 went on to have a further scan at day 442, with progression of ON 
lesions to grade 5. Patient 1 also developed symptoms (knee pain) that 
clinicians felt were consistent with ON, and was found to have changes 
consistent with ON in femora, tibiae and one knee.  
The c-HAQ disability index increased in 8 of 9 patients from induction to end 
of DI, with the median disability index increasing from 0.5 to 0.75 between 
the first and second time-point. Although all of the patients who had an 
increased disability index by time point 2 developed osteonecrotic changes 
during this period of time, the score also increased in the 2 patients who had 
ON at the first time point. Objective physiotherapy assessment found an 
increased limitation in power at the hips and/or knees in 9 of 10 patients who 
developed ON by the end of DI. Of the 18 patients assessed at baseline, 13 
had no limitation in joint power or range (72%), which reduced to 4 out of 13 
patients by the end of DI (31%). Areas that were found to have some degree 




(22%), shoulders (11%), and ankles (6%). By the end of DI, some limitation 
was noted in 69% of hips, 62% of knees, 38% of shoulders and 31% of 
ankles.  
4.3.3 Bone mineral density and vertebral fractures 
DXA results were available for 16 patients who were recruited into BONES. 
Two patients had a second DXA assessment at time of data freezing. Initial 
BMD and VF assessment results are presented in Table 31, with BMD 
results graphically represented in Figures 29 and 30.  
Table 31. Initial bone mineral density and vertebral fracture results 
Patient number Total body less 
head Z-score 
Lumbar spine bone mineral 
apparent density Z-score 
Vertebral fractures 
1 -0.1 -1.5 0 
2 -1.4 0.1 0  
3 -2.4 -2.8 0  
4 0.5 -0.4 0 
5 -2.5 -2.7 0 
7 1.4 3.5 0  
8 0.1 -1.4 0  
9 0 -3.3 Grade 1 T9 + T10 
10 n/a -1.1 n/a 
12 -1.4 -0.7 n/a 
13 -2.3 -1.9 0 
14 1.2 1.9 Grade 1 L2, T5, T7 
15 -1.0 -1.7 0 
16 1.3 1.3 0 
17 -1.3 -1 0 
18 0 0.9 0 
n/a: not available  
T: thoracic vertebra 




Figure 29. Total body less head bone mineral density Z-scores at 
diagnosis of acute lymphoblastic leukaemia. 
 
Shaded area represents normal range of TBLH BMD. Numerical value on x-axis equates to patient number.  
Figure 30. Lumbar spine bone mineral apparent density Z-scores at 
diagnosis of acute lymphoblastic leukaemia 
 






























































The median TBLH of this group of patients was -0.1 SDS (IQR: -1.4 to 0.3), 
with a median lumbar spine BMAD of -1.05 SDS (IQR: -1.75 to 0.3).  Two 
out of fourteen (14%) of patients had evidence of VFs on their initial VF 
assessment.  
Two patients (Patients 1 and 10) have had a second DXA assessment 
reported. For Patient 1, the TBLH Z-score and BMAD Z-scores reduced to -
0.4 and -2.5 respectively. The lumbar spine BMAD for Patient 10 increased 
slightly to -0.8 SDS, with a TBLH of -1SDS. Neither patient had VFs 
identified.  
Back pain was reported by a number of patients (Table 30), with an increase 
in back pain at the end of DI (median back pain score increased from 0 at 
ALL diagnosis to 3.5 at end of DI). Of the 2 patients with vertebral fractures 
at baseline, only one reported baseline back pain (Patient 9), although the 






Chapter 5 Discussion 
The central aim of this research was to gain a greater understanding of the 
bone health of children with ALL, with 2 main objectives to this work. The 
first objective was to complete a retrospective review of the cohort of 
patients enrolled in the national trial for children and young adults with ALL, 
UKALL 2003, which ran from 2003 to 2011. The primary aims were to: 
 Report the UK prevalence of symptomatic ON in young people with ALL 
 Describe the chronology of the development of symptoms related to ON and 
subsequent diagnosis of ON 
 Identify risk factors for the development of ON 
 Determine which joints are affected by ON and methods of diagnosis of ON 
in patients with ALL 
 Describe the medical and surgical management of patients diagnosed with 
ON in UKALL 2003 
 Establish the long-term outcomes of patients affected by ON in UKALL 2003 
A secondary analysis of this population aimed to:  
 Characterize the surgical procedures performed in patients affected by 
symptomatic ON in UKALL 2003, including the identification of sequential 
procedures in individuals.  
 Evaluate the efficacy of femoral head core decompression in prevention of 
joint collapse in young people with symptomatic ON.  
The second objective was to develop a protocol and establish a prospective 
longitudinal cohort study of young people with ALL or LBL which would aim 
to: 
 Identify the incidence of symptomatic and asymptomatic ON in older 
children, teenagers and young adults being treated for ALL or LBL in the UK 
at different time points in their treatment 
 Identify the risk factors for progression and the development of symptomatic 
ON in this population 
 Identify specific radiological features which might predict for either 
progression or regression in those with asymptomatic ON  






 Evaluate changes in BMD and VF incidence during treatment for ALL or 
LBL 
 
Each objective will be reviewed in detail, with an evaluation of the strengths 
and limitations of the work.  
5.1 A retrospective review of the UKALL 2003 cohort  
5.1.1 UK prevalence of symptomatic osteonecrosis  
The overall prevalence of symptomatic ON in the cohort of patients recruited 
to UKALL 2003 was 5.5% (n=170). This finding is consistent with other 
retrospective studies reporting upon the prevalence of symptomatic ON in 
patients with ALL, in which results ranged from 1-15% [109, 111, 112, 115, 
123, 148, 149]. The figure is, unsurprisingly, much higher in prospective 
studies in which there is an assessment of asymptomatic osteonecrotic 
lesions [131, 132], or in studies evaluating only high risk patients [105, 119, 
134].   
There is a lower incidence of ON described in studies with no planned 
reporting of ON [116]. In UKALL 2003 there was reporting to the central trial 
unit of all patients who developed bone toxicity, which included ON, using 
toxicity reporting forms or serious adverse event forms. I found that whilst 
the central trial unit was informed of the majority of cases of ON, our longer 
period of follow-up and the use of a targeted questionnaire revealed an 
additional 55 patients, increasing the reported prevalence of ON in UKALL 
2003 from 3.7% to 5.5% [128]. The central trial unit may not have been 
informed of the diagnosis of ON for a number of reasons, including late 
diagnosis of ON or a lack of awareness of reporting guidelines.  
5.1.2 Chronology of development of symptoms and diagnosis of 
osteonecrosis  
In UKALL 2003 symptoms of ON were reported at a median time of 14 
months after the diagnosis of ALL, with ON subsequently diagnosed at a 
median of 16 months after diagnosis of ALL. The cumulative incidence of 
ON in all patients was 1.1% at 1 year, 4.0% at 2 years, 4.9% after 3 years, 
5.1% at 5 years and 5.2% at 7 years. For patients over the age of 10 years 





higher at all time-points:  3.3% at 1 year, 12.5% at 2 years, 15.1% at 3 
years, 16% at 5 years and 16.2% at 7 years.  
These results are similar to those previously reported in the literature, 
although there are few other retrospective studies with such detailed 
analysis of the timing of ON symptom development. Most previously 
reported studies also had much shorter periods of follow up, potentially 
missing cases of late onset ON. This study found 5% of patients were 
diagnosed with ON between 3 and 5 years after diagnosis of malignancy, 
with 1% of patients diagnosed with ON after 5 years. The longest time to 
diagnosis of ON was 6.26 years after the diagnosis of ALL [286]. Previously 
published retrospective studies suggest that the majority of patients who 
develop symptomatic ON do so within the first 3 years of treatment [109-111, 
115, 119, 127, 150], with one of the most comprehensive studies reporting 
that 35% of cases occurred within the first 12 months after diagnosis of ALL 
[111]. Prospective studies suggest that asymptomatic lesions are likely to 
develop within the first year of treatment [132] with a study by the St Jude’s 
group reporting that 38.7% of patients developed Grade 1 ON by 6.5 months 
after start of ALL treatment [132]. When patients were screened very early 
after the diagnosis of ALL (median 12.5 days), only 9.2% of patients were 
found to have any osteonecrotic lesions [320]. Therefore the critical time-
point of lesion development remains unclear.  
One difficulty with making a diagnosis of ON is the non-specific nature of 
symptoms. Patients undergoing treatment for ALL are exposed to a large 
number of chemotherapeutic agents, some of which have significant side-
effects. Vincristine neuropathy is a well-recognised side effect of vincristine 
treatment [321] and can result in sensory, motor and autonomic neuropathy. 
Although the classical features of vincristine neuropathy are relatively 
distinct, there may be some overlap between pain due to ON and limb pain 
as a result of vincristine treatment, making a diagnosis of ON more 
challenging.  
5.1.3 Risk factors for the development of symptomatic 
osteonecrosis  
In this analysis age, ethnicity, sex and 1 versus 2 blocks of DI were 
assessed as possible risk factors for the development of ON. 
After analysis, age was found to be the only risk factor for the development 





to 37.57) for those aged 10-15 and 16-20 years respectively, when 
compared with patients aged <10 years. Patients over 20 years of age also 
had an increased risk of developing ON, with an odds ratio of 8.10 (CI 2.32 
to 28.22) when compared with patients aged <10 years. This corresponds to 
the literature, which has universally found age >10 years at diagnosis of ALL 
to be a risk factor in the development of ON [109-112, 114-116, 119, 121, 
127, 128, 132, 145]. There has been one previous study which reported 
adolescents younger than 20 years of age at diagnosis of ALL were at 
higher risk of developing ON, compared with older patients [123], and my 
results confirm this finding. The reason for this increased risk of ON in young 
people between 10 and 20 years of age is not fully understood. One 
hypothesis is that the increased risk of ON is related to puberty and 
concurrent increased height velocity, although this has not been proven.  
My study did not find that the sex of the patient was a risk factor for the 
development of ON. This corresponds with the results of a number of other 
studies [110, 111, 114, 123, 125, 127, 131, 140, 170], although the literature 
is inconsistent in this area [100, 109, 117, 119, 134-136, 141, 144]. This is 
the only study to have used a causal inference model to justify the choice of 
confounders, and therefore the results are considered to be more robust 
than similar studies previously carried out.  
One study found that the relationship between risk of developing ON and 
sex of the patient was dependent on the age of the patient [119]. In the study 
by Mattano in 2000 the gender difference was greatest in the 10-15 year age 
group, with 3 year rates of 19.2% for females and 9.8% for males [119]. 
However, among the smaller group of 16-20 year olds with ON, the ON 
incidence was higher in males than in females (20.7% v 13.2% respectively) 
[119]. An age by gender interaction for development of ON was not found in 
my study, which was considerably larger than those mentioned above, but it 
may be that the specific treatment regimen influences the importance of sex 
as a risk factor in the development of ON. 
This study assessed the role of ethnicity on development of ON. However, 
categorisation of ethnicity poses many difficulties due to the subjective 
nature of identification of ethnicity [322, 323]. Comparison of ethnicity data 
with other international studies is challenging, as there are considerable 
inconsistencies between ethnic classifications amongst different countries, 
particularly with the term ‘Asian’. In the UK, being of Asian ethnic origin 





Pakistan and Bangladesh), whereas studies based in the USA typically used 
the term Asian for those of East Asian origin (Hans Chinese and Japanese 
ancestry). In the literature, a number of studies separated patients only into 
White and non-white, whilst others had only White, Black and Hispanic 
groups. Classifying patients as being of White race poses its own 
challenges, as the term may be considered to be a social construct, which 
does not incorporate the reality of biological variation between different 
populations. Few previously reported studies commented on Asian patients 
at all and most studies where race was commented upon were composed of 
predominantly White patients. Some studies have reported White race to be 
a risk factor for development of ON [117, 119, 146], but this has not been a 
consistent finding [131, 132]. 
In this study of patients recruited into UKALL 2003, no single ethnicity was 
found to be a risk factor for the development of ON. However, the risk of ON 
in the Asian population compared to the White population neared 
significance (p=0.053, 95% CI 0.69-2.07). As Asian patients were only 2% of 
all trial patients, these results suggest that with larger numbers of Asian 
patients, statistical significance would have been achieved. That ethnicity 
could have an impact on incidence of ON is biologically plausible, due to the 
differences in bone size, shape and density in people of different ethnic 
backgrounds [324, 325], but the mechanism is unclear, particularly given 
that the development of ON was not found to be associated with BMD at 
baseline [130]. It may be that different ethnic groups have variances in 
genetic risk factors, putting them at differing levels of risk depending on their 
specific treatment regime.  
No relationship was found between the number of blocks of DI and 
prevalence of ON. As an additional block of DI would result in an additional 2 
weeks of dexamethasone at a dose of 10mg/m2/day, it might have been 
anticipated that this would have resulted in an increased risk of ON 
development. The lack of increase in reported cases of ON may be due to 
the timing of the additional dexamethasone, which was at week 32 and 34 of 
treatment. Studies suggest that osteonecrotic lesions are likely to have 
already developed by week 32 [132]. Consequently, dexamethasone given 






5.1.4 Joints affected by symptomatic osteonecrosis and methods 
of diagnosis  
This study found that the majority (85%) of patients in UKALL 2003 who 
developed ON had multiple affected joints. The joints most commonly 
affected by ON were hips and knees (34% and 32% respectively), followed 
by shoulders and ankle joints (14% and 10% respectively). The hip joint was 
affected in 58% of all patients with ON, with 2 hips affected in 35% of 
patients. At least one hip or knee was affected in 89% of patients. Previous 
studies also report that the greatest burden of symptomatic ON is in the 
lower limbs. One retrospective study reported that 46% of patients affected 
by symptomatic ON had at least one hip affected, with hip(s) and/ or knees 
affected in 85% of patients [119]. My study also found that 24% of all 
patients affected by ON had one or more shoulder joint affected, and this 
high prevalence of ON in shoulder joints has not been previously reported.  
5.1.5 Methods of diagnosis of osteonecrosis  
As would be expected, the majority (82%) of patients in UKALL 2003 had the 
diagnosis of ON confirmed by MRI, although there were centre specific 
differences, with plain X-rays used for diagnosis in 16% of patients. MRI is 
the most sensitive modality for detecting and diagnosing low grade ON, with 
plain radiographs only able to detect more advanced disease [159, 161, 
164]. MRI also allows quantification of the area and extent of ON [292], and 
is generally the imaging modality of choice, particularly in the early stages of 
ON.  
5.1.6 Medical management of patients diagnosed with 
osteonecrosis 
The results from this study highlight the significant national variation in 
management of patients with ON. This was likely to be due to both lack of an 
evidence base for the management of patients, and lack of national 
consensus guidance. There were clear regional preferences in certain 
practices. For example, the decision to stop steroids after diagnosis of ON 
would appear to be centre dependent. There is no literature to support or 
reject the practice of cessation of steroids during the treatment of ALL as a 
means of preventing further deterioration of ON lesions. As lesions are likely 
to develop significantly earlier than the onset of symptoms [132], the 
cessation of steroids at the point of development of symptoms may be 





inadequate management of the underlying leukaemic process. The 
counterargument is that continuation of steroids could stimulate progression 
of existing osteonecrotic lesions, and allow development of additional 
lesions, particularly given that patients who develop ON generally develop 
multiple lesions affecting numerous joints. Without further research there can 
be no recommendations regarding best practice in this area.   
Bisphosphonates were used in a number of centres, with pamidronate the 
agent most commonly used. Some form of bisphosphonate was given to 
27% of patients (n=43), with use of bisphosphonates potentially unrelated to 
low BMD in 84% of cases. The review of use of bisphosphonates presented 
in Chapter 2.3.1 suggests that some bisphosphonates (namely pamidronate 
and zolendronate) may be beneficial for pain management [234, 241-243], 
with a number of studies also reporting improvement in functional ability in 
patients with ON who are treated with bisphosphonates [234, 241, 244, 245]. 
There is no evidence that bisphosphonates alter the radiological progression 
of ON in young people [241, 243, 245], although the literature is limited. 
Studies suggest that bisphosphonates are generally well tolerated, with 
minimal short-term side effects other than an initial acute phase reaction 
[326]. However, given the poor quality of the existing literature, additional 
research into the long term side effects and the specific use of 
bisphosphonates in young people with ALL or LBL and ON may be 
warranted.  
Given the role of vitamin D in the maintenance of bone health, it may be 
expected that vitamin D supplementation would be prescribed to individuals 
with vitamin D deficiency and ALL. In our study vitamin D supplementation 
was provided to patients in 32% of cases; 36% received no such 
supplementation and provision was unclear in the remaining 32% of cases. 
However, vitamin D levels and timing of treatment was not requested, and 
specific conclusions cannot be drawn from these data. In the systematic 
review described in Chapter 2.3.2 there were no reported studies which 
assessed the impact of treatment of vitamin D deficiency on prevalence of 
ON. Within some areas of the paediatric haematology community there has 
been a reluctance to start vitamin D supplementation during induction 
therapy, due to the in vitro study by Antony et al [281]. As discussed in 
chapter 2, delaying treatment purely on the basis of the results of this study 
is not appropriate, and our systematic review found that in young patients 





concerns that apparently innocuous medication, including bisphosphonates 
and vitamin D, may have unintended negative consequences on cure rates if 
appropriate research has not been conducted in the patient population of 
interest. This is of particular importance if medication is being given for 
potentially limited benefit. 
5.1.7 Surgical management of patients diagnosed with 
osteonecrosis 
Overall, the high rates of surgical intervention is one of the most striking 
outcomes of this work. In the initial analysis of results, of the 170 patients 
who were diagnosed with ON, 38% were reported to have had surgery 
related to their ON (n=65), and 19% of patients were reported to have at 
least one hip replacement. However, these numbers rose in the detailed 
analysis of surgical interventions performed, with 26% of patients reported to 
have at least one hip replacement, and some form of surgical intervention 
being performed in 47% of patients. In this second analysis hip 
replacements were performed in 43% of all hips affected by ON and 
arthroplasty was carried out in 21% of all joints affected by ON. Core 
decompressions were performed prior to replacement in 31% of patients 
who went on to have a hip replacement. In comparison, a retrospective 
study in the USA found that 22.7% of patients who were diagnosed with ON 
had at least one surgical procedure performed, with only 6% of patients 
requiring joint replacement [115]. However this study had a much shorter 
follow-up period (5 years from diagnosis of ALL), which is likely to result in 
an underestimation of the number of patients having surgical interventions. 
Our results for hip arthroplasty are similar to those of patients recruited to 
NOPHO ALL2008, where of the 65 patients with ON, 15 of 33 patients with 
grade 4 ON had arthroplasty performed (45%), with bilateral hip 
replacements in 9 patients (27%) [120]. In that study of patients, only 1 
patient underwent core decompression, highlighting the differences in 
patient management internationally.  
It can be seen that in our second analysis there was a higher rate of surgery 
reported compared with our earlier work. This may be due to the longer 
duration of follow-up, together with an altered emphasis in data collection. 
By collection of orthopaedic letters and operation notes we were able to 
obtain detailed information on all procedures performed, with confirmation of 
timing and surgical techniques used. When the results from the two studies 





hips and shoulders affected by ON were appropriately represented in the 
second survey, the numbers of knees and ankles were underrepresented. 
This may be because knees and ankles are less likely to be referred to 
orthopaedic surgeons due to limited surgical options, or because symptoms 
are more likely to spontaneously resolve. In our analysis of patients with ON 
affecting knees and ankles, very few had significant surgical intervention. 
Figure 32 illustrates the much higher rate of arthroplasty in our follow-up 
analysis, which is likely to be due to the reasons detailed above.  
Figure 31. Joints affected by osteonecrosis: a comparison of patients 
with confirmed osteonecrosis and those for whom second 
questionnaire responses were received 
 
Figure 32. Joints replacements due to osteonecrosis in UKALL 2003: a 
comparison of patients with confirmed osteonecrosis and those 
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When timing of surgical intervention was assessed, it was found that the 
median time for core decompression was 20 months after diagnosis of ALL. 
This would typically be whilst the patient is still receiving ALL treatment. In 
contrast, joints were replaced at a median time of 3.83 years after ALL 
diagnosis, suggesting that surgeons would usually wait until completion of 
chemotherapy before undertaking arthroplasty.  
Our study also highlights the variation in surgical techniques used across the 
UK.  A variety of prosthetic materials were used for joint replacements, with 
differences in fixation techniques. At present the optimal technique for hip 
replacement in this population is unknown. One study reported that at 10-
year follow up there were lower rates of loosening in hips that had cement-
less total hip replacements than in hips that had cemented replacements 
[327]. However the mean patient age in this study was 43.3 years, with a 
mean BMI of 30.6kg/m2. The study assessed patients with a range of 
different underlying pathologies, which could independently influence rate of 
loosening, as conditions such as Gaucher disease, sickle cell disease and 
renal failure are considered high risk conditions [328].  Much longer follow-
up data would be of value to determine how this distinct patient population 
should be managed if joint replacement is required. 
Core decompression was performed in 30% of hips affected by ON. Core 
decompression as a procedure for patients with ON was first introduced in 
the early 1960’s, when Arlet and Ficat proposed to investigate osteonecrosis 
by a ‘forage-biopsie’ [156]. They introduced the concept of a core biopsy 
[329], which was later popularised by Hungerford as femoral head core 
decompression [330]. Core decompression of the femoral head involves 
drilling a hole through the distal aspect of the greater trochanter. The 
proposed mechanism of action of core decompression includes a direct 
reduction in intramedullary pressure and induction of limited tissue damage 
to promote healing, including vascular sprouting and angiogenesis. There 
are modified versions of this technique, with incorporation of grafts and 
injection of bone morphogenic protein, or autologous bone marrow.  At 
present there is no agreement on the technique that will give the best 
results. In our study, 25% of patients had Osteoset® bone graft substitute 
used, and the most common technique was using 2 cannulated drill passes, 
but this ranged from 1 to 5 drill passes. A comparison of traditional core 
decompression and multiple drilling in patients with sickle cell disease found 





improvement by procedure [331]. Studies of adjunctive therapies with 
decompression are restricted by sample size and quality of evidence, and 
there is no current recommendation for use of any adjuvant therapy [332].  
5.1.8 Efficacy of core decompression in prevention of joint 
collapse 
This is the first study to compare femoral head core decompression with no 
joint preserving surgical intervention for the management of ON of the 
femoral head in young patients with ALL. The survival analysis found there 
to be no significant difference in femoral head survival (joint collapse or 
THR) between those patients who had core decompression compared with 
conservative management, although the hazard ratio suggested that core 
decompression was associated with a 20% lower risk of joint failure 
compared with conservative treatment. Therefore, it is possible that with a 
larger patient group significance would have been achieved. The lack of 
significance has potentially important implications for patient management, 
as core decompression was performed in 30% of hips affected by ON in this 
specific patient population, and highlights the value of a larger study of this 
subject.  
It was found that the majority (85%) of patients had grade 4 or 5 ON at 
diagnosis, and our results cannot be extrapolated to individuals who are 
diagnosed with ON at grades less than 4. These results may suggest that in 
the UK ON in young people with ALL is diagnosed too late for effective 
surgical interventions to prevent hip collapse.  
Previous studies assessing efficacy of core decompression in preservation 
of the femoral head have shown varying results, with grade of ON at time of 
intervention likely to be of critical importance. One of the earliest prospective 
studies was conducted in 1974 by Fairbank et al [333] and assessed 90 
adult patients with 128 affected hips. The total failure rate (conversion to hip 
replacement) was 43%, with a higher failure rate in those who had a higher 
stage of ON at the time of core decompression (73% compared with 22%) 
[333]. There have been 2 randomised studies comparing core 
decompression with conservative management. A study conducted in the 
USA by  Stulberg et al [334] randomised 55 hips in 36 adult patients to core 
decompression or conservative treatment. They reported that core 
decompression produced better clinical results than conservative treatment 
in the early stages of ON, but less successful results were seen in when 





intervention was used as the end-point, which may be affected by other 
considerations, such as patient choice/ insurance coverage. A study 
reported by Koo et al [335] randomised 33 patients (37 hips) with early ON 
without radiological evidence of collapse to core decompression with 
cancellous bone graft, or conservative management. The primary end point 
was collapse of the femoral head. Survival analysis showed no significant 
difference in time to collapse between the two groups and by 24 months, 
72% of hips in the core decompression group and 68% of hips in the non-
operated group had undergone THR (p=0.8). In both of these randomised 
studies some patients had more than one affected hip randomised into the 
study with no adjustment in analysis used, potentially violating the 
independence of failure times assumption required in survival analysis. One 
study which included paediatric patients (age >10 years) was a randomised 
study of 38 patients with sickle cell disease and Steinberg stage 1-3 ON. 
Patients were randomised to core decompression and physiotherapy, or 
physiotherapy alone. This study found that physiotherapy alone appeared to 
be as effective as core decompression in improving hip function and survival 
[336].  A meta-analysis published in 2016 assessed the role of core 
decompression compared with all other joint preserving treatments in 
delaying the development of hip osteoarthritis [337]. Outcomes evaluated 
were patient clinical status, radiographic progression and need for total hip 
arthroplasty or further surgery. With a total of 12 studies, 5 of which were 
randomised trials, there was slight superiority of other joint preserving 
therapies compared with core decompression for all of the outcome 
measures. The main issue with this meta-analysis was the significant 
heterogeneity between studies, and the variation in the management of the 
control group. 
5.1.9 Long-term outcomes of patients affected by osteonecrosis  
This is one of the few studies to specifically assess the long term effects of 
ON on young people treated for ALL. At a median follow up time of 70.5 
months after diagnosis of ALL, 39% of patients who had ON were reported 
to have no long term effects, with 38% reported to have minimal disability. 
Significant disability was reported in 9% of patients, with 3% of patients 
reported as requiring a wheelchair.  
In the follow-up study of these patients, at a median of 83 months, 60% were 
reported to have returned to full mobility, and 71% of patients were reported 





It was reassuring to find that despite the often debilitating effects of ON in 
the short term, long term outcomes are good for the majority of patients. 
However, it must be borne in mind that these encouraging results are often 
after surgical intervention, and patients may need further revision surgeries 
in the future. A modern artificial hip joint is designed to last for at least 15 
years, with a recent meta-analysis suggesting that a hip replacement can 
now be expected to last around 25 years in 58% of patients [338]. However, 
hip replacements in young patients have higher rates of revision surgery 
than in older patients [339, 340] and our cohort of patients are very likely to 
require further surgical intervention and revision surgery.   
5.1.10 Strengths and limitations 
This is the largest single UK study reporting symptomatic ON in children, 
teenagers and young adults with ALL providing long term follow up data of 
patients. Strengths of this work include the use of a national, high quality 
dataset with confirmed diagnosis of ALL and ON, the high questionnaire 
response rate (90%) and the extended follow-up period (median: 8.9 years). 
This study provides a more comprehensive assessment of patient 
demography and management than previous studies assessing patients with 
ALL developing ON, as well as identifying patients who were not previously 
reported to have ON. The subset analysis of surgical management of 
patients is the largest assessment of its type, and is the first time that 
survival analysis of hips affected by ON in young people with ALL has been 
reported, comparing core decompression with conservative management. 
As described in the methodology, the minimal sufficient sets of confounders 
for adjustment was based on our development of a DAG. Chapter 3.2.6 
describes the use of DAGs as a mathematically rigorous method for 
minimising bias and determining true confounders [284]. However, it is also 
important to recognise the limitations of DAGs. One of the main limitations is 
that determination of confounders is based upon the premise that the 
background information provided by the person developing the diagram is 
correct. Some of the assumptions made are of unknown validity and some 
are untested. The graphical assumptions are qualitative and nonparametric, 
and imply nothing about the specific functional form of the relations or 
distributions amongst the variables. However, these limitations are largely 
outweighed by adopting a robust, causal inference methodology which is 
widely accepted as the optimal statistical approach in identifying true 





One of the main limitations of this work is the retrospective nature of the 
study. This may result in recall bias, with more severe forms of ON 
potentially recorded or recalled. This may have enriched our data with a 
higher percentage of adverse outcomes, with patients who have had surgical 
procedures more likely to be recollected.  
During questionnaire development a balance had to be made between depth 
of information collected and ease of questionnaire completion for 
responders. There are a number of sections in which additional detail would 
have been of value, particularly in the areas questioning medical 
management and long term outcomes. In retrospect, the question regarding 
the use of pamidronate would have elicited more information if it was 
changed to include the use of bisphosphonates more generally, with a 
request for information regarding indication, dose and duration of use. When 
identifying patients for whom steroids were stopped, it would have been of 
benefit to establish the date when steroids were stopped, timing of cessation 
of steroids and rationale for cessation. More information around the use of 
vitamin D would also have been of benefit, with identification of vitamin D 
deficient patients, PTH levels, treatment used and timing of treatment. 
Expansion of these sections would have enabled us to gain a much greater 
understanding of management decisions made.   
Depending on the local situation, the questionnaire was variously completed 
by data managers, research nurses, administrative assistants or clinicians. 
This could potentially lead to inconsistency in the manner of completion. 
However, through regular correspondence with each centre, it was clear that 
data managers completed the vast majority of questionnaires, which is likely 
to minimise potential variation. In this study the method of determining 
ethnicity was not clearly defined, largely relying upon data inputted at 
admission to hospital. Patients and families are not consistently requested to 
describe their ethnicity on admission to hospital, which could result in 
incorrect assumptions being made.  
In UKALL 2003 patients were not prospectively imaged for assessment of 
asymptomatic ON, and there were no specified thresholds for imaging of 
patients or criteria for joint imaging. In the initial study MR images were not 
centrally reviewed, and local reports were used to determine the diagnosis of 
ON.  Therefore, the first part of this study did not incorporate grading and 





MR images were requested for the additional analysis, we were only able to 
obtain information for 50% of patients identified.  
The outcome data collected by this study were limited due to a lack of well 
recognised specific, objective, measurable outcome measures for this 
patient population. Long term effects of ON were defined as the effect of ON 
at the most recent follow-up consultation. This varies significantly depending 
on whether the patient had or was due surgery, and our results were 
dependent on the level of documentation in the notes and clinic letters. 
Some of the outcomes, such as pain or mobility status may also be affected 
by factors unrelated to ON. It was also not possible to separate outcome 
data for different interventions (e.g. core decompression), as in many cases 
there was variation in the management of different osteonecrotic lesions 
within one individual. Questionnaires completed by the patients themselves 
could improve the quality of the data in this area, ideally with a control group 
of patients who received treatment for ALL but were unaffected by ON.  
There are a number of limitations to the survival analysis of hips affected by 
ON. Of all the patients identified as having ON affecting the femoral head in 
UKALL 2003, imaging at diagnosis was available for only 36%. However, 
when patient demographics were analysed, there appeared to be no 
differences between those who were identified in the first round of data 
collection and those for whom results were available for the subsequent 
detailed analysis. As mentioned, in this study patients were not routinely 
imaged during ALL treatment, and the majority (85%) of patients had grade 
4 or 5 ON at first imaging. In a survival analysis the ‘ideal’ starting point 
would be to measure the survival time from the moment the participant 
developed ON, but without prospective imaging this is not possible. The lack 
of routine imaging after diagnosis of ON also meant that it was not possible 
to determine accurately the true time to event (development of grade 5 ON), 
which would improve the accuracy of results. It may be that core 
decompression has a beneficial impact on pain, but this could not be 
assessed in this study, due to lack of standardised collection of this 
information. Variation in the care of patients across the country may also 
have affected the results. Differences in surgical techniques were described 
earlier, and it is possible that there was also variation in the conservative 





5.2 Development of a protocol to establish a prospective 
longitudinal cohort of young people with acute 
lymphoblastic leukaemia of lymphoblastic lymphoma 
BONES is the first multi-centre prospective study using MRI imaging for the 
assessment of asymptomatic ON in the UK. It is also the first study to 
combine physiotherapy assessment with imaging and biochemical results.   
5.2.1 Challenges 
The development of BONES has been discussed at length in Chapter 4, with 
a discussion of the rationale for study design. A collaborative approach to 
study design was extremely beneficial in ensuring that the study had a 
robust methodology, but the co-ordination of a large multi-disciplinary team 
was time-consuming and at times challenging. The consultations conducted 
as part of the methodology development process revealed significant 
variation in practices across the country, particularly with respect to 
physiotherapy input. These needed to be accommodated within the study 
design, with provision for centres with more limited physiotherapy 
involvement.   
The other major obstacle was a lack of capacity in interested centres. The 
consultations conducted as part of the scoping work confirmed that there 
was widespread interest in gaining further information about the natural 
history of osteonecrotic lesions in this patient population. Despite this 
enthusiasm and understanding, there were a number of issues that impeded 
the opening of the study in additional centres. One of the main limitations 
was a perceived lack of availability of paediatric MRI slots. This restriction 
prevented at least 2 centres from opening, despite interest from local clinical 
and research staff. In our own centre, limited MRI capacity delayed the start 
of opening of the study by 5 months. Another factor that limited the opening 
of the study in a number of centres was the lack of NIHR portfolio status. 
Unfortunately portfolio status was declined as the funding for the study was 
from a local charity. This meant 3 interested centres were unable to 
participate. Had we appreciated this impact, funding from a national body 
would have been pursued.  
5.2.2 Analysis of preliminary results  
These preliminary results need to be treated with caution due to the small 





It was found that only 2 of 18 patients (11%) had osteonecrotic changes at 
the time of their first MRI scan. This had risen to 10 out of 11 patients (91%) 
having osteonecrotic lesions by the end of DI. These results suggest that the 
majority of patients develop ON between the end of induction of 
chemotherapy (median time of first scan was 20 days), and prior to starting 
maintenance therapy. This is consistent with other prospective studies, 
where osteonecrotic changes were rarely seen at diagnosis [133], but were 
noted in 41% of patients at 6.5 months after initiation of treatment 
[132].Given our patient population (patients aged 10-25 years), a higher rate 
of ON compared with previous studies is to be expected, although a rate of 
91% by end of DI was not anticipated. In the 2 patients who had 
osteonecrotic changes at diagnosis, lesions had resolved by the second 
imaging point in one patient. This may have important implications for 
management of patients, as it may be possible to initiate prophylactic 
therapy after the intense induction period of chemotherapy has been 
completed.   
As we continue to follow up this patient group, we will be able to understand 
more about how lesions evolve, and risk factors for development of 
symptomatic ON. Although osteonecrotic changes were seen in most 
patients by the end of DI, the majority of changes were in the diaphyses of 
the bones, with ON affecting the hips in only 3 out of 11 patients, and knees 
in 7 patients. It has been described that ON affecting the articular surface 
results in a poorer prognosis [159, 165-167], and the clinical impact of ON 
affecting the femoral head has been described in detail [169, 286]. Two of 
the patients with ON affecting a joint became symptomatic and had non-
study MRI scans. One patient with symptomatic ON had a non-study scan 
undertaken, at day 442. ON had progressed from grade 4 at day 223 to 
grade 5 (joint collapse) by day 442. This highlights how lesions may rapidly 
progress, with subjective patient symptoms potentially only described with 
advanced stage lesions.  
By the end of DI there was an overall increase in the disability index and 
pain scores of patients. At present, it is not possible to correlate these 
results with the development of osteonecrotic lesions, but it is hoped with 
more patients and a longer duration of follow-up we will be able to establish 
presence or absence of correlation. One of the difficulties in the assessment 
of patients with ON is that patients may have a number of co-morbidities. 





sensorimotor neuropathy [321]. Vincristine associated peripheral neuropathy 
is experienced by nearly all children who receive vincristine treatment [341], 
although the severity varies. In most cases the neuropathy progresses from 
distal to proximal regions, typically affecting lower limbs first. In the first year 
of vincristine therapy, hyporeflexia is the most common manifestation, 
followed by decreased sensation and strength [341]. The physiotherapy 
assessments carried out as part of this study are not specific enough to only 
detect limitations related to ON. Limitation of gait, power or range of 
movement could reflect vincristine related neuropathy, although it would be 
expected that the pattern of findings would be different to those of a patient 
with limitation due to ON.  
After analysis of DXA results, it was found that at diagnosis the median 
TBLH of this group of patients was -0.1 SDS (IQR: -1.4 to 0.3) with a median 
BMAD of -1.05 SDS (IQR: -1.75 to 0.3). Other studies have reported that 
BMD at diagnosis of ALL, when measured by DXA, was lower than that of 
healthy controls [41, 130, 203], and report similar results to the median 
BMAD SDS presented in our data.  
It can be seen that only 2 of 14 patients (14%) had evidence of vertebral 
fractures on their initial vertebral fracture assessment. This is similar to the 
findings by Halton et al [215], who found that in vertebral radiographs taken 
within 30 days of chemotherapy initiation, 16% of patients had prevalent 
vertebral fractures. Of the 2 patients with vertebral fractures in our study, 
fractures were grade 1 in both patients. Fractures affected 2 vertebrae in 
one patient, and 3 vertebrae in the other. In the study by Halton et al, 52% 
had one prevalent vertebral fracture, 27% had 2 to 5 fractures and 21% had 
between 6 and 10 fractures, with grade 1 fractures in 48% of patients [196].   
Additional results will add to the robustness of our dataset, and it is hoped 
that subsequent scans will enable us to identify risk factors for development 
of vertebral fractures.  
5.2.3 Future data management plan 
Following completion of this thesis, the data will be stored on a secure 
network area within the University of Leeds, School of Medicine. Access will 
only be available to N. Amin, R. Feltbower and S. Kinsey. A request for 
funding for a research nurse has been made, to allow ongoing data 





5.2.4 Strengths and limitations 
The main strengths of BONES are the prospective nature of the study and 
the multidisciplinary team involved in study design, which included paediatric 
radiologists, endocrinologists, orthopaedic surgeons and physiotherapists. 
By using the expertise and knowledge of a diverse group of experts we have 
been able to develop a study that has brought together a range of different 
elements in the assessment of each patient.  
One of the main limitations to the BONES study is the small sample size. 
This is due to practical and resource constraints. However, despite the small 
sample size, the data collected provides a holistic approach to patient 
assessment that has not previously been undertaken.  
During the analysis of patients in UKALL 2003 with symptomatic ON the 
striking variation in patient management was apparent. This lack of 
standardisation of care of patients, which reflects the lack of an evidence 
base for the management of patients with ON, also affects patients in the 
BONES study. Bisphosphonates have been started in one patient and 
vitamin D therapy in another, which may modify our findings.  
The physiotherapy assessment, with use of both objective and subjective 
patient assessment, is one of the unique elements of this study. This will 
enable us to understand patient perception of pain and disability, together 
with standard methods of objective patient assessment. However, the 
physiotherapy assessment is limited by the lack of a validated scoring 
system for assessment of ON in patient with ALL. The discriminatory ability 
of the c-HAQ and the objective assessment was unclear at the start of the 
study. Whilst the c-HAQ was chosen as one of the most widely used 
measures of functional health status of children with musculoskeletal 
difficulties, it was noted that c-HAQ suffers from a ceiling effect in juvenile 
idiopathic arthritis. This means it is impossible to measure improvements at 
the better end of the functional spectrum, with a concurrent reduction in 
clinical validity [315, 342]. Revised versions have been developed to try to 
enhance discriminative validity, but results have been inconsistent [315]. The 
addition of more challenging items in a revised version of the c-HAQ 
reduced the ceiling effect in patients with juvenile arthritis a number of 
studies [315] but other revisions were less able to distinguish between 
patients and controls. It may be that revised or alternative methods of 





preferable, and this is something that would be of significant value to 
develop in further studies with larger cohorts.  
When assessing preliminary study results it was clear that back pain was 
common in patients enrolled in the study. In retrospect formal objective 
assessment of the back would have been of benefit and should be included 
in future studies.  
This is an observational study that aims to obtain detailed information about 
the development of ON in patients being treated for ALL or LBL. One aim of 
this research was to help understand some of the complex relationships 
between multiple different variables. However, correlation is not causation, 
and it may be that it would have been desirable to measure other 
unassessed variables, such as blood pressure or markers of infection. It is 
also possible that patients who are involved in the study may be more aware 






Chapter 6 Conclusion 
6.1 Main findings  
The first part of my work reported upon the prevalence and risk factors for 
the development of symptomatic ON in young people with ALL who were 
recruited into UKALL 2003. I then went on to describe the chronology, risk 
factors and management of ON in this population. This is the first time this 
has been conducted in such detail and a number of novel findings have 
been reported.   
The overall prevalence of symptomatic ON in the cohort of patients recruited 
to UKALL 2003 was found to be 5.5%. As has previously been reported, age 
was the main risk factor for development of ON, and in this study 18% of 
patients aged between 10 and 20 years at diagnosis of ALL developed ON.  
Symptoms of ON were most commonly reported in lower limbs, with multiple 
joints affected in the majority of patients. One of the most significant findings 
to emerge was the high rate of surgical intervention in patients. Hip 
replacements were performed in 43% of all hips affected by ON, with core 
decompression performed prior to replacement in 31% of affected hips. This 
is the first study to specifically assess the impact of core decompression in 
hips affected by ON. Survival analysis found no significant difference in 
femoral head survival (development of grade 5 ON or THR) between 
patients who had core decompression compared with patients who were 
managed conservatively; although with larger numbers significance may 
have been established. This is the first UK study to use the Niinimäki 
classification to assess the grade of ON. It was found that the majority of 
osteonecrotic lesions affecting the femoral head were grade 4 or 5 at 
diagnosis. This is an important finding as the late stage of ON at diagnosis 
may impact upon the efficacy of any interventional therapy.  
This thesis also describes the establishment of a prospective longitudinal 
cohort study of patients aged 10 to 25 years with newly diagnosed ALL or 
LBL. This study assesses the prevalence and development of symptomatic 
and asymptomatic osteonecrotic lesions, together with BMD and VF 
incidence in patients with ALL or LBL. The main findings to date are that 
osteonecrotic changes typically occur between the end of induction and the 
start of maintenance therapy. The majority of lesions affect the diaphysis of 





with symptoms only recognised after joint collapse. Vertebral fractures were 
reported in 14% of patients around the time of diagnosis of ALL.  
Additional results will provide us with more robust data, and it is hoped that 
these will inform future studies and improve patient care.   
6.2 Clinical implications 
These results describe the high prevalence of ON development during 
treatment for ALL, particularly in young people who are aged 10-20 years at 
diagnosis of ALL. They also describe the high rates of surgical intervention 
in affected patients. This work can help UK clinicians provide accurate 
prognostic information about ON to patients with a diagnosis of ALL. ON 
should be discussed with patients at greatest risk (those aged 10 to 20 at 
diagnosis of ALL), and patients in the UK can now be provided with an age 
specific risk of ON development. In patients with symptomatic ON previously 
unavailable joint specific prognostic information and long term outcome data 
can now be offered.   
An important finding of this work is that the diagnosis of symptomatic ON in 
patients with ALL typically occurs when lesions are grade 4 or 5, using the 
Niinimäki classification for ON. No significant difference was found between 
patients who had core decompression, compared with conservative 
management, in prevention of hip collapse in patients with ON affecting the 
femoral head. However, the hazard ratios suggest that with much larger 
numbers of patients, significance may have been achieved, and a 
prospective multicentre study may be of value. This is clinically important as 
unnecessary surgical interventions can put patients at risk from both surgical 
complications and the risk of anaesthesia.   
6.3 Ongoing and future work 
It is hoped that the results from BONES will be able to guide further research 
into ON in young people with ALL and LBL. A greater understanding of the 
timing of lesion development is crucial when considering interventions to 
prevent or treat osteonecrotic lesions, and a recognition of those patients for 
whom intervention is of greatest benefit would allow targeted individualised 
therapy. At present there is limited data available about the subjective 
experience of patients who develop ON, and it is hoped that the results from 





us greater insight into the patient journey. Validation of an assessment tool 
developed for this specific patient population would be of value in a larger 
study. Further analysis on the full dataset will include the use of Chi-squared 
tests and multivariable logistic regression models, to determine differences 
between groups adjusting for a relevant set of confounders identified using 
causal inference methods [283]. Potential confounders that will be assessed 
include age, sex, ethnic group, IMD, treatment arm, highest white cell count, 
immune-phenotype, cytogenetics, phase of puberty, body mass index z-
score, lipids, albumin, presence of VFs, BMD, ALP, PTH and vitamin D 
status. If numbers are sufficiently robust a more sophisticated ordered 
logistic regression analysis could be carried out using an ordered categorical 
outcome variable for severity of ON. 
However, the question of how to prevent the development of osteonecrotic 
lesions, or how to treat existing lesions remains. In order to recruit sufficient 
numbers of patients it is likely that international collaboration is required. 
This would allow the development of a large cohort of patients for whom long 
term follow up data could be obtained, ideally with randomisation to 
treatment arms to ascertain efficacy of medical and/or surgical management 
in patients with ALL or LBL.  
A number of possible interventions have been considered. Bisphosphonates 
have been considered as a possible therapeutic intervention, but our review 
of their use in patients with ALL and ON highlighted the lack of high quality 
evidence available [326]. Although it was suggested that intravenous 
bisphosphonates may be of value for management of pain, there was no 
evidence to suggest they impact on radiological progression. However, 
prophylactic use of bisphosphonates, or use in asymptomatic early grade 
lesions has not been studied in detail. Given that the majority of symptomatic 
lesions are diagnosed at grade 4 or 5, it is likely that any medical 
intervention will be of greatest benefit prior to the development of symptoms.  
It is possible that newer agents affecting bone modelling will be of benefit to 
patients in the prevention of progression of ON. The 
RANK/RANKL/osteoprotegerin system regulates bone formation by 
regulating the osteoblast/osteoclast balance. One study found that the 
expression of RANK and RANKL genes were significantly elevated in 
osteonecrotic areas from femoral head biopsies of adult patients [343], and it 





preventing the progression of ON, although safety data in paediatric patients 
is limited [344].  
Hyperlipidaemia as a risk factor for the development of ON in young people 
with ALL has been previously discussed [143]. Although there have been 
conflicting reports [345], interventions to reduce elevated lipid levels could 
theoretically be used prophylactically to prevent ON development. One study 
assessed the development of ON in adult patients already using statins, who 
were subsequently given glucocorticoids [346]. The results suggest that 
statin use may prevent later development of ON [346], but there is a lack of 
safety data for statin use in young people receiving treatment for ALL. If 
statins are to be used in patients to prevent or reduce development of ON it 
is likely they will need to be used prophylactically, potentially prior to the 
development of any osteonecrotic lesions. 
Optimal surgical management remains unclear. Very long term follow up 
data would be of particular benefit in understanding the outcomes following 
different types of arthroplasty, including the need for subsequent revision 
surgery, and pilot work to determine this is now underway.  The role of core 
decompression has been discussed. It is clear that a prospective study with 
larger patient numbers would be of value. It is possible that patients may 
receive benefit from core decompression if it was performed early in the 
evolution of lesions, but given the high rates of spontaneous resolution of 
asymptomatic lesions [132], surgical intervention in asymptomatic ON is 
controversial.  
There is on-going active research assessing the value of implantation of 
autologous bone-marrow cells at the time of core decompression in patients 
with ON [347, 348], and the use of mesenchymal stem cells (MSCs) for 
tissue repair in ON is biologically plausible. There is evidence that there is 
decreased number and activity of MSCs in osteonecrotic areas [349], and it 
is recognised that MSCs have the potential to provide osteogenic precursors 
to areas of necrosis [349]. There have been a number of randomised studies 
comparing implantation of autologous bone-marrow mononuclear cells at the 
time of core decompression with core decompression alone. These have 
been conducted in in adult patients with ARCO grade 1 or 2 ON [347, 348], 
with results suggesting a significant reduction in pain and joint symptoms, 
and significantly improved joint survival. However, these studies were in a 
different patient population, all of whom had early grade ON, limiting its 





the use of locally implanted autologous mesenchymal stem cells combined 
with core decompression in 2 adolescents with ALL and bilateral femoral 
head ON, ARCO grade 4 [350]. In this report, at 4 year follow up, the 
patients were no longer symptomatic and showed improvement in range of 
movement, pain and functional impairment. This report is limited by sample 
size, but the use of MSCs with core decompression may be of potential 
value in patients with established ON, and further research in this field is 
warranted.   
Other therapeutic interventions for ON that have been discussed in the 
literature include hyperbaric oxygen therapy [351], extracorporeal shock 
wave therapy [352, 353] and free vascularized fibular grafting [354]. The 
evidence for all of these interventions is limited, with no approach 
demonstrating clear impact on the progression of ON in young patients with 
ALL.  
6.4 Overall conclusion 
This research demonstrates the high prevalence of ON in young people 
receiving treatment for ALL, with patients aged 10-20 years at diagnosis of 
ALL at greatest risk.  
Surgical intervention for ON is common in these patients, with hip 
replacements one of the most frequent surgical procedures required. This 
has long term implications for both patients and the healthcare service as a 
whole.   
Patients typically have advanced ON at the point of symptom development, 
and it is likely that interventions to prevent the development of severe ON 
will need to be initiated when lesions are asymptomatic.  
A cohort study has been developed that will allow us to gain further 
understanding about the development of symptomatic and asymptomatic 
osteonecrotic lesions and vertebral fracture risk in this population. As results 
from this study emerge, it is hoped that the outcomes will shape future 







Appendix 1. Chemotherapeutic agents used during treatment 
in UKALL2011 in those eligible for BONES:  
Induction:  
dexamethasone 6mg/m2/day orally for 28 days (maximum single dose 
10mg/day) 
vincristine 1.5mg/m2 intravenously weekly for 2 weeks, starting on day 2 
(maximum single dose 2mg) 
daunorubicin 25mg/m2 intravenously on days 2, 9, 16, 23 
peg-aspargase 1000iu/m2 intramuscular injection day 4 and 18 
methotrexate 12mg intrathecal on days 1, 8, 29  
6-mercaptopurine 60mg/m2/day orally from day 29 to day 35 of 
consolidation.  
 
Standard BFM consolidation: 
cyclophosphamide 1000mg/m2 intravenously days 1 and 15 
cytarabine 75mg/m2/day intravenously or subcutaneously 4 consecutive 
days in weeks 6,7,8,9 
mercaptopurine 60mg/m2/day orally until day 28 of consolidation 
methotrexate 12mg intrathecal days 1, 8, 15 
 
Augmented BFM consolidation: 
cyclophosphamide 1000mg/m2 intravenously days 1, 29 
cytarabine 75mg/m2 IV or subcutaneously 4 consecutive days in weeks 
6,7,10 and 11 
mercaptopurine 60mg/m2/day for 21 days starting week 5 of induction, 
and again for 14 days on days 29-42 
vincristine 1.5mg/m2 IV days 16, 23, 44, 51 (maximum single dose 2mg) 
peg-aspargase 1000 units/m2 intramuscular days 16, 44 






Standard interim maintenance: 
dexamethasone 6mg/m2/day orally days 1-5 and days 29-33  
vincristine 1.5mg/m2 IV day 1, 29 (maximum single dose 2mg) 
mercaptopurine 75mg/m2/day orally days 1056 
methotrexate 20mg/m2 orally once/week on week 11, 12, 14, 15, 16, 18, 
19 
methotrexate 12mg intrathecal days 15, 43 
Protocol M: 
mercaptopurine 25mg/m2/day orally days 1-56 
methotrexate 5g/m2 intravenously days 8, 22, 36, 50 
folinic acid 15mg/m2 intravenously 42,48 and 54 hours after start of 
methotrexate infusion 
methotrexate 12mg intrathecal days 8, 22, 36, 50 
 
Capizzi interim maintenance: 
vincristine 1.5mg/m2 IV days 2, 12, 22, 32, 42 (maximum single dose 
2mg) 
methotrexate 100mg/m2 IV day 2. Escalating subsequent doses as 
tolerated on days 12, 22, 32, 42 
peg-asparagase 1000 units/m2 IM days 3, 23 
methotrexate 12mg intrathecal day 1, 31 
 
Protocol M-A: 
mercaptopurine 25mg/m2/day orally days 1-49 
methotrexate 5g/m2 IV days 1, 15, 29, 43 
folinic acid 15mg/m2 IV 42,48 and 54 hours after start of methotrexate 
infusion 
methotrexate 12mg intrathecal days 1, 15, 29, 43 







dexamethasone 10mg/m2/day orally for 7 days week 20 and 22 
vincristine 1.5mg/m2 intravenously days 2,9,16 (maximum single 
dose 2mg) 
doxorubicin 25mg/m2 intravenously days 2,9,16 
pegaspargase 1000iu/m2 IM day 4 
methotrexate 12mg intrathecal day 1 
cyclophosphamide 1000mg/m2 intravenously day 29 
mercaptopurine 60mg/m2/day orally day 29-42 
cytarabine 75mg/m2/day intravenously or subcutaneously 4 
consecutive days weeks 24,25 
If delayed intensification is part of regimen C the dexamethasone is given 
days 2-5 and 16-22, cytarabine is given in weeks 28 and 29, and vincristine 
given on days 2, 9, 16, 43 and 50. Intrathecal methotrexate is also given on 
days 29 and 36, and pegaspargase is also given on day 43.  
Maintenance: 
mercaptopurine 75mg/m2/day orally throughout maintenance 
methotrexate 20mg/m2 orally days 1, 8, 22, 29, 36, 43, 50, 57, 64, 71, 
78 
If a patient has been randomised to pulses during maintenance they also 
receive:  
dexamethasone 6mg/m2/day orally days 1-5, 29-33, 57-61 
vincristine 1.5mg/m2 IV days 1, 29 and 57 (maximum single dose 
2mg) 
If patient was randomised to standard or Capizzi interim maintenance they 
will also receive 12mg of intrathecal methotrexate on day 15 of each cycle, 
as will T-ALL patients presenting with a white cell count of >100x109/L. 
All patients are also to receive co-trimoxazole prophylaxis for PCP 






Appendix 2. Data extraction form for systematic review 
assessing efficacy and safety of vitamin D in children and 
young people with acute lymphoblastic leukaemia 
Study ID 
Report ID 
Review author ID 
Citation and contact details 
Confirm eligibility for review 
Reason for exclusion 
Notes:  
Participants 
n setting diagnostic 
criteria 
age sex country ethnicity length of follow 
up 
        
 
Interventions 
Specific intervention:  







   
ALL treatment: 
Protocol used Type of steroid  Cumulative steroid dose 
   
Outcomes 
Reported/ collected Outcome definition Unit of measurement  
   
   

























       
       
       
Risk of Bias Assessment 
If randomised study, please complete the Cochrane risk of bias table.  
If non-randomised please complete ROBINS-I table.  
If study describing adverse event, please use Loke method.  
For examples of how to complete tables please refer to supplementary information.  
Cochrane Risk of Bias 
Entry Judgement  Support for judgement 
Random sequence 
generation (selection bias) 
  
Allocation concealment   
Blinding of participants and 
personnel 
  




Blinding of outcome 
assessment (detection bias) 
(Mortality) 
  
Incomplete outcome data 
addressed (attrition bias) 















Confounding factors: socioeconomic status, smoking, calcium intake, BMI 
Co-interventions: Type of ALL treatment inc TBI, steroid dosing, type of steroid used 
 
Bias due to confounding  
o Is there potential for confounding of 
the effect of intervention in this 
study?  
N/PN/Y/PY 
If N/PN, no further signalling 
questions need to be considerd.  
If Y/ PY assess time-varying 
confounding 
1.2 Was analysis based on splitting participants follow up time 
according to the intervention received?  
N/PN/Y/PY/NI 
If N/PN answer questions 1.4-
1.6 
If Y/PY go to question 1.3 
1.3. Were intervention discontinuations or switches likely to 
be related to factors 
that are prognostic for the outcome? 
 
N/PN/Y/PY/NI 
If N/PN answer questions 1.4-
1.6 
If Y/PY answer 1.7-1.8 
1.4. Did the authors use an appropriate analysis method that 
controlled for all the important confounding domains? 
N/PN/Y/PY/NI 
1.5. If Y/PY to 1.4: Were confounding domains that were 
controlled for measured validly and reliably by the variables 
available in this study? 
NA / Y / PY / PN / N / 
NI 
1.6. Did the authors control for any post-intervention 
variables that could have been affected by the intervention? 
NA / Y / PY / PN / N / 
NI 
1.7. Did the authors use an appropriate analysis method that 
controlled for all the important confounding domains and for 
time-varying confounding? 
NA / Y / PY / PN / N / 
NI 
1.8. If Y/PY to 1.7: Were confounding domains that were 
controlled for measured validly and reliably by the 
variables available in this study? 
NA / Y / PY / PN / N / 
NI 
Optional: What is the predicted direction 





Risk of bias judgement Low / Moderate / 





2.1. Was selection of participants into the study (or into the 
analysis) based on participant characteristics observed after 
the start of intervention? 
If N/PN to 2.1: go to 2.4 
Y / PY / PN / N / NI 
2.2. If Y/PY to 2.1: Were the post-intervention variables that 
influenced selection likely to be associated with 
intervention? 
NA / Y / PY / PN / N / 
NI 
2.3 If Y/PY to 2.2: Were the post-intervention variables that 
influenced selection likely to be influenced by the 
outcome or a cause of the outcome? 
NA / Y / PY / PN / N / 
NI 
2.4. Do start of follow-up and start of intervention coincide 
for most participants? 
Y / PY / PN / N / NI 
2.5. If Y/PY to 2.2 and 2.3, or N/PN to 2.4: Were adjustment 
techniques used that are likely to correct for the presence of 
selection biases? 
NA / Y / PY / PN / N / 
NI 
Risk of bias judgement Low / Moderate / 
Serious / Critical / NI 
Optional: What is the predicted direction of bias due to 
selection of participants into the study? 
Favours experimental / 
Favours comparator 
/ Towards null /Away 
from null / Unpredictable 
3.1 Were intervention groups clearly defined? Y / PY / PN / N / NI 
3.2 Was the information used to define intervention groups 
recorded at the start of the intervention? 
Y / PY / PN / N / NI 
3.3 Could classification of intervention status have been 
affected by knowledge of the outcome or risk of the 
outcome? 
Y / PY / PN / N / NI 
Risk of bias judgement Low / Moderate / 
Serious / Critical / NI 
Optional: What is the predicted direction of bias due to 
measurement of outcomes or interventions? 
Favours experimental / 
Favours comparator 
/ Towards null /Away from null 
/ Unpredictable 
4.1. Were there deviations from the 
intended intervention beyond what 
would be expected in usual practice? 
Y / PY / PN / N / NI 
4.2. If Y/PY to 4.1: Were these deviations from intended 
intervention unbalanced between groups and likely to have 






affected the outcome? 
4.3. Were important co-interventions balanced across 
intervention groups? 
Y / PY / PN / N / NI 
4.4. Was the intervention implemented successfully for most 
participants? 
Y / PY / PN / N / NI 
4.5. Did study participants adhere to the 
assigned intervention regimen? 
Y / PY / PN / N / NI 
4.6. If N/PN to 4.3, 4.4 or 4.5: Was an appropriate analysis 
used to estimate the effect of starting and adhering to the 
intervention? 
NA / Y / PY / PN / N / 
NI 
Risk of bias judgement  
Optional: What is the predicted direction 
of bias due to deviations from the 
intended interventions? 
 
5.1 Were outcome data available for all, 
or nearly all, participants? 
Y / PY / PN / N / NI 
5.2 Were participants excluded due to 
missing data on intervention status? 
Y / PY / PN / N / NI 
5.3 Were participants excluded due to 
missing data on other variables needed 
for the analysis? 
Y / PY / PN / N / NI 
5.4 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Are the proportion 
of participants and reasons for missing data similar across 
interventions? 
NA / Y / PY / PN / N / 
NI 
5.5 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Is there evidence 
that results were robust to the presence of missing data? 
NA / Y / PY / PN / N / 
NI 
Risk of bias judgement Low / Moderate / 
Serious / Critical / NI 
Optional: What is the predicted direction 
of bias due to missing data? 
Favours experimental / 
Favours comparator 
/ Towards null /Away 
from null / Unpredictable 
6.1 Could the outcome measure have been influenced by 
knowledge of the intervention received? 
Y / PY / PN / N / NI 
6.2 Were outcome assessors aware of the intervention 
received by study participants? 
Y / PY / PN / N / NI 
6.3 Were the methods of outcome assessment comparable 
across intervention groups? 





6.4 Were any systematic errors in measurement of the 
outcome related to intervention received? 
Y / PY / PN / N / NI 
Risk of bias judgement Low / Moderate / 
Serious / Critical / NI 
Optional: What is the predicted direction 





/ Towards null /Away 
from null / 
Unpredictable 
Is the reported effect estimate likely to be 
selected, on the basis of the results, 
from... 
7.1. ... multiple outcome measurements 
within the outcome domain? 
Y / PY / PN / N / NI 
7.2 ... multiple analyses of the 
intervention-outcome relationship? 
Y / PY / PN / N / NI 
7.3 ... different subgroups? Y / PY / PN / N / NI 
Risk of bias judgement Low / Moderate / 
Serious / Critical / NI 
Optional: What is the predicted direction 





/ Towards null /Away 
from null / 
Unpredictable 
Overall bias Low / Moderate / 













Loke method for quality of studies assessing adverse events: 
  Support for judgement 
How were adverse events data 
collected? 
  
Were any patients excluded 
from the adverse effects 
analysis? 
  
Did the report give numerical 
data by intervention group? 
  
Which categories of adverse 
effects do the investigators 
report? 
  
Did the investigators report on 
all important or serious effects? 
  
How were these defined?   
Were the methods for 






Key conclusions of study authors 
Miscellaneous comments (study author) 
References to other relevant studies 











Appendix 3. Questionnaire distributed for UKALL2003 ON 
data collection 
Audit of osteonecrosis in children and young adults with ALL: UKALL 
2003 trial period 
We would be very grateful if the following information could be provided for 
patients with osteonecrosis on the attached list treated during the time 
period Oct 2003-June 2011.  
Patient Demographics 
Trial Reference number……………………   
Date of birth (dd/mm/yyyy)……………………..   
Date of end of ALL treatment……..................... 
Date of last follow-up……………………………………… 
If available: 
Patient height at diagnosis of ALL……  
Patient weight at diagnosis of ALL……………     
Osteonecrosis and fracture history 











History of fractures? Y/N 
Please detail date and site of fractures if 
applicable........................................................................................... 
 Right Left 
Shoulder   
Hip   
Knee   
Ankle   








Date of diagnosis of 
osteonecrosis....................................................................................................
.................... 
How was diagnosis of osteonecrosis made?  
Symptoms                  Plain X-Ray                MRI               Other (please 
state)         ………………………………………………. 
Imaging 
Date of initial imaging………………………………………… 
Types of imaging around diagnosis:  MRI/ X-ray/DXA/CT 
Please attach reports separately if additional space required, indicating date 
and type of report. If multiple areas of osteonecrosis please attach all 
available diagnostic reports with dates: 
Initial X-Ray report (if applicable): 
 
 
Initial MRI/DEXA reports (if applicable): 
 
 
Follow-up MRI/ DEXA reports if available: 
 
 
Management and outcome of osteonecrosis 
Management (please 






If applicable, date of surgery (dd/mm/yyyy)…………… …………….. 
 Yes No Don’t know 
Steroids stopped    
Pamidronate given    
Vitamin D given    
Surgical intervention required    





Type of surgery………………………………………… 
 








If the patient has died, please indicate cause of death……………..……… 
Are you aware of any children not on our list who developed osteonecrosis 
during this time period?   Y/N                 
 If ‘yes’ please complete form A and B for these patients.  
Many thanks for your help with this audit.  
  
No long term effects  
Minimal disability- able to carry out ADL  
Significant disability- unable to carry out ADL  
Requires wheelchair  
Death  





Appendix 4. Additional form for identification of unreported 
cases of ON in UKALL2003.  
Additional form for patients with osteonecrosis not identified on 
distributed list: 
Trial reference number (if applicable): 
Sex: 
Date of birth: 
Centre (registration): 
Centre (follow up): 
Date of diagnosis of ALL: 
Ethnicity: 
Treatment arm/regimen:  A                   B                     A/C                    B/C              
Other................. 
 
Number of delayed intensification phases:               1                       2 
 
Treatment stage at diagnosis of bone toxicity:  
Induction  
Consolidation  
IM 1  
DI 1  
IM 2  















Appendix 6. Stata code for UKALL2003 data analysis 
Development of categories:  
gen agecat=0 
recode agecat 0=1 if age>10 & age<=15 




replace racecat=0 if race==2 
replace racecat=1 if race==1 
replace racecat=2 if race==3 
replace racecat=3 if race>3 
 
egen agecat4 = cut(age), at (10,16,21,25) 
table agecat4, contents(min age max age) 
 
tabulate agecat4, nolabel 
tab agecat4 on 
egen agecat5 = cut(age), at 
(1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24, 
25) 
. tabulate agecat5 on, row 
egen percent = mean(100*on), by(agecat4) 
. egen total = sum(1), by(agecat4) 
 
Logistic regression:  
logistic on i.agecat gender 
logistic on age gender 





To run each different variable as independent variable* 
logistic on i.agecat gender racecat DI 
logistic on i.racecat gender agecat DI 
logistic on i.gender racecat agecat DI 
logistic on ib(2).DI gender agecat regcat 
 
Univariable logistic on i.agecat 
logistic on i.DI 
logistic on i.gender 
logistic on i.racecat 
 
logistic on i.agecat gender i.racecat ib(2).DI 
 
*calculation of chi2* 
tabi 22 2265 \ 104 506 \ 44 185, chi2 expected 
 
Calculation of contingency table for age by gender interaction: 
. . table agecat4 on gender, row 
Calculation of likelihood ratio for age by gender interaction:  
. estimates store a 
. regress on i.agecat4 gender 
. estimates store b 
. lrtest a b 
*generation of kaplan-meier curve and Cox model using Breslow’s 
method for ties* 
. stset Time, failure(Event) 
. sts graph, by(Intervention) 





Appendix 7. Directed acyclic graph codes 
Graph 1: Development of osteonecrosis in patients with ALL 
ALL%20treatment E @0.705,0.779 
Age 1 @0.146,-0.053 
BMI 1 @0.750,0.120 
Ethnicity 1 @0.178,0.217 
Lipid_levels U @0.628,0.403 
Lipid_metabolism U @0.652,0.661 
Osteonecrosis O @0.873,0.360 
Physical_activity U @0.764,-0.132 
Pubertal_status U @0.433,-0.033 
Sex 1 @0.182,0.693 
Socioeconomic_status U @0.179,0.550 
Steroid_metabolism U @0.819,0.727 
bone_biochemistry U @0.482,0.693 
bone_mineral_density U @0.535,0.844 
cytogenetics_of_ALL_treatment U @0.303,0.844 
diet U @0.455,0.382 




Age ALL%20treatment BMI Lipid_levels Osteonecrosis Physical_activity 
Pubertal_status bone_mineral_density 
number%20of%20delayed%20intensification%20blocks 
BMI Lipid_levels Osteonecrosis bone_mineral_density 
Ethnicity BMI Lipid_levels Lipid_metabolism Osteonecrosis Physical_activity 
Pubertal_status Socioeconomic_status Steroid_metabolism 
bone_mineral_density cytogenetics_of_ALL_treatment diet 
Lipid_levels Osteonecrosis 
Lipid_metabolism Lipid_levels Osteonecrosis 
Physical_activity BMI Lipid_levels Osteonecrosis bone_mineral_density 
Pubertal_status BMI Lipid_levels Lipid_metabolism Osteonecrosis 
Physical_activity bone_mineral_density 







Socioeconomic_status BMI Physical_activity diet 
Steroid_metabolism Lipid_levels Osteonecrosis 








Graph 2: Development of grade 5 osteonecrosis in patients with 
osteonecrosis  
BMI U @0.162,0.164 
Initial_grade_of_ON 1 @0.104,0.120 
Steroid_exposure U @0.096,0.319 
activity_level U @0.349,0.190 
additional_chemotherapeutic_agents U @0.305,0.318 
age 1 @0.032,0.180 
grade%205%20ON%2F%20THR O @0.444,0.248 
pubertal_status U @0.313,0.239 
sex 1 @0.017,0.282 
BMI activity_level pubertal_status 
Initial_grade_of_ON grade%205%20ON%2F%20THR 
Steroid_exposure BMI activity_level grade%205%20ON%2F%20THR 
activity_level Initial_grade_of_ON grade%205%20ON%2F%20THR 
additional_chemotherapeutic_agents grade%205%20ON%2F%20THR 














Number with no 
response 
Addenbrookes 9 4 
Alder Hey Children's hospital 6 0 
Beatson West of Scotland  1 5 
Birmingham Children's Hospital 27 0 
Bristol Royal Hospital for Children10 10 0 
Christie Hospital NHS Trust 9 0 
Clatterbridge Centre for Oncology 1 0 
Great Ormond Street Hospital 14 0 
Guy's and St Thomas's 0 2 
James Cook University Hospital 0 1 
Leeds General Infirmary 24 0 
Leicester Royal Infirmary 8 0 
Milton Keynes General NHS Trust 0 1 
Northampton General Hospital 2 1 
Nottingham City Hospital 0 2 
Nottingham University Hospital 6 0 
Our Lady's Hospital for Sick Children 16 0 
Oxford Radcliffe Hospitals 13 0 
Poole Hospital 0 1 
Queen Elizabeth Hospital 0 1 
Royal Aberdeen Children's Hospital 2 0 
Royal Belfast Hospital 1 0 
Royal Devon and Exeter Hospital 0 1 
Royal Hallamshire Hospital 1 0 
Royal Hospital for Sick Children 9 0 
Royal Manchester Children's Hospital 23 2 
Royal Marsden Hospital 16 1 
Royal Shrewsbury Hospital 1 0 
Royal Victoria Infirmary 15 0 
Royal Wolverhampton Hospital 0 1 
Sheffield Children's Hospital 5 0 
Southampton University Hospital Trust 17 0 
Taunton and Somerset NHS Trust 2 0 
University College Hospital 3 1 
University Hospital Coventry 0 1 
University Hospital of North Staffs 4 0 
University Hospital of Wales 9 2 
Western General Hospital 1 0 
Wexham Park Hospital 0 1 
Yorkhill NHS trust 9 0 





Appendix 9. Questionnaire for surgical sub-study of 
UKALL2003 patients 
Audit of surgical interventions for osteonecrosis in children and young 
adults with ALL: UKALL2003 
 
Trial reference number: …………………………………….. 
NHS number: ……………………………………….. 
Date of birth (dd/mm/yyyy): ………………………………….. 
  
Number of MR images: ___________ 
Number of CDs enclosed: _____________ 
Operation notes enclosed:  
Orthopaedic letters enclosed:  
 
Current mobility status of patient if known: 
Requiring wheelchair/ requiring crutches/ requiring frame/ returned to full 
mobility 
Date of information_____________ 
 
Current pain status of patient if known: 
No pain/ occasional pain relief required / regular pain relief required 






Appendix 10. Study protocol for British OsteoNEcrosis 
Study. Version 5.  
BONES: The British OsteoNEcrosis Study: A prospective multi-centre study 
to examine the natural history of osteonecrosis in older children, teenagers 
and young adults with acute lymphoblastic leukaemia 
Aims 
The aim of this research is to examine the natural history of osteonecrosis in 
older children, teenagers and young adults with acute lymphoblastic 
leukaemia within the UK. 
Objectives 
The objective is to establish a prospective, multi-centre study for older 
children, teenagers and young adults which can address the following 
questions:  
 What is the incidence of osteonecrosis in older children, teenagers and 
young adults being treated for acute lymphoblastic leukaemia (ALL) in the 
UK at different time points in their treatment? 
 What are the risk factors for progression and the development of 
symptomatic osteonecrosis in this population?  
 Are there specific radiological features that predict for either progression or 
regression in those with asymptomatic osteonecrosis? 
Background 
Survival from acute lymphoblastic leukaemia (ALL) has steadily increased 
over the last 40 years so that we now expect to cure >90% children and 
young people presenting with ALL.  This progress shifts the entire treatment 
paradigm so that the goal moves beyond simply cure to returning the young 
person to a normal life. The biggest barrier to this is the burden of treatment 
associated toxicity and attention internationally is now turning to this.  
Osteonecrosis (previously also referred to as avascular necrosis, ischaemic 
necrosis and aseptic necrosis) is one of the most devastating complications 
seen in older children and teenagers treated for ALL, and can cause 





However, despite increasing concern about osteonecrosis, our 
understanding is limited.  Historically, information about osteonecrosis has 
not been well captured in previous studies of ALL - either in the UK or in 
other countries.  This partly reflects lack of good definitions and piecemeal 
reporting.  These deficiencies have been acknowledged and there is now an 
international will to address them.  The starting point for this is 
standardisation of definitions, for which we can use the The National Cancer 
Institute Common Terminology Criteria for Adverse Events (CTCAE) version 
4[355], which will allow future comparison (see appendix 1).  It is imperative 
that we maximise the potential of the current UK study, UKALL 2011, to 
further understanding of osteonecrosis in this population.   
Osteonecrosis is one of the most debilitating complications seen after or 
during treatment for ALL, and is mostly an iatrogenic complication that has 
been attributed mostly to increased use of glucocorticoids[356]; 
asparaginase, high dose methotrexate and cyclophosphamide have also 
been implicated. Development of osteonecrosis appears to be multifactorial, 
but is being seen more commonly in patients as survival improves and high 
dose steroids have become imbedded in treatment regimens. Osteonecrosis 
occurs when there is bone ischaemia and infarction caused by temporary or 
permanent disruption to the blood supply and in ALL typically affects the 
femoral head, humeral head, knee, shoulder and ankles. Glucocorticoids 
predispose to the development of osteonecrosis in a number of ways, with 
proposed aetiologies including: 
 Creation of a hypercoagulable state with endothelial cell apoptosis and 
development of microthrombi; 
 Suppression of osteoblasts and apoptosis of osteocytes impairing the bone 
repair process; 
 Stimulation of intramedullary lipocyte proliferation and hypertrophy resulting 
in increased intraosseous pressure.  
These factors combine to compromise blood circulation to the bone leading 
to cell death in a self-perpetuating cycle[357].  
The most comprehensive prospective study to examine osteonecrosis in 





incidence of 72%, of which 18% had symptomatic osteonecrosis [132].  
Symptomatic osteonecrosis was associated with a low serum albumin and 
high serum cholesterol, both of which were also associated with ACP1 
polymorphisms.  Severe osteonecrosis was associated with poor 
dexamethasone clearance.  There are many more reports which rely on 
proactive reporting to the study centre, with no identification of asymptomatic 
osteonecrosis, and as expected these tend to give far lower incidences. 
These range from 0.67% [116] to 15% [123].The UK data suggests that 4% 
had symptomatic osteonecrosis in UKALL 2003 [128], but it is recognised 
anecdotally that many patients with symptomatic osteonecrosis were not 
reported by clinicians in UKALL 2003. 
Despite the variation in the reported incidence across the different study 
protocols, there is striking agreement in some of the risk factors for the 
development of osteonecrosis, with significant controversy in others.  Age 
has consistently been associated with increased risk with symptomatic 
necrosis, with patients aged <10 years at diagnosis at much lower risk of 
development of osteonecrosis[132]. The significance of female sex as a risk 
factor for development of osteonecrosis is less clear. A number of studies 
found it was a risk factor while it appeared to be non-significant in other 
studies even when similar treatment regimens were used [111]. Even in 
groups with highest rates of osteonecrosis there are disparate results - the 
CCG study reported the disorder more frequently in females [119], whilst no 
gender difference were found in the DFCI ALL consortium [127] and studies 
at SJCRH [140]. In the study by Mattano in 2000 [119] the gender difference 
was greatest in the 10-15 year age group, with 3 year rates of 19.2% for 
females and 9.8% for males. 
Ethnicity is notoriously difficult to capture.  White race was found to be a risk 
factor in a number of studies, but not in others [117, 119, 132]. 
A number of candidate genes have been proposed. In the prospective study 
by Kawedia et al [132] single nucleotide polymorphism (SNP) genotyping 
was performed. After adjustment for age and treatment arm 423 SNPs were 
associated with symptomatic osteonecrosis, of which 27 were associated 





ACP1 gene locus. ACP1 is associated with serum cholesterol and 
triglyceride levels [191], and regulates osteoblast differentiation [192]. Higher 
serum cholesterol and lower serum albumin have been associated with 
grade 2-4 osteonecrosis, suggesting that ACP1 may act via multiple 
mechanisms to affect bone homeostasis. 
Dexamethasone, which is now the steroid of choice in the UK protocols, in 
view of its superiority over prednisolone in reducing central nervous system 
relapse, may be associated with an increase in osteonecrosis compared with 
prednisolone.   
Mattano et al [105] reported higher incidence of osteonecrosis in paediatric 
patients with ALL treated with dexamethasone during induction phase than 
in those treated with prednisone (11.6% and 8.7%, respectively). This 
difference between these types of corticosteroids was observed only in 
patients’ age 13 years or older, suggesting that older children may be more 
vulnerable to the effect of dexamethasone. Similarly, 11% of children treated 
with dexamethasone developed osteonecrosis in one UK report compared 
with only 3.5% those on prednisolone [114]. However, a much larger 
prospective study analysing results from UKALL97 and UKALL97/99 [100] 
found no excess of ON in the dexamethasone arm of the trial, but only 
assessed NCI grade 3 or 4 toxicity, so the impact of dexamethasone versus 
prednisolone in development of osteonecrosis remains unclear. 
In the current UKALL 2011 study there is an upfront randomisation to 
standard versus short course dexamethasone.  Standard dexamethasone 
consists of 4 weeks of dexamethasone 6mg/m2 with a further weaning 
week.  Short course dexamethasone consists of two weeks of 
dexamethasone 10mg/m2.  This is given for the first two weeks 
consecutively in children <10 years old, or split so that it is given for weeks 1 
and 3 in older children and those with Down syndrome. The CCG1961 trial 
evaluated components of therapeutic intensification in high-risk patients 
(white cell count ≥50x109 and/or age ≥10 years). It was found that use of 
alternate week rather than continuous dexamethasone during delayed 
intensification in high risk ALL patients results in a 2-fold reduction in the 





≥10years, and particularly those over the age of 16 years. There was a four-
fold reduction among those randomised to intensified therapy, despite those 
with alternate week dexamethasone having a higher total dexamethasone 
exposure. The incidence of ON was lower among slow responders age ≥ 10 
years assigned to double delayed intensification with alternate-week 
dexamethasone when compared to a similar cohort on the CCG1882 trial 
[119] who were assigned to two delayed intensification phases with 
continuous dexamethasone (11.8% versus 23.2%), and could indicate that in 
this particular patient population dosing manner supersedes cumulative 
exposure. UKALL 2011 offers the first opportunity in the UK to examine the 
effects on osteonecrosis toxicity of short compared with standard 
dexamethasone.  
It is recognised that osteonecrosis may regress, although the reasons for 
this are not understood.  It is possible that some radiological changes 
interpreted as representing steroid associated osteonecrosis are in fact 
changes which have been present at diagnosis and which are a 
consequence of the original leukaemia.  In the prospective study of 364 
children[132], 39% had osteonecrosis changes on their initial MRI, but were 
asymptomatic.  The majority of this group, 74%, did not go on to develop 
symptomatic osteonecrosis.  The current radiological classifications use a 
multi-modal approach combining scores for clinical, X-ray, MRI and in some 
cases bone scan findings.  They were developed specifically for changes in 
the femoral head, over 20 years ago and in an entirely different patient 
population.  
In addition to using internationally agreed standard definitions for 
osteonecrosis (appendix 1), this study will provide the data needed to 
develop a radiological classification which correlates with clinical status. 
Given the very significant morbidity associated with osteonecrosis it is 
imperative that the opportunity afforded by the UKALL study to examine this 
is maximised.  Only once this is done can meaningful intervention studies to 
try to reduce the burden of osteonecrosis be initiated.  Osteonecrosis should 




IRAS Project ID: 185365  
Method 
Participants 
Children, teenagers or young adults between the age of 10 (including the 
day of the 10th birthday) and 24 years 364 days (at the time of diagnosis) 
with a first diagnosis of acute lymphoblastic leukaemia or lymphoblastic 
lymphoma (T-NHL or SmIg negative precursor B-NHL) diagnosed under 
standard criteria are eligible for BONES.  Written informed consent is 
required for all patients.   
Recruitment 
Patients will be recruited locally by the primary treatment centre.  
Target recruitment 
The recruitment target is 50 patients over a 2 year period, which is based on 
an anticipated ascertainment target of 75%.  This is an observational study 
and there is therefore no relevant power calculation.  
Data collection 
Information will be collected on basic demographics, presenting features and 
diagnosis at initial recruitment (see appendix 2).  Further data will be 
collected at 4 subsequent time-points detailed below to ascertain treatment 
and response, along with results of relevant investigations performed (see 
appendix 3). The clinician completing the form will access investigation 
results from the patient’s medical records.  Clinical information collected in 
clinic/ hospital will include height, weight and phase of puberty. At each time 
point (5 in total) further data will be collected, including MR imaging of lower 
limbs, physiotherapy assessment using a structured assessment tool, and 
routine clinical and biochemical information(see appendices 4, 5 and 6). 
Bone mineral density and lateral vertebra assessment will be assessed at 
diagnosis and annually to a total of 4 assessments.  
Investigations 
The results of the following investigations will be collected: 
At diagnosis /earliest results obtained during induction- highest white cell 
count, immunophenotype, cytogenetics, molecular results; albumin; lipid 
profile; vitamin D level, bone profile (calcium, phosphate, PTH, ALP) 
At the end of induction (results nearest to day 29) - MRD result, flow 




IRAS Project ID: 185365  
DXA scans results (performed at diagnosis and annually) – lumbar spine 
bone mineral apparent density (measured in AP direction L1-4) Z-scores, 
and total body less head Z-scores. Vertebral fractures would be 
assessed with DXA lateral vertebral assessment of thoracic and lumbar 
vertebra (T4-L4 if possible), using the Genant semi-quantitative method. If 
DXA VFA is not available, lateral thoracolumbar spine radiographs can be 
used instead and assessed using the same method. 
Pelvic X-rays and full joint assessment via MRI which are performed if 
significant problems are identified by the clinical team, according to 
orthopaedic opinion. 
Investigations specific to patients recruited into the study: 
At the following time-points, patients recruited into the study will have 
additional assessment: 
- Within 4 weeks of diagnosis 
- At the end of delayed intensification 
- One year after the start of maintenance 
- Two years after the start of maintenance 
- Three years after the start of maintenance 
The additional assessment will include:  
MRI of the hips, knees and ankles. These should comprise of unenhanced 
coronal T1 and STIR images as a minimum protocol. Knees and ankles can 
be imaged together. Where further information of a specific joint is needed 
pre-treatment additional sequences in different planes could be performed at 
the discretion of the participating centre.  
Physiotherapy assessment, including completion of patient questionnaire.  
In centres where annual DXA and lateral vertebral assessment is not 
standard of care, additional annual assessments will be requested where 
facilities exist.  
The MRI images obtained are not routine MRI scans, as they are being done 
according to a study protocol developed for BONES, and are not for local 
interpretation. Local reports should simply say that images are for trial 
purposes only. If a significant abnormality (not osteonecrosis) is found when 
images are centrally reviewed, information will be fed back to the local 
centre. In the event of the development of symptomatic osteonecrosis, which 
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protocols and at the discretion of their own consultant (see appendix 7). 
Information on treatment and outcomes will be collected. 
Radiological review 
A central review panel consisting of Paediatric Radiologists with an interest 
in paediatric haematology will review each MRI in order to agree the grade 
of osteonecrosis and noting specific features according to the study 
radiology proforma.  
There will also be retrospective central analysis of DXA and lateral vertebral 
assessment results. Vertebral fracture prevalence will be assessed on lateral 
vertebral assessment using the Genant semi-quantitative method.  
Data management 
Information will be collected centrally at the University of Leeds.  
Local data management 
Local clinician to complete forms at each time point.  
Local physiotherapist to collect questionnaire data, and complete 
physiotherapy assessment form.  
Both forms to be anonymised locally, with only trial number, initials and date 
of birth (in form of month/year) available on forms.  
PI at local centres to be custodians of local data, and to have research file at 
site of personal data.  
Trial centre to send separate encrypted spreadsheet of trial number, date of 
birth and sex to CI.  
Forms and spreadsheet to be sent by secure e-mail. Consent forms to be 
sent to CI.  
Personal data relating to study to be destroyed by PI at end of storage 
period (10 years).  
Radiographic data 
Anonymised images of MRI scans to be put onto CD, (only trial number on 
disk).  
Anonymised DXA scans and lateral vertebral assessment images to be put 
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Central data management  
MRI and DXA CDs, forms and consent forms to be secured in locked filing 
cabinet in University of Leeds, in secure room. Only CI and members of 
research team to have access to this filing cabinet.  
Electronic database to be created with trial numbers, date of birth (mm/yy), 
sex and of investigations/questionnaires.  
Database to be stored on CI University M drive, a secure, password 
protected, University of Leeds server. A copy will be held by one of the MD 
research supervisors (Dr Feltbower) on their secure password protected 
University of Leeds server, and only available to relevant members of the 
research team. They will also provide the long term storage of data, after 
completion of student research time. 
CI to be responsible for deleting data from database at end of storage 
period.  
Statistical analysis 
Epidemiology Unit located within the University of Leeds. 
Participant reimbursement of expenses 
Patients or their parents will be reimbursed for excess travel expenses. This 
will be reimbursement of public transport expenses, or car mileage 
(24p/mile) to a maximum of £20/ journey. Patients can claim travel expenses 
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BONES protocol Appendix 1.  Definition of osteonecrosis 
The National Cancer Institute Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.0 defines ON as ‘a disorder characterised by 
necrotic changes in the bone tissue due to interruption of blood supply. Most 
often affecting the epiphysis of the long bones, necrotic changes result in the 
collapse and the destruction of the bone structure’. 
Grade  
1 Asymptomatic; clinical or diagnostic observations only, intervention 
not indicated. 
2 Symptomatic; limiting instrumental ADL 
3 Severe symptoms; limiting self care ADL; elective operative 
intervention indicated 




IRAS Project ID: 185365  
 
BONES protocol Appendix 2. Form to be completed at initial recruitment 
 
Initials     ___________ 
Date of birth   ___________   
Trial Number     ___________   
Sex                            male/female/prefer not to say 
Date of initiation of therapy ___________  
Ethnicity    ____________ 
Recruiting centre  _________ 
Patient postcode  _________ 
Highest white cell count _________ x 109/l date  _________ 
Immunophenotype  ________________________________ 
Cytogenetics   ________________________________ 
Molecular results  ________________________________ 
 
Height (cm) ________  Weight (kg) ________ 






(Tanner stage 1) 
In Puberty  
(Tanner stage 2-3) 
Completing Puberty 
(Tanner stage 4-5)  
Girls  If all of the 
following: 
No signs of 
pubertal  
development  
If any of the following: 
Any breast 
enlargement pubic or 
axillary hair  
If all of the following 
Started periods with 
signs of pubertal  
development 
Boys If all of the 
following: 
High voice and  
No signs of 
pubertal  
development  
If any of the following: 
Slight deepening of 
the voice  
Early pubic or axillary 
hair growth  
Enlargement of testes 
or penis  
If any of the following: 
Voice fully broken 
Facial hair 
Adult size of penis 
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Hepatomegaly      yes / no 
Splenomegaly      yes / no 
Palpable lymphadenopathy    yes / no 
 
Duration of symptoms before diagnosis  _________ 
Was bone pain present at diagnosis? yes / no 
 
Please document units for all available blood test results: 
Blood test Result  Date 
Serum albumin   
HDL   
LDL   
Cholesterol   
Triglyceride   
25-hydroxyvitamin D   
PTH   
Alkaline phosphatase   
Calcium   
Phosphate   
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BONES protocol Appendix 3.  Form to be completed at day 29 of induction 
 
Trial number _______________   
Patient initials______________ 
Date of day 29 of induction _______________ 
Recruiting centre________________________ 
Treatment regimen for induction  A / B 
Treatment regimen for consolidation  A / B / C 
If changed, why was this? ______________________________ 
Flow cytometry results at end of induction 
______________________________ 
 
MRD status at end of induction  low / high / not able to be assessed 
 
Please document units for all available blood test results with units as 
close to day 29 as possible: 
Blood test Result  Date 
Serum albumin   
HDL   
LDL   
Cholesterol   
Triglyceride   
25-hydroxyvitamin D   
PTH   
Alkaline phosphatase   
Calcium   





IRAS Project ID: 185365  
 
If vitamin D was low, has this been treated? yes / no 
 
If yes, please document treatment____________________ 
Date of induction MRI_________________________ 
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BONES protocol Appendix 4. Form to be completed and sent with relevant 
images at the end of delayed intensification, 1 year after start of 
maintenance, 2 years after start of maintenance, 3 years after start of 
maintenance 
 
Trial number _________________   
Patient initials ________________ 
Recruiting centre ________________________ 
 
Timepoint (please circle and date)  
Timepoint  Date 
end of delayed intensification  
1 year after start of maintenance  
2 years after start of maintenance  
3 years after start of maintenance  
  
Treatment regimen for interim maintenance  
A standard interim maintenance 
     A high dose methotrexate 
     B standard interim maintenance 
     B high dose methotrexate 
     C Capizzi 
     C high dose methotrexate 
 
Treatment regimen for maintenance vincristine/dexamethasone pulses 
      no pulses 
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If yes, please provide further details_______________________________ 
 
Please document units for all available blood test results: 
Blood test Result  Date 
Serum albumin   
HDL   
LDL   
Cholesterol   
Triglyceride   
25-hydroxyvitamin D   
PTH   
Alkaline phosphatase   
Calcium   
Phosphate   
 
At the time of each scan: 
Height (cm) ________ Weight (kg) ________ 





(Tanner stage 1) 
In Puberty  
(Tanner stage 2-3) 
Completing Puberty 
(Tanner stage 4-5)  
Girls  If all of the 
following: 
No signs of 
pubertal  
development  
If any of the following: 
Any breast 
enlargement pubic or 
axillary hair  
If all of the following 
Started periods with 
signs of pubertal  
development 
Boys If all of the 
following: 
High voice and  
No signs of 
pubertal  
development  
If any of the following: 
Slight deepening of 
the voice  
Early pubic or axillary 
hair growth  
Enlargement of testes 
or penis  
If any of the following: 
Voice fully broken 
Facial hair 
Adult size of penis 
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Has there been a diagnosis of osteonecrosis since the last report?   yes / no 
If yes, when was this? _____________ 
Which joints are affected? _____________________________________ 
Which of the following have occurred:  steroids stopped  yes / no 
      mobility problems   yes / no 
      core decompression yes / no 
      joint replacement  yes / no
      
Has a DXA/ lateral vertebral assessment been performed in the last year?
 yes / no 
If yes, please attach report and send anonymised images.  
Have bisphosphonates been used? yes / no 
If yes, then please give details regarding start date, type, dose and 
frequency of treatment 
____________________________________________________________ 
Completed by : ________________________ date _________  
Please also attach physiotherapy assessment and send anonymised MRI 
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BONES protocol Appendix 5. Subjective physiotherapy assessment 
At physiotherapy assessment: 
For completion by physiotherapist: 
Trial number:     Patient initials: 
Recruiting centre:    Date:  
 
For completion by participant 
 
 
                 BONES 
        British OsteoNEcrosis Study 
Activity Levels 
On a typical day, on average how many hours of the day are you active for 
e.g. walking, playing, exercising ………………….hours 
Mobility 
Since you were last seen (if relevant), were you told to continue to fully/ 
partially or not weight bear? Full/Partial/None 
If you use a walking aid, what hand do you use it in?  Right/Left/Both 
If you use a walking aid, how long have you been using it for?  
 
If you use a wheelchair, when going out, how often do you use it? Always/ 












































Left Elbow    ___/10 
Left Shoulder____/10 




















BONES protocol Appendix 6: Objective physiotherapy assessment  
For completion by physiotherapist: 
Trial number:     Patient initials: 











Full range of 
movement 
 If limited range of 
movement, please 
enter degree and 
plane of movement 
that is restricted 
Right hip  Yes/No  
Left hip  Yes/No  
Right knee  Yes/No  
Left knee  Yes/No  
Right ankle  Yes/No  
Left ankle  Yes/No  
Right Shoulder  Yes/No  
Left Shoulder   Yes/No  
 





Assessment completed by Print     …………………………. 




BONES protocol Appendix 7. Management of osteonecrosis 
Whilst this is an observational study, it is recognised from previous 
experience, that management advice may be sought when a young person 
develops osteonecrosis.  The guidelines below represent the usual practice 
of the clinicians involved in designing the study and are in no way mandated. 
Recommendations  
 Asymptomatic ON detected coincidentally.  
No evidence to suggest discontinuation of dexamethasone is routinely 
indicated in asymptomatic cases.  
Monitor closely and early repeat MRI if symptomatic  
Consider orthopaedic referral. The risk of collapse of the femoral head is 
affected by the location and extent of the necrotic lesion. All femoral head 
lesions which are either large or extend to the edge of the epiphysis should 
be referred to orthopaedic team for consideration of core decompression in 
order to prevent femoral head collapse. Using MRI images in both coronal 
and sagittal planes the Kerboul combined necrotic angle is a good MRI-
based method to assess risk of hip collapse.  
 Symptomatic ON.  
Confirm and document duration of symptoms in affected joint/joints. Review 
all other joints.  
Organise physiotherapy assessment. 
Review vitamin D and bone profile results.  
Consider continuation of dexamethasone and 6 monthly MRI screening to 
detect progression of ON.  
For persistent/worsening symptoms or MRI progression, 
reduction/discontinuation of dexamethasone will need to be considered. If in 
doubt contact trial coordinators in these cases.  
Consider orthopaedic referral (see 1c above)  
Routine use of bisphosphonates can ONLY be recommended in patients 
with coexisting osteoporosis, defined by reduced bone mineral density and 




Appendix 11. Patient information sheets and consent forms. 
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